data_2eps_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2eps _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.21 0 CA-C-O 120.788 0.245 . . . . 0.0 112.301 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -59.04 94.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.895 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 11.2 mm -100.72 125.96 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.092 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.7 t -52.84 131.78 35.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.4 mm-40 -91.11 20.4 5.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.533 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.12 -48.8 2.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.0 p -115.45 -41.97 3.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 127.98 -1.43 6.76 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 17.4 mttp -50.99 179.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.879 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.4 143.83 11.76 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 15.2 m-85 -139.64 170.13 16.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.922 0.391 . . . . 0.0 110.836 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 5.3 m -99.96 -32.22 11.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.864 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 27.9 mtp180 -110.81 155.55 42.14 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.596 0.712 . . . . 0.0 110.86 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -45.33 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.65 2.233 . . . . 0.0 112.335 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.48 -40.15 92.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.844 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.7 m170 -54.68 -53.56 53.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.851 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.3 tp -60.64 -44.18 96.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -49.92 -55.17 15.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.63 -40.77 17.9 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.451 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.7 t60 -64.95 -41.41 95.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.745 0.307 . . . . 0.0 110.868 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.7 mt -73.43 -18.34 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.123 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 61.0 tttt -108.84 1.42 20.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -120.16 -27.42 5.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.1 t -112.92 -41.69 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.533 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.8 m-70 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.876 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.749 0.229 . . . . 0.0 112.327 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.5 m-30 -61.44 93.4 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.51 129.67 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.154 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 19.4 t -55.28 132.79 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.4 mm-40 -92.57 21.02 5.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.557 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.13 -48.5 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.83 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.7 p -115.64 -39.69 3.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 123.23 7.96 6.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . 0.424 ' HD2' ' CE1' ' A' ' 431' ' ' HIS . 34.8 mttt -58.19 179.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.427 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.11 144.32 12.43 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.448 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.427 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 8.8 m-85 -138.93 -177.68 4.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.847 0.356 . . . . 0.0 110.927 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 23.9 m -112.32 -35.78 5.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.853 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.403 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 45.6 mtt180 -111.11 155.3 42.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.641 0.734 . . . . 0.0 110.831 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -29.58 23.39 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.65 2.234 . . . . 0.0 112.349 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -80.17 -32.05 38.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.859 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.403 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.9 m170 -65.2 -51.22 62.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 12.0 tp -63.53 -44.3 94.64 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -49.97 -53.04 28.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . 0.488 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.59 -39.46 23.11 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.456 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . 0.424 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.3 t60 -67.54 -42.74 82.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.7 mt -72.99 -19.39 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.109 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.484 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 32.8 tttt -108.35 1.71 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . 0.488 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 8.3 tp-100 -119.92 -28.9 5.08 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.938 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.4 t -112.8 -41.57 3.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.557 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.5 m-70 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 N--CA 1.465 -0.16 0 CA-C-O 120.825 0.26 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.3 m-30 -62.46 95.3 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 17.5 mm -105.87 124.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.084 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.9 t -51.02 128.6 21.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -89.57 19.28 4.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.878 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.535 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.69 -45.72 2.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 12.9 p -117.46 -49.49 2.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.897 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.53 -1.44 3.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 26.4 mttm -54.24 174.72 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.811 0.339 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.31 146.11 16.55 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.505 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -141.14 163.09 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.905 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.58 -27.94 14.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.807 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.421 ' HG3' ' ND1' ' A' ' 427' ' ' HIS . 14.7 mtp180 -110.07 148.94 39.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.849 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -33.17 17.1 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.335 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.52 -38.43 55.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.421 ' ND1' ' HG3' ' A' ' 424' ' ' ARG . 51.2 m170 -58.26 -52.54 65.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.804 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 8.9 tp -57.84 -46.62 84.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -49.5 -52.89 26.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . 0.479 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -49.2 -40.06 28.59 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.49 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.13 -42.96 88.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.1 mt -72.73 -19.93 19.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.139 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 23.8 ttmt -107.91 1.09 22.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.92 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . 0.479 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 71.0 tp60 -119.98 -26.27 5.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.92 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.6 t -114.39 -41.41 3.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.535 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.139 0 CA-C-O 120.759 0.233 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.7 m-30 -60.38 94.13 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 16.4 mm -98.16 128.09 49.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.103 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.8 t -59.23 132.95 55.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.874 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.7 mm-40 -91.9 2.23 56.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.56 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 7.6 m -93.69 -42.5 9.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.9 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.5 p -123.7 -46.44 2.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 132.78 4.46 3.41 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.455 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 31.1 mttm -58.25 178.08 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.824 0.345 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.98 143.06 11.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -138.37 169.59 17.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 9.8 m -101.48 -28.46 12.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -113.73 154.42 45.77 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.612 0.72 . . . . 0.0 110.925 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -47.5 0.93 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.717 2.278 . . . . 0.0 112.327 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -63.88 -37.5 87.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.4 m170 -58.27 -54.27 48.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.66 -44.11 93.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -50.52 -54.31 23.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.934 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.12 -40.38 21.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -65.52 -40.74 93.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.4 mt -74.24 -19.01 17.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . . . . . . . . . 45.4 tttm -104.75 -4.25 22.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 45.2 tp60 -115.85 -26.27 7.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.6 t -114.78 -33.85 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.155 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.56 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.1 m-70 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.806 0.252 . . . . 0.0 112.334 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.76 94.8 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.912 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 27.1 mm -102.94 133.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.125 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 38.4 t -57.47 128.42 36.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.896 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -85.75 22.39 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.482 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.1 t -122.98 -66.41 1.02 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.5 p -92.33 -42.55 9.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 121.86 12.53 5.4 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -65.37 -179.48 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.419 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.18 143.53 11.71 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 11.7 m-85 -139.36 163.2 33.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.855 0.36 . . . . 0.0 110.873 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.3 m -95.47 -24.51 16.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.818 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.567 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.8 mmt85 -117.99 153.16 51.04 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.629 0.728 . . . . 0.0 110.847 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -40.09 5.77 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.643 2.229 . . . . 0.0 112.356 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -69.88 -42.51 73.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.567 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 59.1 m170 -56.48 -42.82 78.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.895 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 6.5 tp -68.82 -44.55 73.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.945 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -51.97 -54.18 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.869 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.23 -40.05 21.34 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.516 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.21 -40.1 93.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.857 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.0 mt -75.33 -18.24 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.193 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 12.7 ttmt -107.15 -2.14 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.938 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -117.15 -25.46 7.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.92 -38.63 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.153 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.482 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.0 m-70 . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.815 0.256 . . . . 0.0 112.342 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.1 m-30 -63.31 97.18 0.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.914 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 21.5 mm -108.15 125.44 64.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.144 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.0 t -52.4 126.53 19.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 -87.32 21.48 2.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.509 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.57 -51.92 2.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.9 p -110.79 -47.09 3.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.37 11.63 2.44 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . 0.418 ' HD2' ' CE1' ' A' ' 431' ' ' HIS . 44.1 mttt -64.63 -179.4 0.49 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.76 143.21 11.16 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.46 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -139.04 159.66 41.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.891 0.377 . . . . 0.0 110.856 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.0 m -92.21 -30.16 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.414 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.2 mtp180 -112.16 154.95 44.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.639 0.733 . . . . 0.0 110.896 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -44.45 2.08 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.715 2.277 . . . . 0.0 112.316 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -66.98 -38.21 85.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.852 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.414 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.8 m170 -56.87 -49.28 75.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 6.6 tp -63.55 -45.94 88.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.896 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -49.05 -53.98 17.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.3 -41.11 31.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.527 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . 0.418 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 12.5 t60 -64.84 -40.97 96.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.787 0.327 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 20.6 mt -73.27 -20.83 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.142 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.421 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.5 OUTLIER -103.68 -2.71 26.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -114.56 -28.56 7.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.4 t -114.22 -37.51 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.509 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.9 m-70 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.232 0.203 0 CA-C-O 120.791 0.246 . . . . 0.0 112.364 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -61.25 93.98 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 11.7 mm -102.07 128.74 54.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 7.7 t -60.19 121.12 11.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 10.1 mm-40 -80.63 -4.19 53.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.567 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 3.2 m -86.95 -45.14 11.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.4 p -121.02 -49.09 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.61 0.77 2.86 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.501 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -55.48 -179.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.842 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.31 147.56 18.44 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 5.3 m-85 -143.96 157.41 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.7 m -90.91 -21.92 21.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.411 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 13.3 mtp85 -120.95 155.52 57.56 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 0.0 110.858 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -48.74 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.701 2.268 . . . . 0.0 112.344 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -63.0 -36.28 83.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.411 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 56.1 m170 -58.85 -52.82 64.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 14.0 tp -61.47 -42.86 99.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -51.22 -55.05 20.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.888 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -46.86 -42.77 15.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -63.36 -43.28 98.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.785 0.326 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -72.33 -15.96 18.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.104 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.405 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 14.2 ttpp -105.26 -7.59 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -114.29 -22.97 9.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.86 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.6 t -116.53 -36.94 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.567 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.7 m-70 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.831 0.263 . . . . 0.0 112.371 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.74 89.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 19.3 mm -100.52 126.82 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.105 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 15.5 t -53.99 131.52 40.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 5.3 mm-40 -91.63 21.31 4.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.565 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.08 -46.24 2.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.843 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 17.9 p -117.97 -47.86 2.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 134.49 2.38 3.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.469 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 22.1 mttm -55.97 176.24 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.28 144.24 12.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 17.2 m-85 -140.04 169.14 18.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.866 0.365 . . . . 0.0 110.87 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -103.03 -26.49 13.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.871 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.426 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 14.4 mtt-85 -112.1 149.51 41.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.591 0.71 . . . . 0.0 110.888 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -31.69 19.8 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.712 2.275 . . . . 0.0 112.347 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -78.73 -36.5 43.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.426 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 48.4 m170 -59.46 -53.32 59.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.864 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.38 -47.23 84.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.921 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.57 -52.8 27.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.39 -41.99 33.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -63.37 -40.78 98.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.778 0.323 . . . . 0.0 110.897 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -71.79 -22.92 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.485 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.8 tttm -102.83 1.8 34.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 72.0 tp60 -119.83 -27.66 5.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.5 t -114.92 -42.41 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.104 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.565 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.2 m-70 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.814 0.256 . . . . 0.0 112.354 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.21 95.49 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 13.2 mm -104.0 127.04 58.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.8 t -52.94 127.81 25.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 6.7 mm-40 -88.06 21.86 2.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.524 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.11 -51.25 2.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.2 p -112.36 -46.39 3.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.49 9.61 2.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.482 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 31.9 mttm -62.81 -179.52 0.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -145.19 142.09 10.48 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -137.51 164.39 28.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.871 0.367 . . . . 0.0 110.856 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.4 m -96.11 -28.37 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.876 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.569 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.5 mmt180 -114.56 152.83 46.57 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.576 0.703 . . . . 0.0 110.886 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -38.05 8.33 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.687 2.258 . . . . 0.0 112.349 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.22 -40.16 71.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.569 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 45.4 m170 -58.37 -44.59 88.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 5.3 tp -66.16 -45.3 81.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.942 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -51.37 -55.26 19.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.52 -40.66 16.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -64.3 -40.59 96.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.809 0.338 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 14.0 mt -72.85 -23.82 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.43 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 58.2 tttt -101.76 -1.99 31.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -115.77 -27.86 6.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.86 -36.88 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.524 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.153 0 CA-C-O 120.846 0.269 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.32 90.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 18.9 mm -101.75 127.24 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 9.5 t -53.16 127.67 25.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.882 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.6 mm-40 -88.35 17.96 4.83 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.57 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.6 m -113.44 -42.88 3.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.6 p -121.92 -49.75 2.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.861 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 138.47 -1.06 2.61 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 39.2 mttt -52.69 179.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.816 0.341 . . . . 0.0 110.881 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.407 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -148.87 144.76 12.57 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.49 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 16.2 m-85 -140.01 165.04 28.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.856 0.36 . . . . 0.0 110.832 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.1 m -94.81 -33.59 12.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.412 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 19.7 mtp180 -109.3 155.25 41.42 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.613 0.721 . . . . 0.0 110.84 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -44.5 2.01 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.695 2.264 . . . . 0.0 112.32 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -65.5 -40.51 93.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.855 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.412 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 57.0 m170 -55.39 -51.12 67.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.907 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.14 -46.27 89.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -49.2 -54.12 18.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.02 -39.91 26.98 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -65.3 -39.04 91.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.846 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -75.27 -18.07 16.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.2 OUTLIER -107.28 -2.01 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.912 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 39.9 tp60 -116.36 -27.01 6.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.919 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 30.5 t -114.95 -40.41 3.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.57 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.4 m-70 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.813 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.786 0.244 . . . . 0.0 112.344 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -58.54 90.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 10.9 mm -98.54 128.58 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.8 t -56.77 129.38 41.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 40.3 mm-40 -88.53 20.29 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.567 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.65 -44.84 2.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.3 p -121.59 -46.5 2.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.51 -8.16 3.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.512 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.5 mttt -46.34 170.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -140.91 144.03 14.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -138.1 170.37 16.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 110.881 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 36.9 m -100.23 -34.16 10.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.567 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 83.9 mtt-85 -107.92 155.0 40.74 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.602 0.715 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -46.18 1.3 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.705 2.27 . . . . 0.0 112.298 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.5 -36.25 83.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.567 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 54.6 m170 -58.65 -51.7 68.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.0 tp -62.27 -44.39 96.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -50.77 -53.38 32.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.57 -40.95 25.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -64.37 -40.75 96.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.816 0.341 . . . . 0.0 110.833 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.0 mt -73.57 -16.97 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.129 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 55.9 tttt -107.9 -1.25 20.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -117.9 -25.78 6.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.09 -39.28 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.567 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.7 m-70 . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.854 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.153 0 CA-C-O 120.798 0.249 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.41 97.88 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 21.6 mm -108.13 130.56 60.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -55.91 123.51 14.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.855 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -86.08 20.24 2.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 417' ' ' SER . . . . . . . . . . . . . 1.8 m -117.17 -46.74 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.864 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.6 p -115.99 -46.53 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.15 10.6 2.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . 0.427 ' HD2' ' CE1' ' A' ' 431' ' ' HIS . 32.2 mttt -64.31 -179.75 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.857 0.361 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.16 142.88 10.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -138.87 162.02 35.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.908 0.385 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.7 m -93.24 -32.33 14.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.481 ' HE ' ' CE1' ' A' ' 427' ' ' HIS . 21.1 mtm180 -112.37 155.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -42.01 3.86 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.282 . . . . 0.0 112.38 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.27 -38.85 85.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.481 ' CE1' ' HE ' ' A' ' 424' ' ' ARG . 51.7 m170 -58.41 -49.24 77.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 6.5 tp -62.68 -45.92 90.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -50.04 -55.29 15.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.852 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.43 -39.44 14.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . 0.427 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.9 t60 -66.54 -41.38 88.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.767 0.317 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 16.2 mt -74.17 -15.65 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.451 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 1.1 ttmp? -110.9 0.89 17.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 61.1 tp60 -119.05 -25.73 6.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.937 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 33.7 t -116.7 -42.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.1 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.966 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.156 0 CA-C-O 120.807 0.253 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -62.67 95.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.938 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 28.9 mm -105.73 132.26 53.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.6 t -57.17 126.69 28.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -86.28 21.13 2.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.515 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.22 -55.83 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.836 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.3 p -106.78 -44.53 4.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.03 9.79 3.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 31.1 mttm -62.87 -179.79 0.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.828 0.347 . . . . 0.0 110.876 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.4 144.64 13.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.424 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 10.7 m-85 -139.26 160.93 38.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 54.2 m -91.67 -32.72 15.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.48 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 26.4 mtt-85 -111.28 154.51 43.61 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.581 0.705 . . . . 0.0 110.877 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -42.62 3.24 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 36.9 t0 -66.77 -38.65 86.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.48 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -57.99 -49.5 76.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.51 -44.42 94.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -49.81 -52.84 29.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 434' ' ' GLN . . . -49.76 -43.5 38.42 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.513 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -63.34 -40.5 97.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 110.865 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 20.4 mt -74.78 -18.72 16.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.478 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.6 tttp -109.82 0.96 19.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.895 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . 0.42 ' N ' ' O ' ' A' ' 430' ' ' GLY . 54.1 tp60 -119.44 -25.8 5.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.9 t -116.39 -40.34 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.179 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.515 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 77.5 m-70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--O 1.232 0.193 0 CA-C-O 120.781 0.242 . . . . 0.0 112.294 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -61.02 90.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.947 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 19.5 mm -103.25 130.5 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.137 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.5 t -57.6 126.72 28.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -86.91 20.9 2.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 417' ' ' SER . . . . . . . . . . . . . 1.7 m -117.48 -52.41 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.816 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.4 p -110.75 -45.52 3.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.889 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.6 11.69 2.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.474 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -64.59 179.88 0.57 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.824 0.345 . . . . 0.0 110.927 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.13 142.73 10.81 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.401 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 9.9 m-85 -137.96 162.4 34.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.893 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 15.8 m -94.67 -30.6 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.834 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.406 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 35.7 mtp85 -111.16 154.54 43.51 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.616 0.722 . . . . 0.0 110.865 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 -45.65 1.47 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.685 2.256 . . . . 0.0 112.321 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.46 -40.28 93.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.406 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 53.1 m170 -54.84 -51.16 66.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.845 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 9.2 tp -62.34 -45.05 94.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -50.27 -55.68 14.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.21 -38.21 18.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -67.26 -40.79 86.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.747 0.308 . . . . 0.0 110.841 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 18.5 mt -74.3 -20.53 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.442 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 49.5 tttt -106.87 -0.82 23.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . 0.474 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.7 tp-100 -116.7 -27.6 6.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 32.1 t -114.96 -39.88 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . . . . . . . . . 82.9 m-70 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.905 179.879 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.145 0 CA-C-O 120.824 0.26 . . . . 0.0 112.365 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -60.92 93.69 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 19.2 mm -100.79 131.51 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.138 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.9 t -56.57 125.29 21.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -86.1 20.29 2.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.572 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.61 -43.08 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.3 p -122.06 -46.99 2.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 135.4 -1.69 3.72 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 40.0 mttt -51.67 179.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.868 0.366 . . . . 0.0 110.872 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -147.41 142.97 10.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -138.28 163.88 30.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.83 0.348 . . . . 0.0 110.93 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 423' ' ' SER . . . . . 0.451 ' O ' ' NH1' ' A' ' 424' ' ' ARG . 3.1 m -96.39 -22.75 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.82 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.574 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 7.8 mmt-85 -119.22 152.95 53.05 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 110.873 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . 0.4 ' O ' ' OD1' ' A' ' 429' ' ' ASN . 53.6 Cg_endo -69.73 -41.99 3.82 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.692 2.262 . . . . 0.0 112.34 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -69.14 -42.02 76.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.574 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 58.8 m170 -55.22 -46.48 75.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.852 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 8.8 tp -65.92 -44.99 83.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 425' ' ' PRO . 16.6 m120 -50.16 -54.81 18.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.71 -43.16 21.95 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.513 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -62.98 -41.65 99.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.876 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 20.0 mt -73.42 -15.92 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.135 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . . . . . . . . . 16.2 ttpp -105.11 -8.43 18.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -112.93 -24.28 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.34 -36.18 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.572 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 79.7 m-70 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.147 0 CA-C-O 120.854 0.272 . . . . 0.0 112.323 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -59.2 94.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 13.5 mm -105.33 123.86 59.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.096 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.1 t -50.95 127.72 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.863 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -88.56 19.23 4.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.904 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.556 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -114.59 -45.92 2.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.2 p -118.62 -49.34 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.72 1.19 2.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 36.4 mttt -55.12 173.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.907 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.403 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -142.41 145.64 15.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.403 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 21.3 m-85 -141.12 167.99 20.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 69.2 m -98.57 -33.63 10.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.859 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.41 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 38.0 mtp180 -110.37 155.15 42.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.654 0.74 . . . . 0.0 110.852 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -37.24 9.32 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.04 -35.3 69.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.819 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.41 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 63.5 m170 -60.66 -52.66 64.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.8 tp -62.34 -46.04 90.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.911 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.2 -53.66 20.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.13 -40.19 20.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.48 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -66.4 -42.52 87.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.771 0.319 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -72.38 -19.42 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 46.6 tttm -107.91 2.11 23.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . 0.409 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 13.1 tp60 -120.96 -25.33 5.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.0 t -116.43 -41.74 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.556 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.3 m-70 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.192 0 CA-C-O 120.802 0.251 . . . . 0.0 112.381 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.09 91.56 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 18.8 mm -98.22 124.82 51.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.15 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -49.89 127.6 16.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 67.1 mm-40 -89.12 20.93 3.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.542 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.72 -45.35 2.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 19.6 p -120.36 -46.56 2.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.864 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.19 -0.48 3.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.438 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 27.7 mttm -51.29 176.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.338 . . . . 0.0 110.89 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.59 146.22 16.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.494 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . 0.458 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 14.3 m-85 -142.46 -179.73 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.896 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 27.9 m -110.77 -34.29 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.444 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 80.1 mtt-85 -111.37 154.54 43.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.569 0.7 . . . . 0.0 110.889 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -33.62 16.3 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.654 2.236 . . . . 0.0 112.355 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -76.42 -31.77 58.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.444 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -65.8 -51.34 59.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.882 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 12.7 tp -64.16 -43.42 95.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -51.92 -50.36 61.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.91 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -51.71 -39.74 47.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.496 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -65.71 -40.6 92.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.895 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 10.7 mt -71.44 -22.42 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -99.95 -1.04 38.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.938 179.854 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -115.76 -31.25 5.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.908 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.11 -38.27 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.137 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.542 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.752 0.23 . . . . 0.0 112.301 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -58.57 92.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 16.2 mm -95.78 133.64 36.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.143 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.1 t -60.62 124.36 20.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -84.76 16.6 3.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.537 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.2 m -112.63 -45.08 3.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 13.3 p -120.22 -47.75 2.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.58 -4.19 3.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.517 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 34.9 mttt -50.43 175.25 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.366 . . . . 0.0 110.867 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.26 141.47 10.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -135.9 168.04 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.838 0.351 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 42.2 m -98.54 -31.02 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.886 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.407 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.8 mtt180 -113.12 155.32 44.51 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.725 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -45.39 1.58 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.332 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -65.1 -36.64 84.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.407 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 51.9 m170 -59.52 -51.41 69.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 13.9 tp -62.9 -45.78 90.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -48.48 -53.86 16.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.92 -42.09 29.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.48 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 14.3 t60 -64.14 -39.78 94.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.82 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 17.2 mt -75.39 -18.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.45 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 33.2 tttt -108.28 -0.82 20.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.91 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -117.75 -27.04 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.1 t -114.93 -36.82 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.537 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.851 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 120.79 0.246 . . . . 0.0 112.299 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -62.14 96.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.909 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.6 mm -101.67 129.1 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.134 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 16.9 t -54.99 130.31 41.21 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 36.3 mm-40 -88.74 22.03 2.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.559 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -119.84 -57.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.3 p -105.56 -41.87 5.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.863 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 124.6 7.51 6.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.499 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -58.97 179.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 110.943 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.64 139.51 8.57 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -134.49 170.59 15.54 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 68.3 m -101.75 -28.55 12.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.852 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.404 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 18.9 mtp180 -116.32 155.68 48.12 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.625 0.726 . . . . 0.0 110.88 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.656 2.237 . . . . 0.0 112.366 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.6 -34.56 78.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.404 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 50.7 m170 -61.65 -50.58 71.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.848 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.7 tp -62.9 -44.68 95.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -50.1 -54.61 19.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.859 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . 0.433 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -47.25 -37.11 10.88 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.484 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -69.6 -40.29 76.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.809 0.338 . . . . 0.0 110.895 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.5 mt -75.29 -16.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.46 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 51.7 tttt -110.86 0.99 17.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . 0.433 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.2 tp-100 -120.48 -29.16 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 34.2 t -110.76 -42.89 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.559 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.8 m-70 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.856 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.231 0.167 0 CA-C-O 120.795 0.248 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -60.92 94.09 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.1 mm -103.99 123.53 57.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.167 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.9 t -52.6 130.71 32.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -91.26 20.97 4.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.942 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 417' ' ' SER . . . . . 0.542 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.03 -45.97 2.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.851 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 16.8 p -119.03 -44.36 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.907 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 131.11 0.4 5.12 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 30.4 mttm -55.09 172.54 0.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 0.0 110.875 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -141.23 143.93 13.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.479 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -137.09 166.88 22.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.893 0.378 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 59.8 m -98.37 -32.27 11.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.837 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 424' ' ' ARG . . . . . 0.416 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 56.3 mtt-85 -110.97 156.22 41.18 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.885 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -46.43 1.24 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.737 2.291 . . . . 0.0 112.364 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -64.42 -38.34 90.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 427' ' ' HIS . . . . . 0.416 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 60.0 m170 -56.87 -53.3 59.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.3 tp -60.92 -45.18 95.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -49.32 -52.75 25.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.56 -42.99 36.16 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -63.3 -40.11 96.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.771 0.319 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.6 mt -74.9 -16.36 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 433' ' ' LYS . . . . . 0.446 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 21.7 ttmt -108.94 -2.23 18.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.875 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 5.3 tp-100 -118.19 -25.68 6.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 14.5 t -115.46 -36.36 2.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 436' ' ' HIS . . . . . 0.542 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.0 m-70 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 33.8 t -87.58 -63.2 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 4.1 m 42.44 44.03 3.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.843 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -174.53 -141.79 3.76 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.516 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 9.7 t 61.33 45.75 8.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.88 0.372 . . . . 0.0 110.865 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 26.7 p -144.7 163.13 34.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.83 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -120.35 -143.9 6.97 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.463 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 61.1 p -128.43 132.48 48.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.914 0.388 . . . . 0.0 110.825 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 90.9 t -88.8 92.27 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 155.9 -69.94 0.28 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.471 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . 0.447 ' HD2' ' N ' ' A' ' 411' ' ' LYS . 0.1 OUTLIER -102.64 97.21 8.65 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.633 0.73 . . . . 0.0 110.877 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -47.62 0.88 Allowed 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.665 2.243 . . . . 0.0 112.301 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -59.04 94.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.895 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 11.2 mm -100.72 125.96 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.092 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.7 t -52.84 131.78 35.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.4 mm-40 -91.11 20.4 5.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.533 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.12 -48.8 2.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.0 p -115.45 -41.97 3.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 127.98 -1.43 6.76 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 17.4 mttp -50.99 179.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.879 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.4 143.83 11.76 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 15.2 m-85 -139.64 170.13 16.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.922 0.391 . . . . 0.0 110.836 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 5.3 m -99.96 -32.22 11.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.864 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 27.9 mtp180 -110.81 155.55 42.14 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.596 0.712 . . . . 0.0 110.86 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -45.33 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.65 2.233 . . . . 0.0 112.335 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.48 -40.15 92.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.844 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.7 m170 -54.68 -53.56 53.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.851 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.3 tp -60.64 -44.18 96.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -49.92 -55.17 15.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.63 -40.77 17.9 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.451 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.7 t60 -64.95 -41.41 95.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.745 0.307 . . . . 0.0 110.868 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.7 mt -73.43 -18.34 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.123 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 61.0 tttt -108.84 1.42 20.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -120.16 -27.42 5.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.1 t -112.92 -41.69 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.533 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.8 m-70 -89.51 -22.63 22.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.876 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.9 t -40.77 129.49 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.135 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 25.1 m -164.95 174.28 10.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.821 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -111.24 141.18 45.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.883 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -136.75 144.05 45.27 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.571 0.701 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 149.79 67.34 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.654 2.236 . . . . 0.0 112.376 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 23.0 p80 -126.34 168.58 13.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -57.06 174.57 0.17 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 32.1 m -80.94 42.37 0.63 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 60.45 36.27 20.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 6.2 p -173.49 150.05 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.144 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 15.7 t-105 -57.35 -61.5 2.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . . . . . . . . . 7.2 p -122.45 133.01 69.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 36.5 t -111.87 -38.35 4.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.886 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -60.92 -158.31 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.517 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 -37.76 8.88 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.675 2.25 . . . . 0.0 112.375 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 4.8 m -171.85 167.63 6.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.846 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 40.5 t -174.13 161.9 3.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.866 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.531 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 1.8 m -134.8 176.95 8.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.844 0.355 . . . . 0.0 110.843 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 67.1 p -112.55 -54.3 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.897 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 108.03 68.74 0.65 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 19.4 m -133.38 -46.53 0.83 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.899 0.38 . . . . 0.0 110.873 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 15.5 t -62.46 132.22 51.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.91 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -138.69 -159.35 8.02 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 20.4 m -78.13 140.11 39.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 60.4 t -121.82 132.94 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.117 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -149.5 31.94 1.13 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . 0.427 ' CB ' ' O ' ' A' ' 422' ' ' PHE . 6.5 mptt -132.2 98.58 16.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 0.0 110.85 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -47.0 1.01 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.673 2.249 . . . . 0.0 112.327 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.5 m-30 -61.44 93.4 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.51 129.67 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.154 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 19.4 t -55.28 132.79 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.4 mm-40 -92.57 21.02 5.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.557 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.13 -48.5 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.83 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.7 p -115.64 -39.69 3.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 123.23 7.96 6.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . 0.424 ' HD2' ' CE1' ' A' ' 431' ' ' HIS . 34.8 mttt -58.19 179.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.427 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.11 144.32 12.43 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.448 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.427 ' O ' ' CB ' ' A' ' 411' ' ' LYS . 8.8 m-85 -138.93 -177.68 4.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.847 0.356 . . . . 0.0 110.927 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 23.9 m -112.32 -35.78 5.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.853 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.403 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 45.6 mtt180 -111.11 155.3 42.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.641 0.734 . . . . 0.0 110.831 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -29.58 23.39 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.65 2.234 . . . . 0.0 112.349 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -80.17 -32.05 38.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.859 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.403 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.9 m170 -65.2 -51.22 62.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 12.0 tp -63.53 -44.3 94.64 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -49.97 -53.04 28.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . 0.488 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.59 -39.46 23.11 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.456 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . 0.424 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.3 t60 -67.54 -42.74 82.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.7 mt -72.99 -19.39 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.109 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.484 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 32.8 tttt -108.35 1.71 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . 0.488 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 8.3 tp-100 -119.92 -28.9 5.08 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.938 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.4 t -112.8 -41.57 3.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.557 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.5 m-70 -89.16 -17.74 28.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.407 ' HB ' ' C ' ' A' ' 433' ' ' LYS . 3.5 t -47.66 132.98 13.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 53.8 m -50.77 146.51 5.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -123.99 164.89 18.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 46.9 mtm180 -70.52 144.72 91.89 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.608 0.718 . . . . 0.0 110.917 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 98.27 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.716 2.277 . . . . 0.0 112.323 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 25.7 m170 -89.42 154.52 19.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.896 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? -44.04 124.62 3.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 30.1 p -128.97 163.75 24.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -82.87 146.37 28.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . 0.439 HG12 ' N ' ' A' ' 447' ' ' TRP . 96.4 t -48.86 137.29 4.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.111 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.439 ' N ' HG12 ' A' ' 446' ' ' VAL . 29.5 t-105 -85.68 -47.67 9.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.959 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . . . . . . . . . 10.5 p -149.54 148.98 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 85.1 p -60.56 170.26 1.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.837 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -76.23 -158.19 7.88 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.485 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 148.04 64.61 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 54.8 p -158.04 162.14 38.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.876 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 49.0 m -77.67 112.29 14.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.531 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 87.4 p -169.07 124.0 0.86 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.838 0.352 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 80.7 p -157.23 156.83 33.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -125.03 131.5 7.76 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 65.6 m -132.22 112.44 12.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.86 0.362 . . . . 0.0 110.882 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 78.9 p -135.73 174.75 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 139.02 69.2 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.463 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 20.7 m -70.84 90.26 0.79 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.897 0.38 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 84.2 t -97.65 88.61 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 167.4 -68.79 0.18 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.53 119.35 76.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -46.66 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.667 2.245 . . . . 0.0 112.38 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.3 m-30 -62.46 95.3 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 17.5 mm -105.87 124.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.084 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.9 t -51.02 128.6 21.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -89.57 19.28 4.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.878 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.535 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.69 -45.72 2.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 12.9 p -117.46 -49.49 2.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.897 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.53 -1.44 3.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 26.4 mttm -54.24 174.72 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.811 0.339 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.31 146.11 16.55 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.505 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -141.14 163.09 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.905 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.58 -27.94 14.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.807 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.421 ' HG3' ' ND1' ' A' ' 427' ' ' HIS . 14.7 mtp180 -110.07 148.94 39.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.849 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -33.17 17.1 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.335 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.52 -38.43 55.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.421 ' ND1' ' HG3' ' A' ' 424' ' ' ARG . 51.2 m170 -58.26 -52.54 65.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.804 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 8.9 tp -57.84 -46.62 84.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -49.5 -52.89 26.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . 0.479 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -49.2 -40.06 28.59 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.49 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.13 -42.96 88.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.1 mt -72.73 -19.93 19.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.139 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 23.8 ttmt -107.91 1.09 22.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.92 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . 0.479 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 71.0 tp60 -119.98 -26.27 5.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.92 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.6 t -114.39 -41.41 3.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.535 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 -89.97 -19.77 24.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 3.4 t -45.35 -44.94 12.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.131 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 88.2 p -47.88 99.59 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -115.35 133.45 56.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -47.9 143.85 6.0 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.633 0.73 . . . . 0.0 110.905 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 168.8 20.46 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.693 2.262 . . . . 0.0 112.343 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 5.7 m170 -99.35 131.88 45.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -75.72 -60.43 2.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 5.0 t -171.7 164.49 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.866 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -97.73 89.67 4.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 93.9 t -137.01 138.44 45.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.442 ' O ' ' C ' ' A' ' 448' ' ' VAL . 37.8 t-105 -130.79 133.7 46.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.919 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' A' ' 447' ' ' TRP . 94.5 t -34.37 109.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.095 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 23.1 m -79.06 103.35 8.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -116.4 -94.71 1.87 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.463 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 103.7 1.19 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.694 2.263 . . . . 0.0 112.377 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 45.3 m -82.73 41.67 0.74 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 16.3 m -128.4 143.55 51.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.833 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.458 -179.962 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 74.4 p -45.1 161.0 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.876 0.369 . . . . 0.0 110.84 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 51.2 p -67.28 128.19 35.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 171.66 118.52 0.48 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 63.6 m -148.94 133.14 17.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.828 0.346 . . . . 0.0 110.853 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 1.9 t -112.32 38.9 2.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.806 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 50.64 101.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 17.1 m -74.36 120.66 20.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.915 0.388 . . . . 0.0 110.825 -179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 4.7 p -78.21 -13.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -88.73 -67.72 1.27 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 8.7 mptt -114.1 95.14 37.42 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.565 0.698 . . . . 0.0 110.936 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -46.88 1.05 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.68 2.253 . . . . 0.0 112.32 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.7 m-30 -60.38 94.13 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 16.4 mm -98.16 128.09 49.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.103 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.8 t -59.23 132.95 55.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.874 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.7 mm-40 -91.9 2.23 56.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.56 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 7.6 m -93.69 -42.5 9.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.9 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.5 p -123.7 -46.44 2.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 132.78 4.46 3.41 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.455 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 31.1 mttm -58.25 178.08 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.824 0.345 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.98 143.06 11.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -138.37 169.59 17.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 9.8 m -101.48 -28.46 12.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -113.73 154.42 45.77 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.612 0.72 . . . . 0.0 110.925 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -47.5 0.93 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.717 2.278 . . . . 0.0 112.327 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -63.88 -37.5 87.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.4 m170 -58.27 -54.27 48.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 9.4 tp -59.66 -44.11 93.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -50.52 -54.31 23.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.934 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.12 -40.38 21.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -65.52 -40.74 93.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.4 mt -74.24 -19.01 17.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.464 ' O ' ' CG2' ' A' ' 437' ' ' THR . 45.4 tttm -104.75 -4.25 22.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 45.2 tp60 -115.85 -26.27 7.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.6 t -114.78 -33.85 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.155 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.56 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.1 m-70 -102.74 15.99 27.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.464 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -89.14 -32.74 17.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.178 -179.95 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 40.6 p -95.11 -47.43 6.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -106.6 132.56 52.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -157.59 151.89 20.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.595 0.712 . . . . 0.0 110.88 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -169.35 0.32 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 50.2 m170 -78.09 133.44 37.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -88.81 140.85 29.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 18.3 m -138.94 130.19 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -83.64 79.4 9.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . 0.453 HG13 ' N ' ' A' ' 447' ' ' TRP . 9.3 p -109.19 -41.55 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.453 ' N ' HG13 ' A' ' 446' ' ' VAL . 1.4 p-90 -47.95 -34.2 8.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.42 ' CG2' ' O ' ' A' ' 447' ' ' TRP . 20.2 t -161.29 131.12 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 8.4 t -131.43 93.27 3.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.858 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 156.89 158.17 8.75 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.83 -5.35 16.04 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.659 2.24 . . . . 0.0 112.287 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 27.1 p -46.86 131.03 12.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 15.1 t -130.08 152.19 49.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 -179.926 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.491 -0.243 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 34.9 m -91.43 165.68 13.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.8 0.333 . . . . 0.0 110.89 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 48.4 t -84.89 82.01 8.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.792 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -126.44 49.03 0.94 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.49 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 27.9 m -157.95 117.02 3.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.885 0.374 . . . . 0.0 110.866 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 35.0 m -76.63 123.25 25.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -43.53 -93.42 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.6 t -126.37 173.46 9.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.945 0.402 . . . . 0.0 110.829 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 84.8 t -69.58 -61.94 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.142 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 163.08 74.3 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.11 98.49 51.51 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.552 0.691 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -47.18 0.97 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.692 2.261 . . . . 0.0 112.334 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.76 94.8 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.912 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 27.1 mm -102.94 133.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.125 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 38.4 t -57.47 128.42 36.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.896 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -85.75 22.39 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.482 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.1 t -122.98 -66.41 1.02 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.5 p -92.33 -42.55 9.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 121.86 12.53 5.4 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -65.37 -179.48 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.419 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.18 143.53 11.71 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 11.7 m-85 -139.36 163.2 33.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.855 0.36 . . . . 0.0 110.873 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.3 m -95.47 -24.51 16.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.818 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.567 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.8 mmt85 -117.99 153.16 51.04 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.629 0.728 . . . . 0.0 110.847 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -40.09 5.77 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.643 2.229 . . . . 0.0 112.356 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -69.88 -42.51 73.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.567 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 59.1 m170 -56.48 -42.82 78.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.895 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 6.5 tp -68.82 -44.55 73.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.945 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -51.97 -54.18 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.869 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.23 -40.05 21.34 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.516 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.21 -40.1 93.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.857 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.0 mt -75.33 -18.24 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.193 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 12.7 ttmt -107.15 -2.14 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.938 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -117.15 -25.46 7.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.92 -38.63 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.153 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.482 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.0 m-70 -93.33 3.77 55.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.407 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 2.8 t -81.12 -41.76 21.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 438' ' ' SER . . . . . 0.406 ' N ' HG23 ' A' ' 437' ' ' THR . 29.1 t -64.82 160.03 21.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -80.1 175.0 11.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.55 144.56 19.54 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.624 0.726 . . . . 0.0 110.819 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -171.89 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.701 2.267 . . . . 0.0 112.301 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -168.18 176.06 6.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.98 174.56 3.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 28.6 p -43.34 162.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -120.35 176.65 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 19.6 m -91.38 177.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.497 ' CD1' HG12 ' A' ' 448' ' ' VAL . 76.3 t-105 -166.5 116.96 0.95 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.497 HG12 ' CD1' ' A' ' 447' ' ' TRP . 9.1 p 33.56 40.73 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.147 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 29.7 p -89.71 84.95 6.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.821 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -119.3 -76.65 0.51 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -29.38 24.06 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.708 2.272 . . . . 0.0 112.376 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 1.4 t -56.92 146.37 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.85 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 60.3 p -81.36 48.26 1.13 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.8 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.481 179.972 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 11.7 t -173.23 157.43 3.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.871 0.367 . . . . 0.0 110.851 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 16.3 m -70.97 94.51 1.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -125.53 126.94 6.05 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 15.5 t -166.82 108.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.867 0.365 . . . . 0.0 110.84 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 45.8 t -136.09 130.07 32.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -135.49 140.2 11.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.47 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 84.2 p -87.39 86.59 7.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.878 0.37 . . . . 0.0 110.851 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 99.6 t -101.13 90.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.124 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 140.21 -83.92 0.23 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.525 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -80.57 121.97 81.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.571 0.701 . . . . 0.0 110.889 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 -47.12 1.01 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.681 2.254 . . . . 0.0 112.342 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.1 m-30 -63.31 97.18 0.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.914 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 21.5 mm -108.15 125.44 64.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.144 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.0 t -52.4 126.53 19.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 -87.32 21.48 2.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.509 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.57 -51.92 2.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.9 p -110.79 -47.09 3.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.37 11.63 2.44 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . 0.418 ' HD2' ' CE1' ' A' ' 431' ' ' HIS . 44.1 mttt -64.63 -179.4 0.49 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.76 143.21 11.16 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.46 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -139.04 159.66 41.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.891 0.377 . . . . 0.0 110.856 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.0 m -92.21 -30.16 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.414 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.2 mtp180 -112.16 154.95 44.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.639 0.733 . . . . 0.0 110.896 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -44.45 2.08 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.715 2.277 . . . . 0.0 112.316 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -66.98 -38.21 85.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.852 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.414 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.8 m170 -56.87 -49.28 75.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 6.6 tp -63.55 -45.94 88.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.896 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -49.05 -53.98 17.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.3 -41.11 31.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.527 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . 0.418 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 12.5 t60 -64.84 -40.97 96.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.787 0.327 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 20.6 mt -73.27 -20.83 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.142 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.468 ' O ' ' CG2' ' A' ' 437' ' ' THR . 0.5 OUTLIER -103.68 -2.71 26.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -114.56 -28.56 7.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.4 t -114.22 -37.51 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.509 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.9 m-70 -97.18 12.89 31.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.85 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.468 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 1.1 t -86.74 132.43 33.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 67.2 p -137.05 130.56 31.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 48.6 mm-40 -93.24 137.72 32.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -167.52 144.1 3.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.613 0.721 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -176.69 1.56 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.344 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 45.0 m80 -57.97 102.36 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.872 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.71 98.33 7.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.917 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 84.2 m -78.67 119.08 21.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -104.39 95.96 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.969 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 12.7 p -168.79 137.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.427 ' CD2' HG23 ' A' ' 448' ' ' VAL . 3.4 p-90 -110.25 -35.77 6.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.427 HG23 ' CD2' ' A' ' 447' ' ' TRP . 63.8 t -146.87 132.92 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.408 ' N ' HG12 ' A' ' 448' ' ' VAL . 20.4 p -127.01 144.82 50.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 138.7 -78.05 0.32 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.458 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 164.98 32.5 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.63 2.22 . . . . 0.0 112.372 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 46.5 t 62.64 42.95 7.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 2.7 t -86.5 158.92 19.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.861 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.514 179.973 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.519 -0.232 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 51.6 p -97.83 147.11 24.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.869 0.366 . . . . 0.0 110.884 -179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 5.7 m -139.01 154.15 48.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.843 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 126.29 95.35 0.96 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 71.1 m -114.44 150.78 34.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 43.9 m -83.53 164.18 19.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -132.36 -147.02 5.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.499 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 408' ' ' SER . . . . . 0.487 ' O ' ' N ' ' A' ' 410' ' ' GLY . 86.8 p -120.43 -49.41 2.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . 0.4 ' C ' ' O ' ' A' ' 408' ' ' SER . 8.3 p 37.98 27.5 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 408' ' ' SER . . . -162.53 -105.19 0.19 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.49 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -85.87 119.78 72.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.612 0.72 . . . . 0.0 110.876 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -47.87 0.83 Allowed 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.679 2.252 . . . . 0.0 112.364 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -61.25 93.98 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 11.7 mm -102.07 128.74 54.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 7.7 t -60.19 121.12 11.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 10.1 mm-40 -80.63 -4.19 53.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.567 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 3.2 m -86.95 -45.14 11.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.4 p -121.02 -49.09 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.61 0.77 2.86 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.501 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 35.8 mttm -55.48 -179.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.842 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.31 147.56 18.44 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 5.3 m-85 -143.96 157.41 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.7 m -90.91 -21.92 21.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.411 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 13.3 mtp85 -120.95 155.52 57.56 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 0.0 110.858 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -48.74 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.701 2.268 . . . . 0.0 112.344 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -63.0 -36.28 83.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.411 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 56.1 m170 -58.85 -52.82 64.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 14.0 tp -61.47 -42.86 99.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -51.22 -55.05 20.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.888 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -46.86 -42.77 15.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -63.36 -43.28 98.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.785 0.326 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -72.33 -15.96 18.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.104 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.492 ' O ' ' CG2' ' A' ' 437' ' ' THR . 14.2 ttpp -105.26 -7.59 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -114.29 -22.97 9.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.86 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.6 t -116.53 -36.94 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.567 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.7 m-70 -98.99 13.69 31.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.492 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 1.3 t -87.58 149.47 24.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 23.1 t 66.05 35.09 6.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -83.5 -176.27 6.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . 0.408 ' HD2' ' N ' ' A' ' 440' ' ' ARG . 3.2 mpt_? -105.27 148.37 36.14 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.591 0.71 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 442' ' ' HIS . 54.0 Cg_endo -69.79 -5.31 15.92 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.644 2.229 . . . . 0.0 112.372 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . 0.429 ' C ' ' O ' ' A' ' 441' ' ' PRO . 5.5 t-80 -35.17 147.65 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.876 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -135.88 149.11 48.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 19.8 t -58.78 96.71 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 26.8 tp60 -54.6 108.66 0.41 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 447' ' ' TRP . 98.7 t -104.49 133.21 49.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.453 ' CD1' ' N ' ' A' ' 448' ' ' VAL . 46.8 p90 -83.55 -49.78 8.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.908 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.453 ' N ' ' CD1' ' A' ' 447' ' ' TRP . 14.6 p -105.43 137.78 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.132 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 50.3 m 52.15 41.44 30.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -97.72 -95.16 1.94 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 138.08 37.07 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 80.3 p -44.04 -50.28 8.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 453' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 454' ' ' GLY . 12.7 t -54.94 -66.17 0.45 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.853 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 453' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.466 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 21.3 m -158.78 177.2 11.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.865 0.364 . . . . 0.0 110.834 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 7.4 t -89.75 42.5 1.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.83 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 53.69 -158.04 5.06 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 31.1 t -71.78 90.93 1.11 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.895 0.378 . . . . 0.0 110.882 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 24.6 t -117.33 98.17 6.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.881 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -102.45 47.24 1.15 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.509 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 82.6 p -97.25 42.66 1.08 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.895 0.379 . . . . 0.0 110.859 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 34.5 m -116.79 144.85 23.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -82.2 -67.67 1.49 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.49 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -54.7 117.81 14.91 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.606 0.717 . . . . 0.0 110.931 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -48.35 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.66 2.24 . . . . 0.0 112.371 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.74 89.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 19.3 mm -100.52 126.82 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.105 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 15.5 t -53.99 131.52 40.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 5.3 mm-40 -91.63 21.31 4.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.565 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.08 -46.24 2.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.843 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 17.9 p -117.97 -47.86 2.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 134.49 2.38 3.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.469 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 22.1 mttm -55.97 176.24 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.28 144.24 12.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 17.2 m-85 -140.04 169.14 18.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.866 0.365 . . . . 0.0 110.87 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -103.03 -26.49 13.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.871 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.426 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 14.4 mtt-85 -112.1 149.51 41.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.591 0.71 . . . . 0.0 110.888 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -31.69 19.8 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.712 2.275 . . . . 0.0 112.347 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -78.73 -36.5 43.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.426 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 48.4 m170 -59.46 -53.32 59.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.864 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.38 -47.23 84.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.921 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.57 -52.8 27.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.39 -41.99 33.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -63.37 -40.78 98.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.778 0.323 . . . . 0.0 110.897 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -71.79 -22.92 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.485 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.8 tttm -102.83 1.8 34.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 72.0 tp60 -119.83 -27.66 5.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.5 t -114.92 -42.41 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.104 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.565 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.2 m-70 -89.66 -3.19 58.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 5.3 t -67.53 88.63 0.22 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 34.6 t -121.34 -46.96 2.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -103.92 171.61 7.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -150.48 145.92 19.13 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.609 0.719 . . . . 0.0 110.896 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 84.21 0.67 Allowed 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.642 2.228 . . . . 0.0 112.336 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . 0.411 ' NE2' ' O ' ' A' ' 443' ' ' LYS . 11.4 t-80 -83.24 155.03 23.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . 0.411 ' O ' ' NE2' ' A' ' 442' ' ' HIS . 1.4 pmtp? -124.44 152.65 43.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 84.8 m -68.76 122.02 17.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -64.33 135.44 56.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 11.6 p -127.61 127.66 68.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.135 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.514 ' CD2' HG21 ' A' ' 448' ' ' VAL . 16.0 t-105 -66.9 -53.07 35.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.958 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.514 HG21 ' CD2' ' A' ' 447' ' ' TRP . 94.2 t -159.4 136.38 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.455 ' CB ' ' HB3' ' A' ' 452' ' ' SER . 69.6 m -52.5 174.21 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -110.07 -87.23 1.8 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.463 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.91 3.12 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.675 2.25 . . . . 0.0 112.367 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 452' ' ' SER . . . . . 0.455 ' HB3' ' CB ' ' A' ' 449' ' ' SER . 11.0 p -39.48 159.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.811 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 22.7 m -64.08 177.99 0.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.439 -0.264 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.8 t -91.82 42.19 1.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 66.9 m -101.13 86.11 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -77.16 91.33 1.02 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 72.9 m -79.45 128.51 33.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.863 0.363 . . . . 0.0 110.844 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 95.7 p -164.26 145.6 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 136.78 170.51 11.96 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 53.6 p -164.73 135.3 4.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.808 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 72.1 t -106.93 130.44 58.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.148 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 145.76 -52.25 0.58 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . 0.443 ' HE3' ' N ' ' A' ' 411' ' ' LYS . 0.0 OUTLIER -88.65 110.2 35.31 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -49.06 0.6 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.21 95.49 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 13.2 mm -104.0 127.04 58.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.8 t -52.94 127.81 25.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 6.7 mm-40 -88.06 21.86 2.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.524 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.11 -51.25 2.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.2 p -112.36 -46.39 3.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.49 9.61 2.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.482 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 31.9 mttm -62.81 -179.52 0.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -145.19 142.09 10.48 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -137.51 164.39 28.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.871 0.367 . . . . 0.0 110.856 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.4 m -96.11 -28.37 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.876 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.569 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.5 mmt180 -114.56 152.83 46.57 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.576 0.703 . . . . 0.0 110.886 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -38.05 8.33 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.687 2.258 . . . . 0.0 112.349 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.22 -40.16 71.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.569 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 45.4 m170 -58.37 -44.59 88.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 5.3 tp -66.16 -45.3 81.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.942 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -51.37 -55.26 19.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.52 -40.66 16.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -64.3 -40.59 96.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.809 0.338 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 14.0 mt -72.85 -23.82 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.442 ' O ' ' CG2' ' A' ' 437' ' ' THR . 58.2 tttt -101.76 -1.99 31.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -115.77 -27.86 6.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.86 -36.88 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.524 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 -98.74 15.34 25.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.442 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -88.96 145.54 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.888 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 438' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 437' ' ' THR . 25.5 t -34.55 148.89 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.898 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -55.79 163.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -135.68 145.91 55.1 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.586 0.707 . . . . 0.0 110.856 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 151.34 68.83 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.636 2.224 . . . . 0.0 112.373 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -108.48 -50.13 3.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.872 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 5.7 mtpm? -119.66 37.15 4.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.916 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 2.5 m -131.92 93.11 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -122.26 42.07 3.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.913 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 58.3 t -132.36 133.78 59.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.448 ' CG ' ' N ' ' A' ' 448' ' ' VAL . 4.6 p-90 -88.07 -42.61 12.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.962 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.448 ' N ' ' CG ' ' A' ' 447' ' ' TRP . 13.5 p -80.65 126.49 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.115 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 5.9 m -128.12 135.58 49.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.79 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -124.2 -94.94 1.1 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.511 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -50.73 0.43 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.726 2.284 . . . . 0.0 112.325 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 81.0 p -175.02 176.92 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 41.7 t -67.57 -56.25 10.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.842 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.456 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 79.0 p -124.28 163.22 22.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.822 0.344 . . . . 0.0 110.883 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 56.9 p -69.88 -51.28 34.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.846 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 69.02 -169.86 42.04 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.523 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 89.5 p -137.09 109.01 7.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.898 0.38 . . . . 0.0 110.855 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 24.6 t -132.39 139.91 48.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.868 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 87.6 82.02 1.22 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.496 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.6 m -84.45 104.4 14.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.952 0.406 . . . . 0.0 110.868 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 3.8 p -173.48 141.01 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.174 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 117.92 -146.64 18.65 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 6.0 mptt -86.87 121.27 71.84 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.551 0.691 . . . . 0.0 110.895 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -48.76 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.676 2.251 . . . . 0.0 112.349 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.32 90.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 18.9 mm -101.75 127.24 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.128 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 9.5 t -53.16 127.67 25.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.882 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.6 mm-40 -88.35 17.96 4.83 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.57 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.6 m -113.44 -42.88 3.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.6 p -121.92 -49.75 2.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.861 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 138.47 -1.06 2.61 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 39.2 mttt -52.69 179.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.816 0.341 . . . . 0.0 110.881 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.407 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -148.87 144.76 12.57 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.49 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 16.2 m-85 -140.01 165.04 28.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.856 0.36 . . . . 0.0 110.832 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.1 m -94.81 -33.59 12.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.412 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 19.7 mtp180 -109.3 155.25 41.42 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.613 0.721 . . . . 0.0 110.84 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -44.5 2.01 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.695 2.264 . . . . 0.0 112.32 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -65.5 -40.51 93.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.855 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.412 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 57.0 m170 -55.39 -51.12 67.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.907 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.14 -46.27 89.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -49.2 -54.12 18.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.02 -39.91 26.98 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -65.3 -39.04 91.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.846 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -75.27 -18.07 16.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.2 OUTLIER -107.28 -2.01 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.912 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 39.9 tp60 -116.36 -27.01 6.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.919 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 30.5 t -114.95 -40.41 3.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.57 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.4 m-70 -93.18 14.55 17.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.813 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.3 t -90.03 100.82 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 87.1 p -55.3 -46.35 76.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.818 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -127.75 138.23 52.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.39 144.99 83.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.668 0.747 . . . . 0.0 110.851 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 109.4 2.31 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.674 2.25 . . . . 0.0 112.33 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . 0.532 ' O ' ' CD2' ' A' ' 442' ' ' HIS . 0.1 OUTLIER -119.54 130.91 55.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.882 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -103.97 73.53 1.16 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.946 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 6.7 t -168.77 105.29 0.42 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.903 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -151.87 139.48 19.7 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.903 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 14.9 p -170.21 152.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.467 ' CE2' HG11 ' A' ' 448' ' ' VAL . 75.8 t-105 -138.62 146.06 41.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.93 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.467 HG11 ' CE2' ' A' ' 447' ' ' TRP . 7.5 p -34.09 137.68 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.42 ' N ' HG21 ' A' ' 448' ' ' VAL . 21.9 t -128.1 91.0 3.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 56.12 -155.4 12.96 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . 0.455 ' O ' ' C ' ' A' ' 452' ' ' SER . 53.4 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.691 2.261 . . . . 0.0 112.314 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 452' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 451' ' ' PRO . 13.4 t -34.32 130.85 0.34 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.822 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 7.6 t -61.91 133.15 55.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.889 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.5 m -140.08 113.61 8.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.939 0.4 . . . . 0.0 110.867 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 55.1 p -67.89 163.73 21.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -178.62 61.47 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.51 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 7.5 t -118.25 110.72 17.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.842 0.353 . . . . 0.0 110.844 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 33.1 t -152.17 132.24 13.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -132.55 -59.99 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 29.5 t -55.89 143.99 29.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.896 0.379 . . . . 0.0 110.862 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 26.8 m -74.25 141.35 16.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -151.3 -164.06 11.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . 0.465 ' HE3' ' N ' ' A' ' 411' ' ' LYS . 0.0 OUTLIER -50.82 107.56 0.84 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.525 0.679 . . . . 0.0 110.874 -179.963 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -49.67 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.624 2.216 . . . . 0.0 112.344 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -58.54 90.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 10.9 mm -98.54 128.58 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.8 t -56.77 129.38 41.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 40.3 mm-40 -88.53 20.29 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.567 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.65 -44.84 2.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.3 p -121.59 -46.5 2.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.51 -8.16 3.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.512 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.5 mttt -46.34 170.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -140.91 144.03 14.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -138.1 170.37 16.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 110.881 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 36.9 m -100.23 -34.16 10.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.567 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 83.9 mtt-85 -107.92 155.0 40.74 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.602 0.715 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -46.18 1.3 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.705 2.27 . . . . 0.0 112.298 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.5 -36.25 83.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.567 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 54.6 m170 -58.65 -51.7 68.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.0 tp -62.27 -44.39 96.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -50.77 -53.38 32.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.57 -40.95 25.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -64.37 -40.75 96.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.816 0.341 . . . . 0.0 110.833 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.0 mt -73.57 -16.97 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.129 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 55.9 tttt -107.9 -1.25 20.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -117.9 -25.78 6.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.09 -39.28 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.567 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.7 m-70 -95.32 14.45 22.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.854 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.3 t -89.96 99.89 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.109 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 68.2 m -133.13 -176.15 4.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.878 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -82.49 148.23 28.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.874 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 29.3 mtt-85 -121.68 150.54 55.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.595 0.712 . . . . 0.0 110.858 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 177.17 5.85 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.679 2.253 . . . . 0.0 112.354 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 13.0 p-80 -51.54 103.49 0.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 444' ' ' CYS . 0.3 OUTLIER -166.8 111.88 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.89 179.98 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 443' ' ' LYS . 27.7 p -34.8 127.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.856 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -110.21 40.87 1.85 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 3.0 m -109.03 -174.98 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.114 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.529 ' CD1' HG11 ' A' ' 448' ' ' VAL . 2.0 p-90 -131.98 -40.64 1.04 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.529 HG11 ' CD1' ' A' ' 447' ' ' TRP . 5.9 p -103.74 -41.85 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.116 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.45 ' N ' HG12 ' A' ' 448' ' ' VAL . 89.1 p -172.0 172.33 4.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -55.36 -93.37 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.452 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.57 3.62 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.647 2.231 . . . . 0.0 112.359 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 7.3 t -81.36 179.82 7.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.837 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 15.9 m -114.98 -49.47 2.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.863 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.952 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.377 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.4 m -84.21 45.73 1.14 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.859 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 2.4 m -135.29 150.82 50.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -128.51 -89.89 0.63 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.524 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 77.8 p -66.6 91.97 0.2 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.898 0.38 . . . . 0.0 110.868 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 5.1 t -124.07 41.66 3.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 168.2 -104.17 0.21 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.458 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 408' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 409' ' ' VAL . 30.4 t -48.86 147.97 2.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.902 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . 0.447 ' C ' ' O ' ' A' ' 408' ' ' SER . 10.2 p 34.33 39.38 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -76.16 -178.92 45.6 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.33 118.67 72.25 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.549 0.69 . . . . 0.0 110.932 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -47.59 0.9 Allowed 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.712 2.275 . . . . 0.0 112.38 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.41 97.88 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 21.6 mm -108.13 130.56 60.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -55.91 123.51 14.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.855 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -86.08 20.24 2.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 417' ' ' SER . . . . . . . . . . . . . 1.8 m -117.17 -46.74 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.864 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.6 p -115.99 -46.53 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.15 10.6 2.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . 0.427 ' HD2' ' CE1' ' A' ' 431' ' ' HIS . 32.2 mttt -64.31 -179.75 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.857 0.361 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.16 142.88 10.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -138.87 162.02 35.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.908 0.385 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.7 m -93.24 -32.33 14.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.481 ' HE ' ' CE1' ' A' ' 427' ' ' HIS . 21.1 mtm180 -112.37 155.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -42.01 3.86 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.282 . . . . 0.0 112.38 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.27 -38.85 85.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.481 ' CE1' ' HE ' ' A' ' 424' ' ' ARG . 51.7 m170 -58.41 -49.24 77.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 6.5 tp -62.68 -45.92 90.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -50.04 -55.29 15.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.852 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.43 -39.44 14.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . 0.427 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.9 t60 -66.54 -41.38 88.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.767 0.317 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 16.2 mt -74.17 -15.65 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.451 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 1.1 ttmp? -110.9 0.89 17.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 61.1 tp60 -119.05 -25.73 6.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.937 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 33.7 t -116.7 -42.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.1 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -89.06 -18.14 27.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 2.6 t -44.02 148.8 0.38 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.164 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 1.4 m 73.12 51.92 0.13 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . 0.417 ' C ' ' HD2' ' A' ' 440' ' ' ARG . 8.0 pt-20 -149.54 147.29 28.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . 0.417 ' HD2' ' C ' ' A' ' 439' ' ' GLU . 2.3 mpt_? -144.62 144.59 25.33 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.673 0.749 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 442' ' ' HIS . 53.6 Cg_endo -69.78 0.44 5.65 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.717 2.278 . . . . 0.0 112.313 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 441' ' ' PRO . 5.7 t60 -36.56 -41.54 0.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.853 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 11.4 mptt -80.61 48.0 1.01 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 1.8 t -141.8 158.94 43.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -110.02 79.94 1.26 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 7.9 p -103.17 142.9 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.446 ' CD1' ' N ' ' A' ' 448' ' ' VAL . 43.9 p90 -73.36 -47.83 39.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.917 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.446 ' N ' ' CD1' ' A' ' 447' ' ' TRP . 5.2 p -94.41 136.43 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 1.8 t -54.21 -69.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 152.98 145.86 4.24 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.473 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 452' ' ' SER . 53.5 Cg_endo -69.76 2.15 3.79 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.713 2.276 . . . . 0.0 112.324 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 452' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 451' ' ' PRO . 1.4 t -34.65 102.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.82 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 70.0 m -107.1 49.35 0.8 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.84 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.516 179.964 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 97.4 p -130.31 106.42 8.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.844 0.355 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 86.9 p -164.83 173.38 11.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 174.92 52.08 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.546 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 41.1 t -171.98 133.9 0.74 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.832 0.349 . . . . 0.0 110.862 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 5.9 t -142.6 129.44 20.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -156.76 114.92 0.63 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 408' ' ' SER . . . . . 0.509 ' O ' ' C ' ' A' ' 409' ' ' VAL . 48.0 m -74.47 -41.16 61.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 110.833 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . 0.509 ' C ' ' O ' ' A' ' 408' ' ' SER . 6.8 m 29.03 46.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 152.68 178.6 27.49 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.491 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -45.99 118.1 4.24 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.551 0.691 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -47.02 1.03 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -62.67 95.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.938 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 28.9 mm -105.73 132.26 53.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.6 t -57.17 126.69 28.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -86.28 21.13 2.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.515 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.22 -55.83 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.836 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.3 p -106.78 -44.53 4.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.03 9.79 3.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 31.1 mttm -62.87 -179.79 0.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.828 0.347 . . . . 0.0 110.876 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.4 144.64 13.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.424 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 10.7 m-85 -139.26 160.93 38.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 54.2 m -91.67 -32.72 15.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.48 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 26.4 mtt-85 -111.28 154.51 43.61 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.581 0.705 . . . . 0.0 110.877 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -42.62 3.24 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 36.9 t0 -66.77 -38.65 86.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.48 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -57.99 -49.5 76.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.51 -44.42 94.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -49.81 -52.84 29.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 434' ' ' GLN . . . -49.76 -43.5 38.42 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.513 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -63.34 -40.5 97.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 110.865 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 20.4 mt -74.78 -18.72 16.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.478 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.6 tttp -109.82 0.96 19.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.895 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . 0.42 ' N ' ' O ' ' A' ' 430' ' ' GLY . 54.1 tp60 -119.44 -25.8 5.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.9 t -116.39 -40.34 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.179 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.515 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 77.5 m-70 -92.47 9.17 35.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.9 t -87.76 -38.97 15.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.106 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 70.1 m -51.78 116.65 2.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.872 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -52.18 141.14 19.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.882 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 18.7 mtt-85 -132.15 154.52 81.69 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.587 0.708 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 179.71 3.53 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.657 2.238 . . . . 0.0 112.364 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 63.9 t-80 -127.62 144.65 51.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.861 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.51 148.09 16.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.938 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 42.4 t -55.9 109.01 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.823 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 -65.9 176.0 1.78 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . 0.428 HG22 ' N ' ' A' ' 447' ' ' TRP . 12.5 p -71.59 152.91 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.081 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.432 ' O ' ' C ' ' A' ' 448' ' ' VAL . 45.0 t-105 -90.38 139.57 30.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 447' ' ' TRP . 70.8 t -34.4 128.91 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.146 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 5.9 t -38.95 -54.54 1.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 135.73 -81.78 0.29 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 92.75 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.273 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 452' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 453' ' ' SER . 21.8 t -76.34 -51.33 12.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.87 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 453' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 452' ' ' SER . 2.1 t -35.36 113.21 0.19 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 179.979 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 4.1 t -96.69 137.45 35.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.908 0.385 . . . . 0.0 110.88 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 3.2 t -124.22 169.61 11.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -114.87 -154.0 10.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.509 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 57.9 m -117.53 134.13 55.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.883 0.373 . . . . 0.0 110.839 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 46.3 m -140.24 155.59 46.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 173.0 140.07 3.05 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.472 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 38.6 m -118.92 130.42 55.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.938 0.399 . . . . 0.0 110.867 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.17 147.91 5.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.134 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 156.68 -73.48 0.23 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.473 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.92 124.3 88.34 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.562 0.696 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -48.8 0.64 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.665 2.243 . . . . 0.0 112.294 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -61.02 90.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.947 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 19.5 mm -103.25 130.5 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.137 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.5 t -57.6 126.72 28.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -86.91 20.9 2.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 417' ' ' SER . . . . . . . . . . . . . 1.7 m -117.48 -52.41 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.816 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.4 p -110.75 -45.52 3.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.889 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.6 11.69 2.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.474 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -64.59 179.88 0.57 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.824 0.345 . . . . 0.0 110.927 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.13 142.73 10.81 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.401 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 9.9 m-85 -137.96 162.4 34.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.893 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 15.8 m -94.67 -30.6 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.834 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.406 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 35.7 mtp85 -111.16 154.54 43.51 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.616 0.722 . . . . 0.0 110.865 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 -45.65 1.47 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.685 2.256 . . . . 0.0 112.321 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.46 -40.28 93.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.406 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 53.1 m170 -54.84 -51.16 66.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.845 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 9.2 tp -62.34 -45.05 94.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -50.27 -55.68 14.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.21 -38.21 18.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -67.26 -40.79 86.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.747 0.308 . . . . 0.0 110.841 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 18.5 mt -74.3 -20.53 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.442 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 49.5 tttt -106.87 -0.82 23.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . 0.474 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.7 tp-100 -116.7 -27.6 6.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 32.1 t -114.96 -39.88 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . . . . . . . . . 82.9 m-70 -93.47 11.36 28.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.905 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.4 t -86.4 128.07 34.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 30.7 m -53.87 111.25 0.71 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -166.71 123.97 1.3 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -142.14 147.38 43.88 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.548 0.69 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 161.58 45.38 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.627 2.218 . . . . 0.0 112.349 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 17.8 m-70 -108.08 42.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.845 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -117.34 86.4 2.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 18.9 p -164.3 156.34 16.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.57 112.52 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 13.6 p -95.46 146.84 6.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.147 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.599 ' CH2' ' O ' ' A' ' 448' ' ' VAL . 0.1 OUTLIER -128.91 141.27 51.33 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.599 ' O ' ' CH2' ' A' ' 447' ' ' TRP . 3.9 m -34.42 98.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.122 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.442 ' HB2' ' CZ3' ' A' ' 447' ' ' TRP . 42.7 t -126.71 86.71 2.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.848 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 141.2 -94.98 0.19 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 98.57 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.631 2.221 . . . . 0.0 112.387 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 68.6 p -81.85 40.9 0.63 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 71.2 p -134.5 165.97 23.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.497 -179.955 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 55.3 p -129.44 147.17 51.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 0.0 110.844 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 40.9 m -79.95 173.03 13.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 136.94 102.72 0.64 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 26.0 p -171.82 145.87 1.99 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 32.3 m -105.56 152.05 23.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -161.39 165.91 35.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 80.7 p -138.97 128.51 24.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.967 0.413 . . . . 0.0 110.884 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 35.2 m -141.59 154.5 19.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.116 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -126.74 52.61 0.81 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.496 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -133.19 107.22 12.34 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.538 0.685 . . . . 0.0 110.922 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -48.04 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.718 2.279 . . . . 0.0 112.365 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -60.92 93.69 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 19.2 mm -100.79 131.51 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.138 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.9 t -56.57 125.29 21.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -86.1 20.29 2.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.572 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.61 -43.08 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.3 p -122.06 -46.99 2.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 135.4 -1.69 3.72 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 40.0 mttt -51.67 179.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.868 0.366 . . . . 0.0 110.872 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -147.41 142.97 10.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -138.28 163.88 30.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.83 0.348 . . . . 0.0 110.93 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 423' ' ' SER . . . . . 0.451 ' O ' ' NH1' ' A' ' 424' ' ' ARG . 3.1 m -96.39 -22.75 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.82 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.574 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 7.8 mmt-85 -119.22 152.95 53.05 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 110.873 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . 0.4 ' O ' ' OD1' ' A' ' 429' ' ' ASN . 53.6 Cg_endo -69.73 -41.99 3.82 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.692 2.262 . . . . 0.0 112.34 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -69.14 -42.02 76.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.574 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 58.8 m170 -55.22 -46.48 75.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.852 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 8.8 tp -65.92 -44.99 83.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 425' ' ' PRO . 16.6 m120 -50.16 -54.81 18.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.71 -43.16 21.95 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.513 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -62.98 -41.65 99.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.876 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 20.0 mt -73.42 -15.92 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.135 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.498 ' O ' ' CG2' ' A' ' 437' ' ' THR . 16.2 ttpp -105.11 -8.43 18.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -112.93 -24.28 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.34 -36.18 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.572 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 79.7 m-70 -100.82 17.81 21.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.498 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 0.7 OUTLIER -90.01 90.53 8.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.171 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 37.4 p -164.36 173.74 11.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -86.48 131.54 34.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 77.4 mtt180 -140.47 150.51 61.05 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.632 0.729 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 90.44 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.715 2.276 . . . . 0.0 112.292 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -97.49 129.15 44.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.878 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 44.3 mmtt -57.56 162.62 2.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 74.7 m -64.17 82.72 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.887 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . 0.403 ' O ' ' CD ' ' A' ' 445' ' ' GLN . 0.8 OUTLIER -90.06 38.63 0.93 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.9 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 447' ' ' TRP . 7.1 p -158.17 139.75 5.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.5 ' CD2' HG22 ' A' ' 448' ' ' VAL . 18.3 t-105 -35.33 -64.74 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.5 HG22 ' CD2' ' A' ' 447' ' ' TRP . 96.3 t -144.81 116.02 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 35.5 t -100.28 -45.62 5.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.889 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 174.22 163.13 27.08 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 131.0 20.38 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.702 2.268 . . . . 0.0 112.35 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 90.3 p -135.5 113.2 10.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.853 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 44.0 t -61.83 -44.71 96.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.495 -180.0 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 40.8 m -59.66 110.97 1.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.866 0.365 . . . . 0.0 110.884 -179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 82.4 p -98.4 161.45 13.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.873 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -141.52 -115.06 1.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.528 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 73.7 m -117.22 127.25 53.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.863 0.364 . . . . 0.0 110.875 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 42.5 p -74.67 -48.13 27.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.858 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -176.0 -126.55 0.96 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.476 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.0 t -142.37 143.99 32.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.961 0.41 . . . . 0.0 110.837 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 34.9 m -64.69 164.59 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 128.43 -93.37 0.35 Allowed Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.467 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.37 113.95 64.06 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.573 0.702 . . . . 0.0 110.902 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -48.89 0.63 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.323 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -59.2 94.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 13.5 mm -105.33 123.86 59.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.096 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.1 t -50.95 127.72 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.863 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -88.56 19.23 4.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.904 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.556 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -114.59 -45.92 2.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.2 p -118.62 -49.34 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.72 1.19 2.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 36.4 mttt -55.12 173.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.907 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.403 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -142.41 145.64 15.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.403 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 21.3 m-85 -141.12 167.99 20.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 69.2 m -98.57 -33.63 10.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.859 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.41 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 38.0 mtp180 -110.37 155.15 42.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.654 0.74 . . . . 0.0 110.852 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -37.24 9.32 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.04 -35.3 69.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.819 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.41 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 63.5 m170 -60.66 -52.66 64.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.8 tp -62.34 -46.04 90.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.911 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.2 -53.66 20.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.13 -40.19 20.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.48 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -66.4 -42.52 87.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.771 0.319 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -72.38 -19.42 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.122 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 46.6 tttm -107.91 2.11 23.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . 0.409 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 13.1 tp60 -120.96 -25.33 5.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.0 t -116.43 -41.74 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.556 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.3 m-70 -89.17 -26.21 21.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.447 ' C ' ' O ' ' A' ' 436' ' ' HIS . 6.3 t -33.9 146.68 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 23.5 m 66.09 54.55 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -78.18 177.36 8.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -114.87 148.51 40.63 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.577 0.703 . . . . 0.0 110.853 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . 0.453 ' O ' ' CD2' ' A' ' 442' ' ' HIS . 53.7 Cg_endo -69.76 92.69 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.695 2.263 . . . . 0.0 112.312 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . 0.453 ' CD2' ' O ' ' A' ' 441' ' ' PRO . 16.7 m170 -161.85 179.0 8.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.836 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 442' ' ' HIS . 8.2 ptpp? 34.84 44.0 0.11 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 56.7 m -105.39 121.78 44.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.855 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 57.2 tp60 -108.39 87.54 2.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 86.2 t -141.98 133.2 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.514 ' CE2' HG13 ' A' ' 448' ' ' VAL . 9.2 p90 -89.12 -42.94 11.4 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.514 HG13 ' CE2' ' A' ' 447' ' ' TRP . 35.7 m -59.69 -178.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.107 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 84.3 p -131.55 100.82 5.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 179.45 138.54 3.33 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 163.12 39.43 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 0.0 112.34 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 31.0 m -66.6 -44.62 81.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.84 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 31.1 t -162.97 150.91 13.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.453 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 20.0 m -97.33 120.51 37.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.917 0.389 . . . . 0.0 110.785 -179.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 2.7 m -146.12 125.74 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.84 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -137.49 -153.15 6.27 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.483 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 1.8 m 43.44 47.88 6.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.864 0.364 . . . . 0.0 110.849 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 29.5 t -104.32 120.61 41.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 66.27 -178.15 14.37 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.475 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 66.4 m -121.8 163.7 18.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.888 0.375 . . . . 0.0 110.884 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 67.8 t -72.28 104.88 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.163 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -137.38 -84.9 0.15 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.451 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . 0.462 ' CG ' ' C ' ' A' ' 422' ' ' PHE . 12.5 mptt -48.16 105.65 0.52 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.521 0.676 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -48.5 0.71 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.68 2.253 . . . . 0.0 112.381 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.09 91.56 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 18.8 mm -98.22 124.82 51.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.15 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -49.89 127.6 16.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 67.1 mm-40 -89.12 20.93 3.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.542 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.72 -45.35 2.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 19.6 p -120.36 -46.56 2.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.864 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.19 -0.48 3.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.438 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 27.7 mttm -51.29 176.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.338 . . . . 0.0 110.89 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.59 146.22 16.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.494 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . 0.462 ' C ' ' CG ' ' A' ' 411' ' ' LYS . 14.3 m-85 -142.46 -179.73 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.896 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 27.9 m -110.77 -34.29 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.444 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 80.1 mtt-85 -111.37 154.54 43.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.569 0.7 . . . . 0.0 110.889 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -33.62 16.3 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.654 2.236 . . . . 0.0 112.355 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -76.42 -31.77 58.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.444 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -65.8 -51.34 59.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.882 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 12.7 tp -64.16 -43.42 95.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -51.92 -50.36 61.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.91 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -51.71 -39.74 47.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.496 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -65.71 -40.6 92.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.895 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 10.7 mt -71.44 -22.42 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -99.95 -1.04 38.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.938 179.854 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -115.76 -31.25 5.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.908 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.11 -38.27 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.137 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.542 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 -95.65 13.13 27.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.8 t -88.81 146.51 24.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 438' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 439' ' ' GLU . 1.5 t -167.71 159.31 11.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 438' ' ' SER . 6.8 pt-20 -37.22 141.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 8.4 mmp_? -69.47 146.51 96.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 110.858 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -2.55 10.4 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.641 2.227 . . . . 0.0 112.34 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -104.12 102.39 12.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -151.91 107.63 3.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 32.9 m -135.19 172.55 12.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -84.33 44.16 1.01 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.912 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 32.2 m -90.9 -40.75 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.466 ' CG ' ' N ' ' A' ' 448' ' ' VAL . 2.4 p-90 -46.71 -42.69 17.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.901 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.466 ' N ' ' CG ' ' A' ' 447' ' ' TRP . 56.1 t -155.2 141.88 11.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.419 ' N ' HG12 ' A' ' 448' ' ' VAL . 9.1 m -45.17 155.78 0.12 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 177.46 139.34 3.3 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.476 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 108.55 2.1 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.716 2.277 . . . . 0.0 112.36 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 8.6 t -98.14 80.38 2.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.81 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 3.5 t -145.62 118.48 8.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.837 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.989 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.504 -0.239 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 71.2 m -95.16 114.73 26.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.833 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 57.6 p -114.22 129.81 56.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.827 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -93.76 -129.32 5.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 37.3 p -162.96 122.1 2.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.904 0.383 . . . . 0.0 110.817 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 2.9 t -87.62 106.35 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.898 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -113.91 68.36 0.25 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.515 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 47.8 t -71.44 124.05 23.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.88 0.371 . . . . 0.0 110.876 -179.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 97.2 t -71.37 113.35 7.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.158 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -132.65 -64.92 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 11.8 mptt -115.17 99.05 51.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.601 0.715 . . . . 0.0 110.883 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 -48.47 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.651 2.234 . . . . 0.0 112.301 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -58.57 92.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 16.2 mm -95.78 133.64 36.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.143 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.1 t -60.62 124.36 20.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -84.76 16.6 3.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.537 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.2 m -112.63 -45.08 3.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 13.3 p -120.22 -47.75 2.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.58 -4.19 3.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.517 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 34.9 mttt -50.43 175.25 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.366 . . . . 0.0 110.867 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.26 141.47 10.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -135.9 168.04 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.838 0.351 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 42.2 m -98.54 -31.02 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.886 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.407 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.8 mtt180 -113.12 155.32 44.51 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.725 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -45.39 1.58 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.332 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -65.1 -36.64 84.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.407 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 51.9 m170 -59.52 -51.41 69.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 13.9 tp -62.9 -45.78 90.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -48.48 -53.86 16.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.92 -42.09 29.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.48 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 14.3 t60 -64.14 -39.78 94.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.82 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 17.2 mt -75.39 -18.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.45 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 33.2 tttt -108.28 -0.82 20.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.91 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -117.75 -27.04 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.1 t -114.93 -36.82 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.537 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 -95.12 7.41 46.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.851 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 2.2 t -86.04 -41.57 14.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 6.2 t -64.37 170.29 3.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -96.15 139.16 32.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 42.0 mtm180 -80.58 153.51 73.46 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.573 0.702 . . . . 0.0 110.904 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -15.63 37.26 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.682 2.255 . . . . 0.0 112.343 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -74.57 -39.02 62.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 10.8 mmmt -104.16 83.7 2.12 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.935 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 24.2 p -114.76 171.88 7.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . 0.415 ' HA ' ' NE2' ' A' ' 445' ' ' GLN . 8.8 mm-40 -69.33 172.72 6.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 90.6 t -67.28 144.52 14.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.109 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.59 ' CH2' ' O ' ' A' ' 448' ' ' VAL . 0.1 OUTLIER -147.17 140.81 25.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.59 ' O ' ' CH2' ' A' ' 447' ' ' TRP . 5.1 m -35.47 100.1 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.069 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.41 ' HA ' ' CZ3' ' A' ' 447' ' ' TRP . 10.1 p -128.62 164.76 22.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -116.79 -76.91 0.61 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.483 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 92.81 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.682 2.254 . . . . 0.0 112.353 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 57.7 p -139.18 126.18 21.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 98.9 p -95.13 -47.95 6.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.835 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.947 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 15.1 t 56.43 45.89 21.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 0.0 110.899 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 54.6 p -97.41 133.25 42.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 113.12 53.27 0.47 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.53 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 31.0 p -101.76 87.6 3.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.899 0.38 . . . . 0.0 110.84 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 16.7 t -129.81 88.64 2.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.881 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -110.05 101.99 1.5 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 72.3 m -129.04 129.59 45.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.827 -179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 10.1 p -137.99 143.67 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 77.51 -81.17 1.24 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.504 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -108.5 107.47 60.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.614 0.721 . . . . 0.0 110.87 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -48.16 0.77 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.744 2.296 . . . . 0.0 112.299 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -62.14 96.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.909 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.6 mm -101.67 129.1 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.134 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 16.9 t -54.99 130.31 41.21 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 36.3 mm-40 -88.74 22.03 2.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.559 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -119.84 -57.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.3 p -105.56 -41.87 5.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.863 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 124.6 7.51 6.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.499 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -58.97 179.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 110.943 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.64 139.51 8.57 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -134.49 170.59 15.54 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 68.3 m -101.75 -28.55 12.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.852 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.404 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 18.9 mtp180 -116.32 155.68 48.12 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.625 0.726 . . . . 0.0 110.88 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.656 2.237 . . . . 0.0 112.366 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.6 -34.56 78.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.404 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 50.7 m170 -61.65 -50.58 71.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.848 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.7 tp -62.9 -44.68 95.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -50.1 -54.61 19.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.859 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . 0.433 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -47.25 -37.11 10.88 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.484 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -69.6 -40.29 76.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.809 0.338 . . . . 0.0 110.895 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.5 mt -75.29 -16.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.46 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 51.7 tttt -110.86 0.99 17.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . 0.433 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.2 tp-100 -120.48 -29.16 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 34.2 t -110.76 -42.89 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.559 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.8 m-70 -88.3 -18.78 27.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.856 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.7 t -44.27 143.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.102 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 74.1 m -142.71 171.1 14.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.86 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -116.75 162.89 16.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -144.35 141.32 17.86 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.608 0.718 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 172.29 12.89 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.694 2.263 . . . . 0.0 112.352 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . 0.435 ' CG ' ' O ' ' A' ' 442' ' ' HIS . 3.0 p-80 -40.39 104.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 2.0 ttmp? -130.02 160.56 33.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 73.5 m 56.94 45.19 21.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 2.8 tp-100 -69.5 161.52 29.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 29.5 m -51.15 -20.87 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -55.27 -27.37 46.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.855 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . . . . . . . . . 10.7 p -98.88 46.62 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.104 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 35.9 t -147.45 129.41 15.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.877 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -53.41 -175.24 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 103.47 1.16 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.665 2.243 . . . . 0.0 112.337 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 60.8 m -109.05 135.61 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 1.4 t -85.56 97.14 9.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.872 -179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.491 -179.964 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 63.8 m -82.7 44.46 0.91 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 14.5 t -82.54 41.86 0.73 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -84.53 160.56 36.14 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.495 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 23.3 p -141.92 167.54 21.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.867 0.365 . . . . 0.0 110.894 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 1.2 t -165.87 157.69 14.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 122.93 89.73 0.94 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.484 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 37.3 p -119.81 119.52 33.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 110.856 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.55 116.03 41.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 172.05 -127.31 1.39 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.9 117.68 23.15 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.909 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -47.74 0.89 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.724 2.283 . . . . 0.0 112.349 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -60.92 94.09 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.1 mm -103.99 123.53 57.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.167 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.9 t -52.6 130.71 32.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -91.26 20.97 4.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.942 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 417' ' ' SER . . . . . 0.542 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.03 -45.97 2.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.851 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 16.8 p -119.03 -44.36 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.907 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 131.11 0.4 5.12 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 30.4 mttm -55.09 172.54 0.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 0.0 110.875 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -141.23 143.93 13.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.479 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -137.09 166.88 22.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.893 0.378 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 59.8 m -98.37 -32.27 11.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.837 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 424' ' ' ARG . . . . . 0.416 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 56.3 mtt-85 -110.97 156.22 41.18 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.885 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -46.43 1.24 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.737 2.291 . . . . 0.0 112.364 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -64.42 -38.34 90.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 427' ' ' HIS . . . . . 0.416 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 60.0 m170 -56.87 -53.3 59.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.3 tp -60.92 -45.18 95.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -49.32 -52.75 25.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.56 -42.99 36.16 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -63.3 -40.11 96.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.771 0.319 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.6 mt -74.9 -16.36 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 433' ' ' LYS . . . . . 0.446 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 21.7 ttmt -108.94 -2.23 18.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.875 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 5.3 tp-100 -118.19 -25.68 6.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 14.5 t -115.46 -36.36 2.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 436' ' ' HIS . . . . . 0.542 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.0 m-70 -100.4 15.52 27.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.891 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 437' ' ' THR . . . . . 0.423 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -89.45 142.99 27.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.105 -179.894 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 24.2 m -49.81 125.78 12.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.802 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -172.13 125.78 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 3.4 ptp180 -155.57 144.32 14.78 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 441' ' ' PRO . . . . . 0.412 ' O ' ' C ' ' A' ' 442' ' ' HIS . 53.6 Cg_endo -69.77 -177.52 1.92 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.702 2.268 . . . . 0.0 112.348 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 442' ' ' HIS . . . . . 0.489 ' CG ' ' O ' ' A' ' 442' ' ' HIS . 9.4 p80 -37.37 113.28 0.25 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -122.43 135.19 54.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.914 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 29.5 p -122.35 60.81 0.99 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -74.45 95.71 2.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 13.1 p -52.76 145.73 2.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.131 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 447' ' ' TRP . . . . . 0.528 ' CE2' HG21 ' A' ' 448' ' ' VAL . 24.6 t-105 -128.08 145.35 51.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 448' ' ' VAL . . . . . 0.528 HG21 ' CE2' ' A' ' 447' ' ' TRP . 26.9 m -35.25 142.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.165 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 449' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 450' ' ' GLY . 1.9 m -175.03 161.0 2.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 450' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 449' ' ' SER . . . 33.86 -96.31 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.492 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 451' ' ' PRO . . . . . 0.432 ' N ' ' O ' ' A' ' 449' ' ' SER . 54.0 Cg_endo -69.7 87.68 0.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.729 2.286 . . . . 0.0 112.359 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 24.6 p -84.5 141.8 30.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 70.9 m -117.69 99.37 6.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.878 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.21 0 CA-C-O 120.788 0.245 . . . . 0.0 112.301 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -59.04 94.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.895 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.605 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.2 mm -100.72 125.96 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.092 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.7 t -52.84 131.78 35.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.4 mm-40 -91.11 20.4 5.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.556 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.12 -48.8 2.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.0 p -115.45 -41.97 3.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 419' ' ' GLY . . . . . 0.426 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 127.98 -1.43 6.76 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.605 ' O ' HG23 ' A' ' 414' ' ' ILE . 17.4 mttp -50.99 179.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.879 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.4 143.83 11.76 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 15.2 m-85 -139.64 170.13 16.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.922 0.391 . . . . 0.0 110.836 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 5.3 m -99.96 -32.22 11.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.864 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.4 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 27.9 mtp180 -110.81 155.55 42.14 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.596 0.712 . . . . 0.0 110.86 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -45.33 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.65 2.233 . . . . 0.0 112.335 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.48 -40.15 92.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.844 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.4 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 54.7 m170 -54.68 -53.56 53.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.851 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.401 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.64 -44.18 96.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -49.92 -55.17 15.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.63 -40.77 17.9 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.451 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.7 t60 -64.95 -41.41 95.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.745 0.307 . . . . 0.0 110.868 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.401 HD11 HD11 ' A' ' 428' ' ' LEU . 13.7 mt -73.43 -18.34 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.123 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 61.0 tttt -108.84 1.42 20.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -120.16 -27.42 5.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.1 t -112.92 -41.69 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.556 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.8 m-70 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.876 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.749 0.229 . . . . 0.0 112.327 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.5 m-30 -61.44 93.4 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.661 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.1 mm -98.51 129.67 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.154 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 19.4 t -55.28 132.79 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.4 mm-40 -92.57 21.02 5.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.581 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.13 -48.5 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.83 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.7 p -115.64 -39.69 3.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 123.23 7.96 6.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.8 mttt -58.19 179.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.427 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.11 144.32 12.43 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.448 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.427 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 8.8 m-85 -138.93 -177.68 4.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.847 0.356 . . . . 0.0 110.927 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 23.9 m -112.32 -35.78 5.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.853 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.402 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 45.6 mtt180 -111.11 155.3 42.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.641 0.734 . . . . 0.0 110.831 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -29.58 23.39 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.65 2.234 . . . . 0.0 112.349 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -80.17 -32.05 38.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.859 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.402 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.9 m170 -65.2 -51.22 62.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.406 HD11 HD11 ' A' ' 432' ' ' ILE . 12.0 tp -63.53 -44.3 94.64 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -49.97 -53.04 28.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 430' ' ' GLY . . . . . 0.488 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.59 -39.46 23.11 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.456 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 431' ' ' HIS . . . . . 0.419 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.3 t60 -67.54 -42.74 82.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.406 HD11 HD11 ' A' ' 428' ' ' LEU . 11.7 mt -72.99 -19.39 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.109 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.484 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 32.8 tttt -108.35 1.71 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 434' ' ' GLN . . . . . 0.488 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 8.3 tp-100 -119.92 -28.9 5.08 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.938 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.4 t -112.8 -41.57 3.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.581 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.5 m-70 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 N--CA 1.465 -0.16 0 CA-C-O 120.825 0.26 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 413' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.3 m-30 -62.46 95.3 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.458 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.5 mm -105.87 124.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.084 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.9 t -51.02 128.6 21.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -89.57 19.28 4.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.878 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.558 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.69 -45.72 2.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 12.9 p -117.46 -49.49 2.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.897 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.53 -1.44 3.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.458 ' O ' HG23 ' A' ' 414' ' ' ILE . 26.4 mttm -54.24 174.72 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.811 0.339 . . . . 0.0 110.9 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.31 146.11 16.55 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.505 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -141.14 163.09 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.905 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.58 -27.94 14.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.807 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.41 ' HG3' ' ND1' ' A' ' 427' ' ' HIS . 14.7 mtp180 -110.07 148.94 39.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.849 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -33.17 17.1 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.335 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.52 -38.43 55.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.41 ' ND1' ' HG3' ' A' ' 424' ' ' ARG . 51.2 m170 -58.26 -52.54 65.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.804 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.607 HD11 HD11 ' A' ' 432' ' ' ILE . 8.9 tp -57.84 -46.62 84.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 8.7 m-20 -49.5 -52.89 26.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 430' ' ' GLY . . . . . 0.479 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -49.2 -40.06 28.59 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.49 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.13 -42.96 88.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.607 HD11 HD11 ' A' ' 428' ' ' LEU . 12.1 mt -72.73 -19.93 19.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.139 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 23.8 ttmt -107.91 1.09 22.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.92 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 434' ' ' GLN . . . . . 0.479 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 71.0 tp60 -119.98 -26.27 5.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.92 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.6 t -114.39 -41.41 3.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.558 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.139 0 CA-C-O 120.759 0.233 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.7 m-30 -60.38 94.13 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.516 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.4 mm -98.16 128.09 49.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.103 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.8 t -59.23 132.95 55.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.874 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.7 mm-40 -91.9 2.23 56.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.584 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 7.6 m -93.69 -42.5 9.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.9 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.5 p -123.7 -46.44 2.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 132.78 4.46 3.41 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.455 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -58.25 178.08 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.824 0.345 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.98 143.06 11.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -138.37 169.59 17.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 9.8 m -101.48 -28.46 12.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -113.73 154.42 45.77 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.612 0.72 . . . . 0.0 110.925 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -47.5 0.93 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.717 2.278 . . . . 0.0 112.327 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -63.88 -37.5 87.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.4 m170 -58.27 -54.27 48.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.412 HD11 HD11 ' A' ' 432' ' ' ILE . 9.4 tp -59.66 -44.11 93.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -50.52 -54.31 23.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.934 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.12 -40.38 21.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -65.52 -40.74 93.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.412 HD11 HD11 ' A' ' 428' ' ' LEU . 11.4 mt -74.24 -19.01 17.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 433' ' ' LYS . . . . . . . . . . . . . 45.4 tttm -104.75 -4.25 22.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 45.2 tp60 -115.85 -26.27 7.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.6 t -114.78 -33.85 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.155 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.584 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.1 m-70 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.806 0.252 . . . . 0.0 112.334 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.76 94.8 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.912 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 420' ' ' LYS . 27.1 mm -102.94 133.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.125 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 38.4 t -57.47 128.42 36.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.896 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -85.75 22.39 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.481 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.1 t -122.98 -66.41 1.02 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.5 p -92.33 -42.55 9.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 121.86 12.53 5.4 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.707 ' O ' HG23 ' A' ' 414' ' ' ILE . 28.2 mttm -65.37 -179.48 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.419 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.18 143.53 11.71 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 11.7 m-85 -139.36 163.2 33.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.855 0.36 . . . . 0.0 110.873 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.3 m -95.47 -24.51 16.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.818 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.572 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.8 mmt85 -117.99 153.16 51.04 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.629 0.728 . . . . 0.0 110.847 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -40.09 5.77 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.643 2.229 . . . . 0.0 112.356 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -69.88 -42.51 73.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.572 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 59.1 m170 -56.48 -42.82 78.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.895 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -68.82 -44.55 73.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.945 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -51.97 -54.18 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.869 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.23 -40.05 21.34 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.516 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.21 -40.1 93.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.857 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 13.0 mt -75.33 -18.24 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.193 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 12.7 ttmt -107.15 -2.14 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.938 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -117.15 -25.46 7.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.92 -38.63 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.153 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.481 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.0 m-70 . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.815 0.256 . . . . 0.0 112.342 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 413' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.1 m-30 -63.31 97.18 0.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.914 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.5 mm -108.15 125.44 64.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.144 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.0 t -52.4 126.53 19.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 -87.32 21.48 2.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.57 -51.92 2.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.9 p -110.79 -47.09 3.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.37 11.63 2.44 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.599 ' O ' HG23 ' A' ' 414' ' ' ILE . 44.1 mttt -64.63 -179.4 0.49 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.76 143.21 11.16 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.46 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -139.04 159.66 41.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.891 0.377 . . . . 0.0 110.856 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.0 m -92.21 -30.16 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.415 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.2 mtp180 -112.16 154.95 44.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.639 0.733 . . . . 0.0 110.896 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -44.45 2.08 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.715 2.277 . . . . 0.0 112.316 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -66.98 -38.21 85.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.852 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.415 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.8 m170 -56.87 -49.28 75.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 432' ' ' ILE . 6.6 tp -63.55 -45.94 88.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.896 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -49.05 -53.98 17.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.3 -41.11 31.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.527 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 431' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 12.5 t60 -64.84 -40.97 96.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.787 0.327 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.653 HD11 HD11 ' A' ' 428' ' ' LEU . 20.6 mt -73.27 -20.83 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.142 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.421 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.5 OUTLIER -103.68 -2.71 26.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -114.56 -28.56 7.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.4 t -114.22 -37.51 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.532 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.9 m-70 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.232 0.203 0 CA-C-O 120.791 0.246 . . . . 0.0 112.364 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -61.25 93.98 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.497 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.7 mm -102.07 128.74 54.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 7.7 t -60.19 121.12 11.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 10.1 mm-40 -80.63 -4.19 53.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.589 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 3.2 m -86.95 -45.14 11.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.4 p -121.02 -49.09 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.61 0.77 2.86 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.501 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 414' ' ' ILE . 35.8 mttm -55.48 -179.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.842 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.31 147.56 18.44 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 5.3 m-85 -143.96 157.41 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.7 m -90.91 -21.92 21.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.416 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 13.3 mtp85 -120.95 155.52 57.56 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 0.0 110.858 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -48.74 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.701 2.268 . . . . 0.0 112.344 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -63.0 -36.28 83.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.416 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 56.1 m170 -58.85 -52.82 64.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 14.0 tp -61.47 -42.86 99.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -51.22 -55.05 20.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.888 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -46.86 -42.77 15.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -63.36 -43.28 98.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.785 0.326 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -72.33 -15.96 18.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.104 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.405 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 14.2 ttpp -105.26 -7.59 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -114.29 -22.97 9.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.86 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.6 t -116.53 -36.94 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.589 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.7 m-70 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.831 0.263 . . . . 0.0 112.371 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.74 89.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.3 mm -100.52 126.82 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 15.5 t -53.99 131.52 40.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 12.2 mm100 -91.63 21.31 4.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.08 -46.24 2.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.843 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 17.9 p -117.97 -47.86 2.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 134.49 2.38 3.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.469 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 414' ' ' ILE . 22.1 mttm -55.97 176.24 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.28 144.24 12.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 17.2 m-85 -140.04 169.14 18.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.866 0.365 . . . . 0.0 110.87 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -103.03 -26.49 13.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.871 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 14.4 mtt-85 -112.1 149.51 41.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.591 0.71 . . . . 0.0 110.888 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -31.69 19.8 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.712 2.275 . . . . 0.0 112.347 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -78.73 -36.5 43.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 48.4 m170 -59.46 -53.32 59.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.864 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.38 -47.23 84.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.921 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -49.57 -52.8 27.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.39 -41.99 33.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -63.37 -40.78 98.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.778 0.323 . . . . 0.0 110.897 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -71.79 -22.92 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.485 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.8 tttm -102.83 1.8 34.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 72.0 tp60 -119.83 -27.66 5.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.5 t -114.92 -42.41 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.104 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.2 m-70 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.814 0.256 . . . . 0.0 112.354 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.21 95.49 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.535 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.2 mm -104.0 127.04 58.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.098 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.8 t -52.94 127.81 25.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -88.06 21.86 2.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.546 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.11 -51.25 2.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.2 p -112.36 -46.39 3.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.49 9.61 2.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.482 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.535 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.9 mttm -62.81 -179.52 0.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 110.887 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -145.19 142.09 10.48 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -137.51 164.39 28.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.871 0.367 . . . . 0.0 110.856 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.4 m -96.11 -28.37 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.876 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.577 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.5 mmt180 -114.56 152.83 46.57 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.576 0.703 . . . . 0.0 110.886 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -38.05 8.33 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.687 2.258 . . . . 0.0 112.349 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.22 -40.16 71.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.577 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 45.4 m170 -58.37 -44.59 88.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.551 HD11 HD11 ' A' ' 432' ' ' ILE . 5.3 tp -66.16 -45.3 81.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.942 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -51.37 -55.26 19.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.52 -40.66 16.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -64.3 -40.59 96.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.809 0.338 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.551 HD11 HD11 ' A' ' 428' ' ' LEU . 14.0 mt -72.85 -23.82 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.43 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 58.2 tttt -101.76 -1.99 31.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -115.77 -27.86 6.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.86 -36.88 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.546 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.153 0 CA-C-O 120.846 0.269 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.32 90.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.9 mm -101.75 127.24 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.128 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 9.5 t -53.16 127.67 25.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.882 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.6 mm-40 -88.35 17.96 4.83 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.593 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.6 m -113.44 -42.88 3.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.6 p -121.92 -49.75 2.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.861 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 138.47 -1.06 2.61 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.623 ' O ' HG23 ' A' ' 414' ' ' ILE . 39.2 mttt -52.69 179.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.816 0.341 . . . . 0.0 110.881 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.407 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -148.87 144.76 12.57 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.49 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 16.2 m-85 -140.01 165.04 28.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.856 0.36 . . . . 0.0 110.832 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.1 m -94.81 -33.59 12.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 19.7 mtp180 -109.3 155.25 41.42 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.613 0.721 . . . . 0.0 110.84 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -44.5 2.01 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.695 2.264 . . . . 0.0 112.32 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -65.5 -40.51 93.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.855 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.413 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 57.0 m170 -55.39 -51.12 67.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.907 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.14 -46.27 89.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -49.2 -54.12 18.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.02 -39.91 26.98 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -65.3 -39.04 91.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.846 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -75.27 -18.07 16.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.2 OUTLIER -107.28 -2.01 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.912 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 39.9 tp60 -116.36 -27.01 6.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.919 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 30.5 t -114.95 -40.41 3.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.593 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.4 m-70 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.813 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.786 0.244 . . . . 0.0 112.344 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -58.54 90.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.553 HG23 ' O ' ' A' ' 419' ' ' GLY . 10.9 mm -98.54 128.58 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.8 t -56.77 129.38 41.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 40.3 mm-40 -88.53 20.29 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.65 -44.84 2.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.3 p -121.59 -46.5 2.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 419' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.51 -8.16 3.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.5 mttt -46.34 170.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -140.91 144.03 14.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -138.1 170.37 16.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 110.881 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 36.9 m -100.23 -34.16 10.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.563 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 83.9 mtt-85 -107.92 155.0 40.74 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.602 0.715 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -46.18 1.3 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.705 2.27 . . . . 0.0 112.298 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.5 -36.25 83.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.563 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 54.6 m170 -58.65 -51.7 68.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.0 tp -62.27 -44.39 96.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -50.77 -53.38 32.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.57 -40.95 25.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -64.37 -40.75 96.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.816 0.341 . . . . 0.0 110.833 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.0 mt -73.57 -16.97 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.129 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 55.9 tttt -107.9 -1.25 20.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -117.9 -25.78 6.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.09 -39.28 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.7 m-70 . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.854 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.153 0 CA-C-O 120.798 0.249 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.41 97.88 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.6 mm -108.13 130.56 60.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -55.91 123.51 14.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.855 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -86.08 20.24 2.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.403 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.17 -46.74 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.864 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.6 p -115.99 -46.53 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.15 10.6 2.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.671 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.31 -179.75 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.857 0.361 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.16 142.88 10.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -138.87 162.02 35.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.908 0.385 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.7 m -93.24 -32.33 14.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.506 ' HE ' ' CE1' ' A' ' 427' ' ' HIS . 21.1 mtm180 -112.37 155.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -42.01 3.86 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.282 . . . . 0.0 112.38 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.27 -38.85 85.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.506 ' CE1' ' HE ' ' A' ' 424' ' ' ARG . 51.7 m170 -58.41 -49.24 77.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.688 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -62.68 -45.92 90.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -50.04 -55.29 15.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.852 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.43 -39.44 14.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 431' ' ' HIS . . . . . 0.422 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.9 t60 -66.54 -41.38 88.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.767 0.317 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.688 HD11 HD11 ' A' ' 428' ' ' LEU . 16.2 mt -74.17 -15.65 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.451 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 1.1 ttmp? -110.9 0.89 17.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 61.1 tp60 -119.05 -25.73 6.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.937 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 33.7 t -116.7 -42.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.1 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.403 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.156 0 CA-C-O 120.807 0.253 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -62.67 95.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.938 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.682 HG23 ' O ' ' A' ' 420' ' ' LYS . 28.9 mm -105.73 132.26 53.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.6 t -57.17 126.69 28.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -86.28 21.13 2.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.537 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.22 -55.83 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.836 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.3 p -106.78 -44.53 4.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.03 9.79 3.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.682 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -62.87 -179.79 0.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.828 0.347 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.4 144.64 13.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.424 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 10.7 m-85 -139.26 160.93 38.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 54.2 m -91.67 -32.72 15.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.487 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 26.4 mtt-85 -111.28 154.51 43.61 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.581 0.705 . . . . 0.0 110.877 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -42.62 3.24 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 36.9 t0 -66.77 -38.65 86.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.487 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -57.99 -49.5 76.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -63.51 -44.42 94.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -49.81 -52.84 29.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 430' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 434' ' ' GLN . . . -49.76 -43.5 38.42 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.513 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -63.34 -40.5 97.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 110.865 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 20.4 mt -74.78 -18.72 16.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.478 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.6 tttp -109.82 0.96 19.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.895 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 434' ' ' GLN . . . . . 0.42 ' N ' ' O ' ' A' ' 430' ' ' GLY . 54.1 tp60 -119.44 -25.8 5.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.9 t -116.39 -40.34 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.179 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.537 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 77.5 m-70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--O 1.232 0.193 0 CA-C-O 120.781 0.242 . . . . 0.0 112.294 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -61.02 90.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.947 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.5 mm -103.25 130.5 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.5 t -57.6 126.72 28.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -86.91 20.9 2.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.48 -52.41 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.816 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.4 p -110.75 -45.52 3.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.889 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.6 11.69 2.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.474 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.575 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.59 179.88 0.57 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.824 0.345 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.13 142.73 10.81 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.401 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 9.9 m-85 -137.96 162.4 34.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.893 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 15.8 m -94.67 -30.6 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.834 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.408 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 35.7 mtp85 -111.16 154.54 43.51 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.616 0.722 . . . . 0.0 110.865 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 -45.65 1.47 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.685 2.256 . . . . 0.0 112.321 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.46 -40.28 93.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.408 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 53.1 m170 -54.84 -51.16 66.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.845 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 432' ' ' ILE . 9.2 tp -62.34 -45.05 94.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -50.27 -55.68 14.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 430' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.21 -38.21 18.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -67.26 -40.79 86.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.747 0.308 . . . . 0.0 110.841 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.508 HD11 HD11 ' A' ' 428' ' ' LEU . 18.5 mt -74.3 -20.53 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.442 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 49.5 tttt -106.87 -0.82 23.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 434' ' ' GLN . . . . . 0.474 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.7 tp-100 -116.7 -27.6 6.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 32.1 t -114.96 -39.88 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.407 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.905 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.145 0 CA-C-O 120.824 0.26 . . . . 0.0 112.365 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -60.92 93.69 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.2 mm -100.79 131.51 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.138 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.9 t -56.57 125.29 21.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -86.1 20.29 2.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.594 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.61 -43.08 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.3 p -122.06 -46.99 2.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 419' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 135.4 -1.69 3.72 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.657 ' O ' HG23 ' A' ' 414' ' ' ILE . 40.0 mttt -51.67 179.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.868 0.366 . . . . 0.0 110.872 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -147.41 142.97 10.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -138.28 163.88 30.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.83 0.348 . . . . 0.0 110.93 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 423' ' ' SER . . . . . 0.451 ' O ' ' NH1' ' A' ' 424' ' ' ARG . 3.1 m -96.39 -22.75 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.82 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.581 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 7.8 mmt-85 -119.22 152.95 53.05 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 110.873 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 425' ' ' PRO . . . . . 0.4 ' O ' ' OD1' ' A' ' 429' ' ' ASN . 53.6 Cg_endo -69.73 -41.99 3.82 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.692 2.262 . . . . 0.0 112.34 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -69.14 -42.02 76.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.581 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 58.8 m170 -55.22 -46.48 75.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.852 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.568 HD11 HD11 ' A' ' 432' ' ' ILE . 8.8 tp -65.92 -44.99 83.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 429' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 425' ' ' PRO . 16.6 m120 -50.16 -54.81 18.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.71 -43.16 21.95 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.513 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -62.98 -41.65 99.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.876 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 428' ' ' LEU . 20.0 mt -73.42 -15.92 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 433' ' ' LYS . . . . . . . . . . . . . 16.2 ttpp -105.11 -8.43 18.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -112.93 -24.28 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.34 -36.18 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.594 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 79.7 m-70 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.147 0 CA-C-O 120.854 0.272 . . . . 0.0 112.323 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -59.2 94.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.5 mm -105.33 123.86 59.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.096 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.1 t -50.95 127.72 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.863 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -88.56 19.23 4.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.904 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.58 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -114.59 -45.92 2.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.2 p -118.62 -49.34 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.72 1.19 2.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.422 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.4 mttt -55.12 173.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.907 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.403 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -142.41 145.64 15.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.403 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 21.3 m-85 -141.12 167.99 20.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 69.2 m -98.57 -33.63 10.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.859 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.407 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 38.0 mtp180 -110.37 155.15 42.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.654 0.74 . . . . 0.0 110.852 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -37.24 9.32 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.04 -35.3 69.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.819 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.407 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 63.5 m170 -60.66 -52.66 64.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.432 HD11 HD11 ' A' ' 432' ' ' ILE . 10.8 tp -62.34 -46.04 90.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.911 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -49.2 -53.66 20.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 430' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.13 -40.19 20.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.48 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -66.4 -42.52 87.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.771 0.319 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.432 HD11 HD11 ' A' ' 428' ' ' LEU . 15.3 mt -72.38 -19.42 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.122 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 46.6 tttm -107.91 2.11 23.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 434' ' ' GLN . . . . . 0.409 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 13.1 tp60 -120.96 -25.33 5.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.0 t -116.43 -41.74 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.58 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.3 m-70 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.192 0 CA-C-O 120.802 0.251 . . . . 0.0 112.381 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.09 91.56 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.518 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.8 mm -98.22 124.82 51.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.15 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -49.89 127.6 16.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 67.1 mm-40 -89.12 20.93 3.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.564 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.72 -45.35 2.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 19.6 p -120.36 -46.56 2.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.864 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.19 -0.48 3.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.438 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.518 ' O ' HG23 ' A' ' 414' ' ' ILE . 27.7 mttm -51.29 176.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.338 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 421' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.59 146.22 16.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.494 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 422' ' ' PHE . . . . . 0.466 ' CD1' HD13 ' A' ' 428' ' ' LEU . 14.3 m-85 -142.46 -179.73 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.896 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 27.9 m -110.77 -34.29 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.437 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 80.1 mtt-85 -111.37 154.54 43.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.569 0.7 . . . . 0.0 110.889 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -33.62 16.3 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.654 2.236 . . . . 0.0 112.355 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -76.42 -31.77 58.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.437 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -65.8 -51.34 59.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.882 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.466 HD13 ' CD1' ' A' ' 422' ' ' PHE . 12.7 tp -64.16 -43.42 95.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -51.92 -50.36 61.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.91 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -51.71 -39.74 47.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.496 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -65.71 -40.6 92.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.895 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 10.7 mt -71.44 -22.42 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -99.95 -1.04 38.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.938 179.854 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -115.76 -31.25 5.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.908 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.11 -38.27 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.137 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.564 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.752 0.23 . . . . 0.0 112.301 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -58.57 92.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.472 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.2 mm -95.78 133.64 36.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.143 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.1 t -60.62 124.36 20.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -84.76 16.6 3.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.559 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.2 m -112.63 -45.08 3.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 13.3 p -120.22 -47.75 2.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 419' ' ' GLY . . . . . 0.428 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.58 -4.19 3.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.517 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.472 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.9 mttt -50.43 175.25 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.366 . . . . 0.0 110.867 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.26 141.47 10.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -135.9 168.04 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.838 0.351 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 42.2 m -98.54 -31.02 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.886 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.8 mtt180 -113.12 155.32 44.51 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.725 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -45.39 1.58 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.332 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -65.1 -36.64 84.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 51.9 m170 -59.52 -51.41 69.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 13.9 tp -62.9 -45.78 90.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -48.48 -53.86 16.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.92 -42.09 29.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.48 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 14.3 t60 -64.14 -39.78 94.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.82 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 17.2 mt -75.39 -18.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.45 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 33.2 tttt -108.28 -0.82 20.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.91 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -117.75 -27.04 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.1 t -114.93 -36.82 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.559 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.851 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 120.79 0.246 . . . . 0.0 112.299 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -62.14 96.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.909 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.573 HG23 ' O ' ' A' ' 420' ' ' LYS . 12.6 mm -101.67 129.1 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.134 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 16.9 t -54.99 130.31 41.21 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 36.3 mm-40 -88.74 22.03 2.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.583 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -119.84 -57.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.3 p -105.56 -41.87 5.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.863 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 124.6 7.51 6.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.499 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 420' ' ' LYS . . . . . 0.573 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.0 mttt -58.97 179.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 110.943 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.64 139.51 8.57 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -134.49 170.59 15.54 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 68.3 m -101.75 -28.55 12.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.852 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 18.9 mtp180 -116.32 155.68 48.12 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.625 0.726 . . . . 0.0 110.88 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.656 2.237 . . . . 0.0 112.366 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.6 -34.56 78.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 50.7 m170 -61.65 -50.58 71.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.848 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.7 tp -62.9 -44.68 95.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -50.1 -54.61 19.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.859 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 430' ' ' GLY . . . . . 0.433 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -47.25 -37.11 10.88 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.484 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -69.6 -40.29 76.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.809 0.338 . . . . 0.0 110.895 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.5 mt -75.29 -16.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.46 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 51.7 tttt -110.86 0.99 17.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 434' ' ' GLN . . . . . 0.433 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.2 tp-100 -120.48 -29.16 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 34.2 t -110.76 -42.89 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.583 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.8 m-70 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.856 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.231 0.167 0 CA-C-O 120.795 0.248 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -60.92 94.09 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.1 mm -103.99 123.53 57.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.167 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.9 t -52.6 130.71 32.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -91.26 20.97 4.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.942 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 417' ' ' SER . . . . . 0.566 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.03 -45.97 2.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.851 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 16.8 p -119.03 -44.36 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.907 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 131.11 0.4 5.12 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 30.4 mttm -55.09 172.54 0.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 0.0 110.875 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -141.23 143.93 13.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.479 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -137.09 166.88 22.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.893 0.378 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 59.8 m -98.37 -32.27 11.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.837 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 424' ' ' ARG . . . . . 0.418 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 56.3 mtt-85 -110.97 156.22 41.18 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.885 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -46.43 1.24 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.737 2.291 . . . . 0.0 112.364 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -64.42 -38.34 90.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 427' ' ' HIS . . . . . 0.418 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 60.0 m170 -56.87 -53.3 59.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 428' ' ' LEU . . . . . 0.495 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.92 -45.18 95.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -49.32 -52.75 25.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.56 -42.99 36.16 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -63.3 -40.11 96.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.771 0.319 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 432' ' ' ILE . . . . . 0.495 HD11 HD11 ' A' ' 428' ' ' LEU . 13.6 mt -74.9 -16.36 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 433' ' ' LYS . . . . . 0.446 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 21.7 ttmt -108.94 -2.23 18.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.875 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 5.3 tp-100 -118.19 -25.68 6.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 14.5 t -115.46 -36.36 2.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 436' ' ' HIS . . . . . 0.566 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.0 m-70 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 33.8 t -87.58 -63.2 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 4.1 m 42.44 44.03 3.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.843 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -174.53 -141.79 3.76 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.516 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 9.7 t 61.33 45.75 8.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.88 0.372 . . . . 0.0 110.865 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 26.7 p -144.7 163.13 34.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.83 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -120.35 -143.9 6.97 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.463 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 61.1 p -128.43 132.48 48.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.914 0.388 . . . . 0.0 110.825 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 90.9 t -88.8 92.27 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 155.9 -69.94 0.28 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.471 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.456 ' HD2' ' N ' ' A' ' 411' ' ' LYS . 0.1 OUTLIER -102.64 97.21 8.65 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.633 0.73 . . . . 0.0 110.877 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 412' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.8 Cg_endo -69.79 -47.62 0.88 Allowed 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.665 2.243 . . . . 0.0 112.301 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -59.04 94.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.895 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.605 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.2 mm -100.72 125.96 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.092 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.7 t -52.84 131.78 35.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.4 mm-40 -91.11 20.4 5.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.556 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.12 -48.8 2.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.0 p -115.45 -41.97 3.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 419' ' ' GLY . . . . . 0.426 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 127.98 -1.43 6.76 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.605 ' O ' HG23 ' A' ' 414' ' ' ILE . 17.4 mttp -50.99 179.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.879 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.4 143.83 11.76 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 15.2 m-85 -139.64 170.13 16.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.922 0.391 . . . . 0.0 110.836 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 5.3 m -99.96 -32.22 11.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.864 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.4 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 27.9 mtp180 -110.81 155.55 42.14 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.596 0.712 . . . . 0.0 110.86 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -45.33 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.65 2.233 . . . . 0.0 112.335 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.48 -40.15 92.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.844 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.4 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 54.7 m170 -54.68 -53.56 53.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.851 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.401 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.64 -44.18 96.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -49.92 -55.17 15.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.63 -40.77 17.9 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.451 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.7 t60 -64.95 -41.41 95.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.745 0.307 . . . . 0.0 110.868 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.401 HD11 HD11 ' A' ' 428' ' ' LEU . 13.7 mt -73.43 -18.34 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.123 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 61.0 tttt -108.84 1.42 20.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -120.16 -27.42 5.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.1 t -112.92 -41.69 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.556 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.8 m-70 -89.51 -22.63 22.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.876 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.9 t -40.77 129.49 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.135 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 25.1 m -164.95 174.28 10.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.821 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -111.24 141.18 45.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.883 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -136.75 144.05 45.27 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.571 0.701 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 149.79 67.34 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.654 2.236 . . . . 0.0 112.376 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 23.0 p80 -126.34 168.58 13.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -57.06 174.57 0.17 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 32.1 m -80.94 42.37 0.63 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 60.45 36.27 20.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 6.2 p -173.49 150.05 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.144 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 15.7 t-105 -57.35 -61.5 2.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 448' ' ' VAL . . . . . . . . . . . . . 7.2 p -122.45 133.01 69.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 36.5 t -111.87 -38.35 4.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.886 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -60.92 -158.31 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.517 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 -37.76 8.88 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.675 2.25 . . . . 0.0 112.375 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 4.8 m -171.85 167.63 6.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.846 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 40.5 t -174.13 161.9 3.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.866 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.531 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 1.8 m -134.8 176.95 8.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.844 0.355 . . . . 0.0 110.843 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 67.1 p -112.55 -54.3 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.897 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 108.03 68.74 0.65 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 19.4 m -133.38 -46.53 0.83 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.899 0.38 . . . . 0.0 110.873 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 15.5 t -62.46 132.22 51.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.91 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -138.69 -159.35 8.02 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 20.4 m -78.13 140.11 39.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 60.4 t -121.82 132.94 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.117 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -149.5 31.94 1.13 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.427 ' CB ' ' O ' ' A' ' 422' ' ' PHE . 6.5 mptt -132.2 98.58 16.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 0.0 110.85 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 412' ' ' PRO . . . . . 0.421 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.78 -47.0 1.01 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.673 2.249 . . . . 0.0 112.327 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.5 m-30 -61.44 93.4 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.661 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.1 mm -98.51 129.67 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.154 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 19.4 t -55.28 132.79 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.4 mm-40 -92.57 21.02 5.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.581 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.13 -48.5 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.83 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.7 p -115.64 -39.69 3.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 123.23 7.96 6.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.8 mttt -58.19 179.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.427 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.11 144.32 12.43 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.448 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.427 ' O ' ' CB ' ' A' ' 411' ' ' LYS . 8.8 m-85 -138.93 -177.68 4.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.847 0.356 . . . . 0.0 110.927 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 23.9 m -112.32 -35.78 5.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.853 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.402 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 45.6 mtt180 -111.11 155.3 42.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.641 0.734 . . . . 0.0 110.831 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -29.58 23.39 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.65 2.234 . . . . 0.0 112.349 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -80.17 -32.05 38.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.859 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.402 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.9 m170 -65.2 -51.22 62.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.406 HD11 HD11 ' A' ' 432' ' ' ILE . 12.0 tp -63.53 -44.3 94.64 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -49.97 -53.04 28.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 430' ' ' GLY . . . . . 0.488 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.59 -39.46 23.11 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.456 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 431' ' ' HIS . . . . . 0.419 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.3 t60 -67.54 -42.74 82.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.406 HD11 HD11 ' A' ' 428' ' ' LEU . 11.7 mt -72.99 -19.39 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.109 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.484 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 32.8 tttt -108.35 1.71 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 434' ' ' GLN . . . . . 0.488 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 8.3 tp-100 -119.92 -28.9 5.08 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.938 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.4 t -112.8 -41.57 3.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.581 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.5 m-70 -89.16 -17.74 28.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.415 ' HB ' ' C ' ' A' ' 433' ' ' LYS . 3.5 t -47.66 132.98 13.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 53.8 m -50.77 146.51 5.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -123.99 164.89 18.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 46.9 mtm180 -70.52 144.72 91.89 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.608 0.718 . . . . 0.0 110.917 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 98.27 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.716 2.277 . . . . 0.0 112.323 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 25.7 m170 -89.42 154.52 19.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.896 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? -44.04 124.62 3.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 30.1 p -128.97 163.75 24.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -82.87 146.37 28.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 96.4 t -48.86 137.29 4.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.111 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 29.5 t-105 -85.68 -47.67 9.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 448' ' ' VAL . . . . . . . . . . . . . 10.5 p -149.54 148.98 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 85.1 p -60.56 170.26 1.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.837 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -76.23 -158.19 7.88 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.485 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 148.04 64.61 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 54.8 p -158.04 162.14 38.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.876 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 49.0 m -77.67 112.29 14.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.531 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 87.4 p -169.07 124.0 0.86 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.838 0.352 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 80.7 p -157.23 156.83 33.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -125.03 131.5 7.76 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 65.6 m -132.22 112.44 12.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.86 0.362 . . . . 0.0 110.882 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 78.9 p -135.73 174.75 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 139.02 69.2 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.463 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 20.7 m -70.84 90.26 0.79 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.897 0.38 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 84.2 t -97.65 88.61 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 167.4 -68.79 0.18 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.53 119.35 76.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -46.66 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.667 2.245 . . . . 0.0 112.38 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 413' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.3 m-30 -62.46 95.3 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.458 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.5 mm -105.87 124.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.084 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.9 t -51.02 128.6 21.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -89.57 19.28 4.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.878 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.558 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.69 -45.72 2.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 12.9 p -117.46 -49.49 2.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.897 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.53 -1.44 3.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.458 ' O ' HG23 ' A' ' 414' ' ' ILE . 26.4 mttm -54.24 174.72 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.811 0.339 . . . . 0.0 110.9 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.31 146.11 16.55 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.505 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -141.14 163.09 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.905 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.58 -27.94 14.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.807 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.41 ' HG3' ' ND1' ' A' ' 427' ' ' HIS . 14.7 mtp180 -110.07 148.94 39.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.849 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -33.17 17.1 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.335 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.52 -38.43 55.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.41 ' ND1' ' HG3' ' A' ' 424' ' ' ARG . 51.2 m170 -58.26 -52.54 65.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.804 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.607 HD11 HD11 ' A' ' 432' ' ' ILE . 8.9 tp -57.84 -46.62 84.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 8.7 m-20 -49.5 -52.89 26.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 430' ' ' GLY . . . . . 0.479 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -49.2 -40.06 28.59 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.49 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.13 -42.96 88.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.607 HD11 HD11 ' A' ' 428' ' ' LEU . 12.1 mt -72.73 -19.93 19.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.139 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 23.8 ttmt -107.91 1.09 22.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.92 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 434' ' ' GLN . . . . . 0.479 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 71.0 tp60 -119.98 -26.27 5.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.92 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.6 t -114.39 -41.41 3.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.558 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 -89.97 -19.77 24.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 3.4 t -45.35 -44.94 12.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.131 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 88.2 p -47.88 99.59 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -115.35 133.45 56.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -47.9 143.85 6.0 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.633 0.73 . . . . 0.0 110.905 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 168.8 20.46 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.693 2.262 . . . . 0.0 112.343 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 5.7 m170 -99.35 131.88 45.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -75.72 -60.43 2.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 5.0 t -171.7 164.49 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.866 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -97.73 89.67 4.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 93.9 t -137.01 138.44 45.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.442 ' O ' ' C ' ' A' ' 448' ' ' VAL . 37.8 t-105 -130.79 133.7 46.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.919 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' A' ' 447' ' ' TRP . 94.5 t -34.37 109.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.095 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 23.1 m -79.06 103.35 8.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -116.4 -94.71 1.87 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.463 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 103.7 1.19 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.694 2.263 . . . . 0.0 112.377 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 45.3 m -82.73 41.67 0.74 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 16.3 m -128.4 143.55 51.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.833 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.458 -179.962 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 74.4 p -45.1 161.0 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.876 0.369 . . . . 0.0 110.84 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 51.2 p -67.28 128.19 35.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 171.66 118.52 0.48 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 63.6 m -148.94 133.14 17.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.828 0.346 . . . . 0.0 110.853 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 1.9 t -112.32 38.9 2.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.806 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 50.64 101.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 17.1 m -74.36 120.66 20.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.915 0.388 . . . . 0.0 110.825 -179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 409' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 409' ' ' VAL . 4.7 p -78.21 -13.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -88.73 -67.72 1.27 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.408 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 8.7 mptt -114.1 95.14 37.42 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.565 0.698 . . . . 0.0 110.936 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 412' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.3 Cg_endo -69.79 -46.88 1.05 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.68 2.253 . . . . 0.0 112.32 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.7 m-30 -60.38 94.13 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.516 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.4 mm -98.16 128.09 49.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.103 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.8 t -59.23 132.95 55.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.874 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.7 mm-40 -91.9 2.23 56.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.584 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 7.6 m -93.69 -42.5 9.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.9 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.5 p -123.7 -46.44 2.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 132.78 4.46 3.41 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.455 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -58.25 178.08 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.824 0.345 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.98 143.06 11.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -138.37 169.59 17.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 9.8 m -101.48 -28.46 12.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -113.73 154.42 45.77 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.612 0.72 . . . . 0.0 110.925 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -47.5 0.93 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.717 2.278 . . . . 0.0 112.327 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -63.88 -37.5 87.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.4 m170 -58.27 -54.27 48.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.412 HD11 HD11 ' A' ' 432' ' ' ILE . 9.4 tp -59.66 -44.11 93.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -50.52 -54.31 23.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.934 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.12 -40.38 21.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -65.52 -40.74 93.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.412 HD11 HD11 ' A' ' 428' ' ' LEU . 11.4 mt -74.24 -19.01 17.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.498 ' O ' HG21 ' A' ' 437' ' ' THR . 45.4 tttm -104.75 -4.25 22.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 45.2 tp60 -115.85 -26.27 7.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.6 t -114.78 -33.85 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.155 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.584 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.1 m-70 -102.74 15.99 27.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.498 HG21 ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -89.14 -32.74 17.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.178 -179.95 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 40.6 p -95.11 -47.43 6.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -106.6 132.56 52.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -157.59 151.89 20.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.595 0.712 . . . . 0.0 110.88 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -169.35 0.32 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 50.2 m170 -78.09 133.44 37.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -88.81 140.85 29.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 18.3 m -138.94 130.19 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -83.64 79.4 9.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 446' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 447' ' ' TRP . 9.3 p -109.19 -41.55 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.624 ' O ' HG23 ' A' ' 448' ' ' VAL . 1.4 p-90 -47.95 -34.2 8.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 447' ' ' TRP . 20.2 t -161.29 131.12 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 8.4 t -131.43 93.27 3.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.858 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 156.89 158.17 8.75 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.83 -5.35 16.04 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.659 2.24 . . . . 0.0 112.287 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 27.1 p -46.86 131.03 12.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 15.1 t -130.08 152.19 49.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 -179.926 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.491 -0.243 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 34.9 m -91.43 165.68 13.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.8 0.333 . . . . 0.0 110.89 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 48.4 t -84.89 82.01 8.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.792 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -126.44 49.03 0.94 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.49 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 27.9 m -157.95 117.02 3.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.885 0.374 . . . . 0.0 110.866 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 35.0 m -76.63 123.25 25.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -43.53 -93.42 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.6 t -126.37 173.46 9.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.945 0.402 . . . . 0.0 110.829 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 84.8 t -69.58 -61.94 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.142 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 163.08 74.3 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.11 98.49 51.51 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.552 0.691 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -47.18 0.97 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.692 2.261 . . . . 0.0 112.334 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.76 94.8 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.912 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 420' ' ' LYS . 27.1 mm -102.94 133.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.125 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 38.4 t -57.47 128.42 36.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.896 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -85.75 22.39 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.481 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.1 t -122.98 -66.41 1.02 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.5 p -92.33 -42.55 9.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 121.86 12.53 5.4 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.707 ' O ' HG23 ' A' ' 414' ' ' ILE . 28.2 mttm -65.37 -179.48 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.419 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.18 143.53 11.71 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 11.7 m-85 -139.36 163.2 33.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.855 0.36 . . . . 0.0 110.873 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.3 m -95.47 -24.51 16.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.818 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.572 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.8 mmt85 -117.99 153.16 51.04 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.629 0.728 . . . . 0.0 110.847 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -40.09 5.77 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.643 2.229 . . . . 0.0 112.356 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -69.88 -42.51 73.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.572 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 59.1 m170 -56.48 -42.82 78.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.895 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -68.82 -44.55 73.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.945 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -51.97 -54.18 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.869 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.23 -40.05 21.34 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.516 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.21 -40.1 93.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.857 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 13.0 mt -75.33 -18.24 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.193 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.476 ' O ' HG21 ' A' ' 437' ' ' THR . 12.7 ttmt -107.15 -2.14 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.938 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -117.15 -25.46 7.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.92 -38.63 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.153 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.481 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.0 m-70 -93.33 3.77 55.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.476 HG21 ' O ' ' A' ' 433' ' ' LYS . 2.8 t -81.12 -41.76 21.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 29.1 t -64.82 160.03 21.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -80.1 175.0 11.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.55 144.56 19.54 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.624 0.726 . . . . 0.0 110.819 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -171.89 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.701 2.267 . . . . 0.0 112.301 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -168.18 176.06 6.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.98 174.56 3.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 28.6 p -43.34 162.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -120.35 176.65 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 19.6 m -91.38 177.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.457 ' O ' ' C ' ' A' ' 448' ' ' VAL . 76.3 t-105 -166.5 116.96 0.95 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 448' ' ' VAL . 9.1 p 33.56 40.73 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.147 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 29.7 p -89.71 84.95 6.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.821 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -119.3 -76.65 0.51 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -29.38 24.06 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.708 2.272 . . . . 0.0 112.376 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 1.4 t -56.92 146.37 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.85 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 60.3 p -81.36 48.26 1.13 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.8 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.481 179.972 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 11.7 t -173.23 157.43 3.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.871 0.367 . . . . 0.0 110.851 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 16.3 m -70.97 94.51 1.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -125.53 126.94 6.05 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 15.5 t -166.82 108.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.867 0.365 . . . . 0.0 110.84 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 45.8 t -136.09 130.07 32.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -135.49 140.2 11.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.47 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 84.2 p -87.39 86.59 7.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.878 0.37 . . . . 0.0 110.851 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 99.6 t -101.13 90.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.124 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 140.21 -83.92 0.23 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.525 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -80.57 121.97 81.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.571 0.701 . . . . 0.0 110.889 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 -47.12 1.01 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.681 2.254 . . . . 0.0 112.342 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 413' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.1 m-30 -63.31 97.18 0.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.914 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.5 mm -108.15 125.44 64.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.144 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.0 t -52.4 126.53 19.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 -87.32 21.48 2.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.57 -51.92 2.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.9 p -110.79 -47.09 3.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.37 11.63 2.44 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.599 ' O ' HG23 ' A' ' 414' ' ' ILE . 44.1 mttt -64.63 -179.4 0.49 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.76 143.21 11.16 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.46 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -139.04 159.66 41.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.891 0.377 . . . . 0.0 110.856 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.0 m -92.21 -30.16 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.415 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.2 mtp180 -112.16 154.95 44.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.639 0.733 . . . . 0.0 110.896 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -44.45 2.08 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.715 2.277 . . . . 0.0 112.316 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -66.98 -38.21 85.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.852 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.415 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.8 m170 -56.87 -49.28 75.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 432' ' ' ILE . 6.6 tp -63.55 -45.94 88.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.896 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -49.05 -53.98 17.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.3 -41.11 31.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.527 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 431' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 12.5 t60 -64.84 -40.97 96.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.787 0.327 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.653 HD11 HD11 ' A' ' 428' ' ' LEU . 20.6 mt -73.27 -20.83 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.142 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.508 ' O ' HG21 ' A' ' 437' ' ' THR . 0.5 OUTLIER -103.68 -2.71 26.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -114.56 -28.56 7.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.4 t -114.22 -37.51 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.532 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.9 m-70 -97.18 12.89 31.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.85 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.508 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.1 t -86.74 132.43 33.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 67.2 p -137.05 130.56 31.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 48.6 mm-40 -93.24 137.72 32.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -167.52 144.1 3.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.613 0.721 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -176.69 1.56 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.344 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 45.0 m80 -57.97 102.36 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.872 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.71 98.33 7.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.917 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 84.2 m -78.67 119.08 21.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -104.39 95.96 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.969 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 12.7 p -168.79 137.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.722 ' CD2' HG23 ' A' ' 448' ' ' VAL . 3.4 p-90 -110.25 -35.77 6.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.722 HG23 ' CD2' ' A' ' 447' ' ' TRP . 63.8 t -146.87 132.92 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 20.4 p -127.01 144.82 50.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 138.7 -78.05 0.32 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.458 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 164.98 32.5 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.63 2.22 . . . . 0.0 112.372 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 46.5 t 62.64 42.95 7.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 2.7 t -86.5 158.92 19.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.861 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.514 179.973 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.519 -0.232 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 51.6 p -97.83 147.11 24.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.869 0.366 . . . . 0.0 110.884 -179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 5.7 m -139.01 154.15 48.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.843 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 126.29 95.35 0.96 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 71.1 m -114.44 150.78 34.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 43.9 m -83.53 164.18 19.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -132.36 -147.02 5.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.499 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 408' ' ' SER . . . . . 0.487 ' O ' ' N ' ' A' ' 410' ' ' GLY . 86.8 p -120.43 -49.41 2.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 409' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 409' ' ' VAL . 8.3 p 37.98 27.5 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 410' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 408' ' ' SER . . . -162.53 -105.19 0.19 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.49 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -85.87 119.78 72.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.612 0.72 . . . . 0.0 110.876 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -47.87 0.83 Allowed 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.679 2.252 . . . . 0.0 112.364 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -61.25 93.98 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.497 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.7 mm -102.07 128.74 54.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 7.7 t -60.19 121.12 11.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 10.1 mm-40 -80.63 -4.19 53.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.589 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 3.2 m -86.95 -45.14 11.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.4 p -121.02 -49.09 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.61 0.77 2.86 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.501 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 414' ' ' ILE . 35.8 mttm -55.48 -179.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.842 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.31 147.56 18.44 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 5.3 m-85 -143.96 157.41 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.7 m -90.91 -21.92 21.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.416 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 13.3 mtp85 -120.95 155.52 57.56 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 0.0 110.858 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -48.74 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.701 2.268 . . . . 0.0 112.344 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -63.0 -36.28 83.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.416 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 56.1 m170 -58.85 -52.82 64.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 14.0 tp -61.47 -42.86 99.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -51.22 -55.05 20.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.888 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -46.86 -42.77 15.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -63.36 -43.28 98.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.785 0.326 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -72.33 -15.96 18.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.104 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.507 ' O ' HG21 ' A' ' 437' ' ' THR . 14.2 ttpp -105.26 -7.59 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -114.29 -22.97 9.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.86 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.6 t -116.53 -36.94 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.589 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.7 m-70 -98.99 13.69 31.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.507 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.3 t -87.58 149.47 24.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 23.1 t 66.05 35.09 6.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -83.5 -176.27 6.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 440' ' ' ARG . . . . . 0.405 ' HD2' ' N ' ' A' ' 440' ' ' ARG . 3.2 mpt_? -105.27 148.37 36.14 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.591 0.71 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 441' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 442' ' ' HIS . 54.0 Cg_endo -69.79 -5.31 15.92 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.644 2.229 . . . . 0.0 112.372 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 442' ' ' HIS . . . . . 0.429 ' C ' ' O ' ' A' ' 441' ' ' PRO . 5.5 t-80 -35.17 147.65 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.876 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -135.88 149.11 48.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 444' ' ' CYS . . . . . 0.527 ' O ' HG23 ' A' ' 446' ' ' VAL . 19.8 t -58.78 96.71 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 26.8 tp60 -54.6 108.66 0.41 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 446' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 444' ' ' CYS . 98.7 t -104.49 133.21 49.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.453 ' CD1' ' N ' ' A' ' 448' ' ' VAL . 46.8 p90 -83.55 -49.78 8.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.908 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.453 ' N ' ' CD1' ' A' ' 447' ' ' TRP . 14.6 p -105.43 137.78 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.132 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 50.3 m 52.15 41.44 30.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -97.72 -95.16 1.94 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 138.08 37.07 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 80.3 p -44.04 -50.28 8.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 453' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 454' ' ' GLY . 12.7 t -54.94 -66.17 0.45 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.853 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 454' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 453' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.466 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 21.3 m -158.78 177.2 11.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.865 0.364 . . . . 0.0 110.834 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 7.4 t -89.75 42.5 1.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.83 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 53.69 -158.04 5.06 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 31.1 t -71.78 90.93 1.11 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.895 0.378 . . . . 0.0 110.882 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 24.6 t -117.33 98.17 6.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.881 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -102.45 47.24 1.15 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.509 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 82.6 p -97.25 42.66 1.08 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.895 0.379 . . . . 0.0 110.859 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 34.5 m -116.79 144.85 23.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -82.2 -67.67 1.49 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.49 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -54.7 117.81 14.91 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.606 0.717 . . . . 0.0 110.931 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -48.35 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.66 2.24 . . . . 0.0 112.371 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.74 89.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.3 mm -100.52 126.82 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 15.5 t -53.99 131.52 40.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 12.2 mm100 -91.63 21.31 4.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.08 -46.24 2.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.843 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 17.9 p -117.97 -47.86 2.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 134.49 2.38 3.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.469 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 414' ' ' ILE . 22.1 mttm -55.97 176.24 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.28 144.24 12.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 17.2 m-85 -140.04 169.14 18.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.866 0.365 . . . . 0.0 110.87 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -103.03 -26.49 13.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.871 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 14.4 mtt-85 -112.1 149.51 41.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.591 0.71 . . . . 0.0 110.888 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -31.69 19.8 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.712 2.275 . . . . 0.0 112.347 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -78.73 -36.5 43.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 48.4 m170 -59.46 -53.32 59.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.864 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.38 -47.23 84.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.921 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -49.57 -52.8 27.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.39 -41.99 33.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -63.37 -40.78 98.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.778 0.323 . . . . 0.0 110.897 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -71.79 -22.92 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.485 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.8 tttm -102.83 1.8 34.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 72.0 tp60 -119.83 -27.66 5.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.5 t -114.92 -42.41 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.104 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.2 m-70 -89.66 -3.19 58.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.584 HG23 ' O ' ' A' ' 437' ' ' THR . 5.3 t -67.53 88.63 0.22 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 34.6 t -121.34 -46.96 2.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -103.92 171.61 7.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -150.48 145.92 19.13 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.609 0.719 . . . . 0.0 110.896 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 84.21 0.67 Allowed 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.642 2.228 . . . . 0.0 112.336 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 442' ' ' HIS . . . . . 0.411 ' NE2' ' O ' ' A' ' 443' ' ' LYS . 11.4 t-80 -83.24 155.03 23.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 443' ' ' LYS . . . . . 0.411 ' O ' ' NE2' ' A' ' 442' ' ' HIS . 1.4 pmtp? -124.44 152.65 43.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 84.8 m -68.76 122.02 17.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -64.33 135.44 56.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 446' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 446' ' ' VAL . 11.6 p -127.61 127.66 68.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.135 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.496 ' CD2' HG23 ' A' ' 448' ' ' VAL . 16.0 t-105 -66.9 -53.07 35.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.958 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.496 HG23 ' CD2' ' A' ' 447' ' ' TRP . 94.2 t -159.4 136.38 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 449' ' ' SER . . . . . 0.47 ' CB ' ' HB3' ' A' ' 452' ' ' SER . 69.6 m -52.5 174.21 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -110.07 -87.23 1.8 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.463 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.91 3.12 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.675 2.25 . . . . 0.0 112.367 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 452' ' ' SER . . . . . 0.47 ' HB3' ' CB ' ' A' ' 449' ' ' SER . 11.0 p -39.48 159.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.811 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 22.7 m -64.08 177.99 0.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.439 -0.264 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.8 t -91.82 42.19 1.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 66.9 m -101.13 86.11 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -77.16 91.33 1.02 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 72.9 m -79.45 128.51 33.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.863 0.363 . . . . 0.0 110.844 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 95.7 p -164.26 145.6 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 136.78 170.51 11.96 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 53.6 p -164.73 135.3 4.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.808 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 72.1 t -106.93 130.44 58.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.148 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 145.76 -52.25 0.58 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.449 ' HE3' ' N ' ' A' ' 411' ' ' LYS . 0.0 OUTLIER -88.65 110.2 35.31 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -49.06 0.6 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.21 95.49 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.535 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.2 mm -104.0 127.04 58.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.098 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.8 t -52.94 127.81 25.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -88.06 21.86 2.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.546 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.11 -51.25 2.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.2 p -112.36 -46.39 3.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.49 9.61 2.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.482 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.535 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.9 mttm -62.81 -179.52 0.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 110.887 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -145.19 142.09 10.48 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -137.51 164.39 28.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.871 0.367 . . . . 0.0 110.856 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.4 m -96.11 -28.37 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.876 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.577 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.5 mmt180 -114.56 152.83 46.57 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.576 0.703 . . . . 0.0 110.886 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -38.05 8.33 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.687 2.258 . . . . 0.0 112.349 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.22 -40.16 71.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.577 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 45.4 m170 -58.37 -44.59 88.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.551 HD11 HD11 ' A' ' 432' ' ' ILE . 5.3 tp -66.16 -45.3 81.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.942 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -51.37 -55.26 19.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.52 -40.66 16.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -64.3 -40.59 96.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.809 0.338 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.551 HD11 HD11 ' A' ' 428' ' ' LEU . 14.0 mt -72.85 -23.82 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.501 ' O ' HG21 ' A' ' 437' ' ' THR . 58.2 tttt -101.76 -1.99 31.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -115.77 -27.86 6.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.86 -36.88 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.546 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 -98.74 15.34 25.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.501 HG21 ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -88.96 145.54 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.888 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 438' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 437' ' ' THR . 25.5 t -34.55 148.89 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.898 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -55.79 163.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -135.68 145.91 55.1 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.586 0.707 . . . . 0.0 110.856 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 151.34 68.83 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.636 2.224 . . . . 0.0 112.373 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -108.48 -50.13 3.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.872 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 5.7 mtpm? -119.66 37.15 4.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.916 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 2.5 m -131.92 93.11 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -122.26 42.07 3.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.913 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 58.3 t -132.36 133.78 59.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.448 ' CG ' ' N ' ' A' ' 448' ' ' VAL . 4.6 p-90 -88.07 -42.61 12.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.962 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.449 ' O ' HG13 ' A' ' 448' ' ' VAL . 13.5 p -80.65 126.49 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.115 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 5.9 m -128.12 135.58 49.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.79 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -124.2 -94.94 1.1 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.511 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -50.73 0.43 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.726 2.284 . . . . 0.0 112.325 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 81.0 p -175.02 176.92 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 41.7 t -67.57 -56.25 10.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.842 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.456 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 79.0 p -124.28 163.22 22.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.822 0.344 . . . . 0.0 110.883 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 56.9 p -69.88 -51.28 34.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.846 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 69.02 -169.86 42.04 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.523 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 89.5 p -137.09 109.01 7.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.898 0.38 . . . . 0.0 110.855 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 24.6 t -132.39 139.91 48.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.868 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 87.6 82.02 1.22 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.496 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.6 m -84.45 104.4 14.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.952 0.406 . . . . 0.0 110.868 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 3.8 p -173.48 141.01 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.174 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 117.92 -146.64 18.65 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 6.0 mptt -86.87 121.27 71.84 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.551 0.691 . . . . 0.0 110.895 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -48.76 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.676 2.251 . . . . 0.0 112.349 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.32 90.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.9 mm -101.75 127.24 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.128 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 9.5 t -53.16 127.67 25.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.882 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.6 mm-40 -88.35 17.96 4.83 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.593 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.6 m -113.44 -42.88 3.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.6 p -121.92 -49.75 2.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.861 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 138.47 -1.06 2.61 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.623 ' O ' HG23 ' A' ' 414' ' ' ILE . 39.2 mttt -52.69 179.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.816 0.341 . . . . 0.0 110.881 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.407 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -148.87 144.76 12.57 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.49 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 16.2 m-85 -140.01 165.04 28.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.856 0.36 . . . . 0.0 110.832 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.1 m -94.81 -33.59 12.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 19.7 mtp180 -109.3 155.25 41.42 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.613 0.721 . . . . 0.0 110.84 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -44.5 2.01 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.695 2.264 . . . . 0.0 112.32 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -65.5 -40.51 93.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.855 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.413 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 57.0 m170 -55.39 -51.12 67.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.907 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.14 -46.27 89.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -49.2 -54.12 18.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.02 -39.91 26.98 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -65.3 -39.04 91.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.846 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -75.27 -18.07 16.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.2 OUTLIER -107.28 -2.01 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.912 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 39.9 tp60 -116.36 -27.01 6.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.919 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 30.5 t -114.95 -40.41 3.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.593 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.4 m-70 -93.18 14.55 17.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.813 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.3 t -90.03 100.82 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 87.1 p -55.3 -46.35 76.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.818 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -127.75 138.23 52.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.39 144.99 83.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.668 0.747 . . . . 0.0 110.851 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 109.4 2.31 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.674 2.25 . . . . 0.0 112.33 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 1.9 p-80 -119.54 130.91 55.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.882 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -103.97 73.53 1.16 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.946 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 6.7 t -168.77 105.29 0.42 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.903 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -151.87 139.48 19.7 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.903 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 14.9 p -170.21 152.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.476 ' CE2' HG12 ' A' ' 448' ' ' VAL . 75.8 t-105 -138.62 146.06 41.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.93 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.476 HG12 ' CE2' ' A' ' 447' ' ' TRP . 7.5 p -34.09 137.68 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 21.9 t -128.1 91.0 3.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 56.12 -155.4 12.96 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 451' ' ' PRO . . . . . 0.455 ' O ' ' C ' ' A' ' 452' ' ' SER . 53.4 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.691 2.261 . . . . 0.0 112.314 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 452' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 451' ' ' PRO . 13.4 t -34.32 130.85 0.34 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.822 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 7.6 t -61.91 133.15 55.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.889 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.5 m -140.08 113.61 8.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.939 0.4 . . . . 0.0 110.867 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 55.1 p -67.89 163.73 21.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -178.62 61.47 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.51 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 7.5 t -118.25 110.72 17.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.842 0.353 . . . . 0.0 110.844 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 33.1 t -152.17 132.24 13.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -132.55 -59.99 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 29.5 t -55.89 143.99 29.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.896 0.379 . . . . 0.0 110.862 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 26.8 m -74.25 141.35 16.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -151.3 -164.06 11.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.475 ' HE3' ' N ' ' A' ' 411' ' ' LYS . 0.0 OUTLIER -50.82 107.56 0.84 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.525 0.679 . . . . 0.0 110.874 -179.963 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -49.67 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.624 2.216 . . . . 0.0 112.344 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -58.54 90.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.553 HG23 ' O ' ' A' ' 419' ' ' GLY . 10.9 mm -98.54 128.58 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.8 t -56.77 129.38 41.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 40.3 mm-40 -88.53 20.29 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.65 -44.84 2.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.3 p -121.59 -46.5 2.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 419' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.51 -8.16 3.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.5 mttt -46.34 170.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -140.91 144.03 14.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -138.1 170.37 16.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 110.881 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 36.9 m -100.23 -34.16 10.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.563 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 83.9 mtt-85 -107.92 155.0 40.74 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.602 0.715 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -46.18 1.3 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.705 2.27 . . . . 0.0 112.298 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.5 -36.25 83.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.563 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 54.6 m170 -58.65 -51.7 68.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.0 tp -62.27 -44.39 96.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -50.77 -53.38 32.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.57 -40.95 25.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -64.37 -40.75 96.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.816 0.341 . . . . 0.0 110.833 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.0 mt -73.57 -16.97 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.129 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 55.9 tttt -107.9 -1.25 20.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -117.9 -25.78 6.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.09 -39.28 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.7 m-70 -95.32 14.45 22.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.854 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.436 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.3 t -89.96 99.89 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.109 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 68.2 m -133.13 -176.15 4.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.878 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -82.49 148.23 28.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.874 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 29.3 mtt-85 -121.68 150.54 55.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.595 0.712 . . . . 0.0 110.858 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 177.17 5.85 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.679 2.253 . . . . 0.0 112.354 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 13.0 p-80 -51.54 103.49 0.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 443' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 444' ' ' CYS . 0.3 OUTLIER -166.8 111.88 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.89 179.98 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 444' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 443' ' ' LYS . 27.7 p -34.8 127.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.856 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -110.21 40.87 1.85 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 446' ' ' VAL . . . . . 0.555 HG11 ' HA2' ' A' ' 450' ' ' GLY . 3.0 m -109.03 -174.98 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.114 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.504 ' CD1' HG12 ' A' ' 448' ' ' VAL . 2.0 p-90 -131.98 -40.64 1.04 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.504 HG12 ' CD1' ' A' ' 447' ' ' TRP . 5.9 p -103.74 -41.85 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.116 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 89.1 p -172.0 172.33 4.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 450' ' ' GLY . . . . . 0.555 ' HA2' HG11 ' A' ' 446' ' ' VAL . . . -55.36 -93.37 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.452 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.57 3.62 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.647 2.231 . . . . 0.0 112.359 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 7.3 t -81.36 179.82 7.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.837 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 15.9 m -114.98 -49.47 2.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.863 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.952 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.377 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.4 m -84.21 45.73 1.14 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.859 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 2.4 m -135.29 150.82 50.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -128.51 -89.89 0.63 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.524 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 77.8 p -66.6 91.97 0.2 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.898 0.38 . . . . 0.0 110.868 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 5.1 t -124.07 41.66 3.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 168.2 -104.17 0.21 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.458 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 408' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 409' ' ' VAL . 30.4 t -48.86 147.97 2.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.902 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 409' ' ' VAL . . . . . 0.52 HG22 ' O ' ' A' ' 409' ' ' VAL . 10.2 p 34.33 39.38 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -76.16 -178.92 45.6 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.33 118.67 72.25 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.549 0.69 . . . . 0.0 110.932 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -47.59 0.9 Allowed 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.712 2.275 . . . . 0.0 112.38 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.41 97.88 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.6 mm -108.13 130.56 60.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -55.91 123.51 14.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.855 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -86.08 20.24 2.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.403 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.17 -46.74 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.864 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.6 p -115.99 -46.53 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.15 10.6 2.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.671 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.31 -179.75 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.857 0.361 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.16 142.88 10.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -138.87 162.02 35.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.908 0.385 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.7 m -93.24 -32.33 14.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.506 ' HE ' ' CE1' ' A' ' 427' ' ' HIS . 21.1 mtm180 -112.37 155.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -42.01 3.86 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.282 . . . . 0.0 112.38 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.27 -38.85 85.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.506 ' CE1' ' HE ' ' A' ' 424' ' ' ARG . 51.7 m170 -58.41 -49.24 77.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.688 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -62.68 -45.92 90.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -50.04 -55.29 15.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.852 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.43 -39.44 14.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 431' ' ' HIS . . . . . 0.422 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.9 t60 -66.54 -41.38 88.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.767 0.317 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.688 HD11 HD11 ' A' ' 428' ' ' LEU . 16.2 mt -74.17 -15.65 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.451 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 1.1 ttmp? -110.9 0.89 17.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 61.1 tp60 -119.05 -25.73 6.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.937 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 33.7 t -116.7 -42.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.1 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.403 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 -89.06 -18.14 27.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.401 ' HB ' ' C ' ' A' ' 433' ' ' LYS . 2.6 t -44.02 148.8 0.38 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.164 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 1.4 m 73.12 51.92 0.13 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 439' ' ' GLU . . . . . 0.414 ' C ' ' HD2' ' A' ' 440' ' ' ARG . 8.0 pt-20 -149.54 147.29 28.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 440' ' ' ARG . . . . . 0.414 ' HD2' ' C ' ' A' ' 439' ' ' GLU . 2.3 mpt_? -144.62 144.59 25.33 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.673 0.749 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 441' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 442' ' ' HIS . 53.6 Cg_endo -69.78 0.44 5.65 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.717 2.278 . . . . 0.0 112.313 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 442' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 441' ' ' PRO . 5.7 t60 -36.56 -41.54 0.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.853 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 11.4 mptt -80.61 48.0 1.01 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 1.8 t -141.8 158.94 43.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -110.02 79.94 1.26 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 7.9 p -103.17 142.9 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.446 ' CD1' ' N ' ' A' ' 448' ' ' VAL . 43.9 p90 -73.36 -47.83 39.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.917 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.446 ' N ' ' CD1' ' A' ' 447' ' ' TRP . 5.2 p -94.41 136.43 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 1.8 t -54.21 -69.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 152.98 145.86 4.24 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.473 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 451' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 452' ' ' SER . 53.5 Cg_endo -69.76 2.15 3.79 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.713 2.276 . . . . 0.0 112.324 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 452' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 451' ' ' PRO . 1.4 t -34.65 102.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.82 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 70.0 m -107.1 49.35 0.8 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.84 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.516 179.964 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 97.4 p -130.31 106.42 8.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.844 0.355 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 86.9 p -164.83 173.38 11.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 174.92 52.08 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.546 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 41.1 t -171.98 133.9 0.74 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.832 0.349 . . . . 0.0 110.862 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 5.9 t -142.6 129.44 20.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -156.76 114.92 0.63 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 408' ' ' SER . . . . . 0.509 ' O ' ' C ' ' A' ' 409' ' ' VAL . 48.0 m -74.47 -41.16 61.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 110.833 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 409' ' ' VAL . . . . . 0.674 ' O ' HG23 ' A' ' 409' ' ' VAL . 6.8 m 29.03 46.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 152.68 178.6 27.49 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.491 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -45.99 118.1 4.24 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.551 0.691 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -47.02 1.03 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -62.67 95.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.938 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.682 HG23 ' O ' ' A' ' 420' ' ' LYS . 28.9 mm -105.73 132.26 53.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.6 t -57.17 126.69 28.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -86.28 21.13 2.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.537 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.22 -55.83 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.836 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.3 p -106.78 -44.53 4.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.03 9.79 3.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.682 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -62.87 -179.79 0.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.828 0.347 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.4 144.64 13.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.424 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 10.7 m-85 -139.26 160.93 38.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 54.2 m -91.67 -32.72 15.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.487 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 26.4 mtt-85 -111.28 154.51 43.61 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.581 0.705 . . . . 0.0 110.877 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -42.62 3.24 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 36.9 t0 -66.77 -38.65 86.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.487 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -57.99 -49.5 76.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -63.51 -44.42 94.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -49.81 -52.84 29.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 430' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 434' ' ' GLN . . . -49.76 -43.5 38.42 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.513 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -63.34 -40.5 97.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 110.865 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 20.4 mt -74.78 -18.72 16.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.478 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.6 tttp -109.82 0.96 19.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.895 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 434' ' ' GLN . . . . . 0.42 ' N ' ' O ' ' A' ' 430' ' ' GLY . 54.1 tp60 -119.44 -25.8 5.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.9 t -116.39 -40.34 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.179 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.537 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 77.5 m-70 -92.47 9.17 35.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.476 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.9 t -87.76 -38.97 15.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.106 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 70.1 m -51.78 116.65 2.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.872 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -52.18 141.14 19.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.882 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 18.7 mtt-85 -132.15 154.52 81.69 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.587 0.708 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 179.71 3.53 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.657 2.238 . . . . 0.0 112.364 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 63.9 t-80 -127.62 144.65 51.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.861 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.51 148.09 16.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.938 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 42.4 t -55.9 109.01 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.823 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 -65.9 176.0 1.78 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 12.5 p -71.59 152.91 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.081 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.432 ' O ' ' C ' ' A' ' 448' ' ' VAL . 45.0 t-105 -90.38 139.57 30.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 447' ' ' TRP . 70.8 t -34.4 128.91 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.146 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 5.9 t -38.95 -54.54 1.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 135.73 -81.78 0.29 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 92.75 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.273 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 452' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 453' ' ' SER . 21.8 t -76.34 -51.33 12.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.87 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 453' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 452' ' ' SER . 2.1 t -35.36 113.21 0.19 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 179.979 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 4.1 t -96.69 137.45 35.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.908 0.385 . . . . 0.0 110.88 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 3.2 t -124.22 169.61 11.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -114.87 -154.0 10.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.509 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 57.9 m -117.53 134.13 55.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.883 0.373 . . . . 0.0 110.839 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 46.3 m -140.24 155.59 46.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 173.0 140.07 3.05 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.472 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 38.6 m -118.92 130.42 55.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.938 0.399 . . . . 0.0 110.867 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.17 147.91 5.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.134 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 156.68 -73.48 0.23 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.473 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.92 124.3 88.34 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.562 0.696 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -48.8 0.64 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.665 2.243 . . . . 0.0 112.294 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -61.02 90.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.947 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.5 mm -103.25 130.5 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.5 t -57.6 126.72 28.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -86.91 20.9 2.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.48 -52.41 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.816 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.4 p -110.75 -45.52 3.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.889 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.6 11.69 2.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.474 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.575 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.59 179.88 0.57 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.824 0.345 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.13 142.73 10.81 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.401 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 9.9 m-85 -137.96 162.4 34.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.893 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 15.8 m -94.67 -30.6 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.834 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.408 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 35.7 mtp85 -111.16 154.54 43.51 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.616 0.722 . . . . 0.0 110.865 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 -45.65 1.47 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.685 2.256 . . . . 0.0 112.321 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.46 -40.28 93.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.408 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 53.1 m170 -54.84 -51.16 66.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.845 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 432' ' ' ILE . 9.2 tp -62.34 -45.05 94.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -50.27 -55.68 14.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 430' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.21 -38.21 18.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -67.26 -40.79 86.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.747 0.308 . . . . 0.0 110.841 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.508 HD11 HD11 ' A' ' 428' ' ' LEU . 18.5 mt -74.3 -20.53 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.442 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 49.5 tttt -106.87 -0.82 23.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 434' ' ' GLN . . . . . 0.474 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.7 tp-100 -116.7 -27.6 6.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 32.1 t -114.96 -39.88 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.407 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 -93.47 11.36 28.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.905 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.403 ' H ' HG22 ' A' ' 437' ' ' THR . 1.4 t -86.4 128.07 34.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 30.7 m -53.87 111.25 0.71 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -166.71 123.97 1.3 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -142.14 147.38 43.88 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.548 0.69 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 161.58 45.38 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.627 2.218 . . . . 0.0 112.349 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 17.8 m-70 -108.08 42.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.845 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -117.34 86.4 2.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 18.9 p -164.3 156.34 16.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.57 112.52 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 13.6 p -95.46 146.84 6.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.147 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.599 ' CH2' ' O ' ' A' ' 448' ' ' VAL . 0.1 OUTLIER -128.91 141.27 51.33 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.599 ' O ' ' CH2' ' A' ' 447' ' ' TRP . 3.9 m -34.42 98.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.122 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 449' ' ' SER . . . . . 0.44 ' HB2' ' CE3' ' A' ' 447' ' ' TRP . 42.7 t -126.71 86.71 2.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.848 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 141.2 -94.98 0.19 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 98.57 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.631 2.221 . . . . 0.0 112.387 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 68.6 p -81.85 40.9 0.63 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 71.2 p -134.5 165.97 23.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.497 -179.955 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 55.3 p -129.44 147.17 51.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 0.0 110.844 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 40.9 m -79.95 173.03 13.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 136.94 102.72 0.64 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 26.0 p -171.82 145.87 1.99 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 32.3 m -105.56 152.05 23.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -161.39 165.91 35.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 80.7 p -138.97 128.51 24.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.967 0.413 . . . . 0.0 110.884 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 35.2 m -141.59 154.5 19.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.116 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -126.74 52.61 0.81 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.496 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.409 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 11.5 mptt -133.19 107.22 12.34 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.538 0.685 . . . . 0.0 110.922 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 412' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.74 -48.04 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.718 2.279 . . . . 0.0 112.365 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -60.92 93.69 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.2 mm -100.79 131.51 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.138 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.9 t -56.57 125.29 21.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -86.1 20.29 2.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.594 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.61 -43.08 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.3 p -122.06 -46.99 2.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 419' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 135.4 -1.69 3.72 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.657 ' O ' HG23 ' A' ' 414' ' ' ILE . 40.0 mttt -51.67 179.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.868 0.366 . . . . 0.0 110.872 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -147.41 142.97 10.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -138.28 163.88 30.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.83 0.348 . . . . 0.0 110.93 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 423' ' ' SER . . . . . 0.451 ' O ' ' NH1' ' A' ' 424' ' ' ARG . 3.1 m -96.39 -22.75 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.82 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.581 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 7.8 mmt-85 -119.22 152.95 53.05 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 110.873 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 425' ' ' PRO . . . . . 0.4 ' O ' ' OD1' ' A' ' 429' ' ' ASN . 53.6 Cg_endo -69.73 -41.99 3.82 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.692 2.262 . . . . 0.0 112.34 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -69.14 -42.02 76.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.581 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 58.8 m170 -55.22 -46.48 75.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.852 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.568 HD11 HD11 ' A' ' 432' ' ' ILE . 8.8 tp -65.92 -44.99 83.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 429' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 425' ' ' PRO . 16.6 m120 -50.16 -54.81 18.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.71 -43.16 21.95 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.513 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -62.98 -41.65 99.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.876 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 428' ' ' LEU . 20.0 mt -73.42 -15.92 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.498 ' O ' ' CG2' ' A' ' 437' ' ' THR . 16.2 ttpp -105.11 -8.43 18.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -112.93 -24.28 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.34 -36.18 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.594 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 79.7 m-70 -100.82 17.81 21.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.498 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 0.7 OUTLIER -90.01 90.53 8.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.171 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 37.4 p -164.36 173.74 11.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -86.48 131.54 34.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 77.4 mtt180 -140.47 150.51 61.05 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.632 0.729 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 90.44 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.715 2.276 . . . . 0.0 112.292 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -97.49 129.15 44.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.878 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 44.3 mmtt -57.56 162.62 2.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 74.7 m -64.17 82.72 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.887 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 445' ' ' GLN . . . . . 0.403 ' O ' ' CD ' ' A' ' 445' ' ' GLN . 0.8 OUTLIER -90.06 38.63 0.93 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.9 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 446' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 447' ' ' TRP . 7.1 p -158.17 139.75 5.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.598 ' CE2' HG23 ' A' ' 448' ' ' VAL . 18.3 t-105 -35.33 -64.74 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.598 HG23 ' CE2' ' A' ' 447' ' ' TRP . 96.3 t -144.81 116.02 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 449' ' ' SER . . . . . 0.405 ' HB2' ' CG1' ' A' ' 446' ' ' VAL . 35.5 t -100.28 -45.62 5.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.889 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 174.22 163.13 27.08 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 131.0 20.38 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.702 2.268 . . . . 0.0 112.35 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 90.3 p -135.5 113.2 10.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.853 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 44.0 t -61.83 -44.71 96.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.495 -180.0 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 40.8 m -59.66 110.97 1.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.866 0.365 . . . . 0.0 110.884 -179.771 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 82.4 p -98.4 161.45 13.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.873 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -141.52 -115.06 1.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.528 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 73.7 m -117.22 127.25 53.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.863 0.364 . . . . 0.0 110.875 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 42.5 p -74.67 -48.13 27.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.858 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -176.0 -126.55 0.96 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.476 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.0 t -142.37 143.99 32.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.961 0.41 . . . . 0.0 110.837 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 34.9 m -64.69 164.59 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 128.43 -93.37 0.35 Allowed Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.467 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.37 113.95 64.06 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.573 0.702 . . . . 0.0 110.902 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -48.89 0.63 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.323 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -59.2 94.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.5 mm -105.33 123.86 59.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.096 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.1 t -50.95 127.72 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.863 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -88.56 19.23 4.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.904 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.58 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -114.59 -45.92 2.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.2 p -118.62 -49.34 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.72 1.19 2.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.422 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.4 mttt -55.12 173.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.907 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.403 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -142.41 145.64 15.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.403 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 21.3 m-85 -141.12 167.99 20.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 69.2 m -98.57 -33.63 10.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.859 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.407 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 38.0 mtp180 -110.37 155.15 42.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.654 0.74 . . . . 0.0 110.852 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -37.24 9.32 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.04 -35.3 69.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.819 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.407 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 63.5 m170 -60.66 -52.66 64.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.432 HD11 HD11 ' A' ' 432' ' ' ILE . 10.8 tp -62.34 -46.04 90.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.911 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -49.2 -53.66 20.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 430' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.13 -40.19 20.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.48 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -66.4 -42.52 87.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.771 0.319 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.432 HD11 HD11 ' A' ' 428' ' ' LEU . 15.3 mt -72.38 -19.42 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.122 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 46.6 tttm -107.91 2.11 23.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 434' ' ' GLN . . . . . 0.409 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 13.1 tp60 -120.96 -25.33 5.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.0 t -116.43 -41.74 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.58 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.3 m-70 -89.17 -26.21 21.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.447 ' C ' ' O ' ' A' ' 436' ' ' HIS . 6.3 t -33.9 146.68 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 23.5 m 66.09 54.55 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -78.18 177.36 8.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -114.87 148.51 40.63 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.577 0.703 . . . . 0.0 110.853 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 92.69 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.695 2.263 . . . . 0.0 112.312 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 442' ' ' HIS . . . . . 0.435 ' O ' ' C ' ' A' ' 443' ' ' LYS . 22.4 m-70 -161.85 179.0 8.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.836 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 443' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 442' ' ' HIS . 8.2 ptpp? 34.84 44.0 0.11 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 56.7 m -105.39 121.78 44.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.855 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 57.2 tp60 -108.39 87.54 2.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 446' ' ' VAL . . . . . 0.441 ' CG1' HG22 ' A' ' 448' ' ' VAL . 86.2 t -141.98 133.2 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.812 ' CE2' HG13 ' A' ' 448' ' ' VAL . 9.2 p90 -89.12 -42.94 11.4 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.812 HG13 ' CE2' ' A' ' 447' ' ' TRP . 35.7 m -59.69 -178.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.107 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 84.3 p -131.55 100.82 5.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 179.45 138.54 3.33 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 163.12 39.43 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 0.0 112.34 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 31.0 m -66.6 -44.62 81.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.84 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 31.1 t -162.97 150.91 13.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.453 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 20.0 m -97.33 120.51 37.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.917 0.389 . . . . 0.0 110.785 -179.698 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 2.7 m -146.12 125.74 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.84 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -137.49 -153.15 6.27 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.483 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 1.8 m 43.44 47.88 6.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.864 0.364 . . . . 0.0 110.849 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 29.5 t -104.32 120.61 41.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 66.27 -178.15 14.37 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.475 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 66.4 m -121.8 163.7 18.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.888 0.375 . . . . 0.0 110.884 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 67.8 t -72.28 104.88 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.163 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -137.38 -84.9 0.15 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.451 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.462 ' CG ' ' C ' ' A' ' 422' ' ' PHE . 12.5 mptt -48.16 105.65 0.52 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.521 0.676 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 412' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.76 -48.5 0.71 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.68 2.253 . . . . 0.0 112.381 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.09 91.56 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.518 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.8 mm -98.22 124.82 51.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.15 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -49.89 127.6 16.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 67.1 mm-40 -89.12 20.93 3.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.564 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.72 -45.35 2.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 19.6 p -120.36 -46.56 2.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.864 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.19 -0.48 3.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.438 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.518 ' O ' HG23 ' A' ' 414' ' ' ILE . 27.7 mttm -51.29 176.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.338 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 421' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.59 146.22 16.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.494 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 422' ' ' PHE . . . . . 0.466 ' CD1' HD13 ' A' ' 428' ' ' LEU . 14.3 m-85 -142.46 -179.73 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.896 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 27.9 m -110.77 -34.29 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.437 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 80.1 mtt-85 -111.37 154.54 43.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.569 0.7 . . . . 0.0 110.889 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -33.62 16.3 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.654 2.236 . . . . 0.0 112.355 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -76.42 -31.77 58.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.437 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -65.8 -51.34 59.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.882 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.466 HD13 ' CD1' ' A' ' 422' ' ' PHE . 12.7 tp -64.16 -43.42 95.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -51.92 -50.36 61.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.91 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -51.71 -39.74 47.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.496 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -65.71 -40.6 92.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.895 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 10.7 mt -71.44 -22.42 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.471 ' O ' HG21 ' A' ' 437' ' ' THR . 0.8 OUTLIER -99.95 -1.04 38.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.938 179.854 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -115.76 -31.25 5.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.908 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.11 -38.27 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.137 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.564 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 -95.65 13.13 27.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.471 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.8 t -88.81 146.51 24.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 438' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 439' ' ' GLU . 1.5 t -167.71 159.31 11.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 439' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 438' ' ' SER . 6.8 pt-20 -37.22 141.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 8.4 mmp_? -69.47 146.51 96.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 110.858 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -2.55 10.4 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.641 2.227 . . . . 0.0 112.34 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -104.12 102.39 12.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -151.91 107.63 3.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 32.9 m -135.19 172.55 12.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -84.33 44.16 1.01 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.912 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 446' ' ' VAL . . . . . 0.427 HG23 ' N ' ' A' ' 447' ' ' TRP . 32.2 m -90.9 -40.75 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.466 ' CG ' ' N ' ' A' ' 448' ' ' VAL . 2.4 p-90 -46.71 -42.69 17.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.901 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.466 ' N ' ' CG ' ' A' ' 447' ' ' TRP . 56.1 t -155.2 141.88 11.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 9.1 m -45.17 155.78 0.12 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 177.46 139.34 3.3 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.476 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 108.55 2.1 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.716 2.277 . . . . 0.0 112.36 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 8.6 t -98.14 80.38 2.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.81 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 3.5 t -145.62 118.48 8.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.837 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.989 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.504 -0.239 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 71.2 m -95.16 114.73 26.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.833 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 57.6 p -114.22 129.81 56.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.827 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -93.76 -129.32 5.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 37.3 p -162.96 122.1 2.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.904 0.383 . . . . 0.0 110.817 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 2.9 t -87.62 106.35 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.898 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -113.91 68.36 0.25 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.515 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 47.8 t -71.44 124.05 23.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.88 0.371 . . . . 0.0 110.876 -179.726 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 97.2 t -71.37 113.35 7.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.158 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -132.65 -64.92 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.409 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 11.8 mptt -115.17 99.05 51.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.601 0.715 . . . . 0.0 110.883 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 412' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.1 Cg_endo -69.82 -48.47 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.651 2.234 . . . . 0.0 112.301 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -58.57 92.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.472 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.2 mm -95.78 133.64 36.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.143 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.1 t -60.62 124.36 20.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -84.76 16.6 3.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.559 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.2 m -112.63 -45.08 3.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 13.3 p -120.22 -47.75 2.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 419' ' ' GLY . . . . . 0.428 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.58 -4.19 3.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.517 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.472 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.9 mttt -50.43 175.25 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.366 . . . . 0.0 110.867 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.26 141.47 10.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -135.9 168.04 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.838 0.351 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 42.2 m -98.54 -31.02 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.886 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.8 mtt180 -113.12 155.32 44.51 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.725 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -45.39 1.58 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.332 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -65.1 -36.64 84.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 51.9 m170 -59.52 -51.41 69.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 13.9 tp -62.9 -45.78 90.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -48.48 -53.86 16.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.92 -42.09 29.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.48 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 14.3 t60 -64.14 -39.78 94.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.82 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 17.2 mt -75.39 -18.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' HG21 ' A' ' 437' ' ' THR . 33.2 tttt -108.28 -0.82 20.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.91 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -117.75 -27.04 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.1 t -114.93 -36.82 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.559 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 -95.12 7.41 46.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.851 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.48 HG21 ' O ' ' A' ' 433' ' ' LYS . 2.2 t -86.04 -41.57 14.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 6.2 t -64.37 170.29 3.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -96.15 139.16 32.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 42.0 mtm180 -80.58 153.51 73.46 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.573 0.702 . . . . 0.0 110.904 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -15.63 37.26 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.682 2.255 . . . . 0.0 112.343 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 13.6 t-80 -74.57 -39.02 62.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 10.8 mmmt -104.16 83.7 2.12 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.935 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 24.2 p -114.76 171.88 7.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 7.8 mm100 -69.33 172.72 6.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 90.6 t -67.28 144.52 14.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.109 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.59 ' CH2' ' O ' ' A' ' 448' ' ' VAL . 0.1 OUTLIER -147.17 140.81 25.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.59 ' O ' ' CH2' ' A' ' 447' ' ' TRP . 5.1 m -35.47 100.1 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.069 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 449' ' ' SER . . . . . 0.411 ' HA ' ' CZ3' ' A' ' 447' ' ' TRP . 10.1 p -128.62 164.76 22.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -116.79 -76.91 0.61 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.483 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 92.81 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.682 2.254 . . . . 0.0 112.353 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 57.7 p -139.18 126.18 21.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 98.9 p -95.13 -47.95 6.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.835 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.947 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 15.1 t 56.43 45.89 21.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 0.0 110.899 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 54.6 p -97.41 133.25 42.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 113.12 53.27 0.47 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.53 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 31.0 p -101.76 87.6 3.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.899 0.38 . . . . 0.0 110.84 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 16.7 t -129.81 88.64 2.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.881 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -110.05 101.99 1.5 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 72.3 m -129.04 129.59 45.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.827 -179.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 10.1 p -137.99 143.67 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 77.51 -81.17 1.24 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.504 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 411' ' ' LYS . . . . . 0.4 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 0.2 OUTLIER -108.5 107.47 60.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.614 0.721 . . . . 0.0 110.87 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 412' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.79 -48.16 0.77 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.744 2.296 . . . . 0.0 112.299 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -62.14 96.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.909 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.573 HG23 ' O ' ' A' ' 420' ' ' LYS . 12.6 mm -101.67 129.1 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.134 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 16.9 t -54.99 130.31 41.21 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 36.3 mm-40 -88.74 22.03 2.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.583 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -119.84 -57.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.3 p -105.56 -41.87 5.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.863 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 124.6 7.51 6.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.499 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 420' ' ' LYS . . . . . 0.573 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.0 mttt -58.97 179.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 110.943 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.64 139.51 8.57 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -134.49 170.59 15.54 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 68.3 m -101.75 -28.55 12.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.852 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 18.9 mtp180 -116.32 155.68 48.12 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.625 0.726 . . . . 0.0 110.88 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.656 2.237 . . . . 0.0 112.366 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.6 -34.56 78.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 50.7 m170 -61.65 -50.58 71.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.848 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.7 tp -62.9 -44.68 95.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -50.1 -54.61 19.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.859 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 430' ' ' GLY . . . . . 0.433 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -47.25 -37.11 10.88 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.484 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -69.6 -40.29 76.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.809 0.338 . . . . 0.0 110.895 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.5 mt -75.29 -16.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.46 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 51.7 tttt -110.86 0.99 17.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 434' ' ' GLN . . . . . 0.433 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.2 tp-100 -120.48 -29.16 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 34.2 t -110.76 -42.89 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.583 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.8 m-70 -88.3 -18.78 27.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.856 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.7 t -44.27 143.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.102 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 74.1 m -142.71 171.1 14.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.86 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -116.75 162.89 16.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -144.35 141.32 17.86 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.608 0.718 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 172.29 12.89 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.694 2.263 . . . . 0.0 112.352 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 442' ' ' HIS . . . . . 0.435 ' CG ' ' O ' ' A' ' 442' ' ' HIS . 3.0 p-80 -40.39 104.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 2.0 ttmp? -130.02 160.56 33.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 73.5 m 56.94 45.19 21.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 445' ' ' GLN . . . . . 0.679 ' O ' HG12 ' A' ' 448' ' ' VAL . 2.8 tp-100 -69.5 161.52 29.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 29.5 m -51.15 -20.87 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -55.27 -27.37 46.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.855 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.679 HG12 ' O ' ' A' ' 445' ' ' GLN . 10.7 p -98.88 46.62 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.104 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 35.9 t -147.45 129.41 15.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.877 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -53.41 -175.24 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 103.47 1.16 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.665 2.243 . . . . 0.0 112.337 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 60.8 m -109.05 135.61 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 1.4 t -85.56 97.14 9.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.872 -179.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.491 -179.964 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 63.8 m -82.7 44.46 0.91 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 14.5 t -82.54 41.86 0.73 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -84.53 160.56 36.14 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.495 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 23.3 p -141.92 167.54 21.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.867 0.365 . . . . 0.0 110.894 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 1.2 t -165.87 157.69 14.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 122.93 89.73 0.94 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.484 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 37.3 p -119.81 119.52 33.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 110.856 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.55 116.03 41.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 172.05 -127.31 1.39 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.9 117.68 23.15 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.909 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -47.74 0.89 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.724 2.283 . . . . 0.0 112.349 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -60.92 94.09 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.1 mm -103.99 123.53 57.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.167 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.9 t -52.6 130.71 32.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -91.26 20.97 4.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.942 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 417' ' ' SER . . . . . 0.566 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.03 -45.97 2.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.851 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 16.8 p -119.03 -44.36 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.907 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 131.11 0.4 5.12 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 30.4 mttm -55.09 172.54 0.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 0.0 110.875 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -141.23 143.93 13.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.479 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -137.09 166.88 22.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.893 0.378 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 59.8 m -98.37 -32.27 11.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.837 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 424' ' ' ARG . . . . . 0.418 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 56.3 mtt-85 -110.97 156.22 41.18 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.885 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -46.43 1.24 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.737 2.291 . . . . 0.0 112.364 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -64.42 -38.34 90.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 427' ' ' HIS . . . . . 0.418 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 60.0 m170 -56.87 -53.3 59.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.495 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.92 -45.18 95.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -49.32 -52.75 25.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.56 -42.99 36.16 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -63.3 -40.11 96.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.771 0.319 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 432' ' ' ILE . . . . . 0.495 HD11 HD11 ' A' ' 428' ' ' LEU . 13.6 mt -74.9 -16.36 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 433' ' ' LYS . . . . . 0.511 ' O ' HG21 ' A' ' 437' ' ' THR . 21.7 ttmt -108.94 -2.23 18.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.875 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 5.3 tp-100 -118.19 -25.68 6.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 14.5 t -115.46 -36.36 2.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 436' ' ' HIS . . . . . 0.566 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.0 m-70 -100.4 15.52 27.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.891 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 437' ' ' THR . . . . . 0.511 HG21 ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -89.45 142.99 27.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.105 -179.894 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 24.2 m -49.81 125.78 12.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.802 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -172.13 125.78 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 3.4 ptp180 -155.57 144.32 14.78 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 441' ' ' PRO . . . . . 0.412 ' O ' ' C ' ' A' ' 442' ' ' HIS . 53.6 Cg_endo -69.77 -177.52 1.92 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.702 2.268 . . . . 0.0 112.348 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 442' ' ' HIS . . . . . 0.489 ' CG ' ' O ' ' A' ' 442' ' ' HIS . 9.4 p80 -37.37 113.28 0.25 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -122.43 135.19 54.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.914 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 29.5 p -122.35 60.81 0.99 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -74.45 95.71 2.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 13.1 p -52.76 145.73 2.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.131 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 447' ' ' TRP . . . . . 0.779 ' CE2' HG22 ' A' ' 448' ' ' VAL . 24.6 t-105 -128.08 145.35 51.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 448' ' ' VAL . . . . . 0.779 HG22 ' CE2' ' A' ' 447' ' ' TRP . 26.9 m -35.25 142.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.165 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 449' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 450' ' ' GLY . 1.9 m -175.03 161.0 2.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 450' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 449' ' ' SER . . . 33.86 -96.31 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.492 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 451' ' ' PRO . . . . . 0.432 ' N ' ' O ' ' A' ' 449' ' ' SER . 54.0 Cg_endo -69.7 87.68 0.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.729 2.286 . . . . 0.0 112.359 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 24.6 p -84.5 141.8 30.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 70.9 m -117.69 99.37 6.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.878 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.21 0 CA-C-O 120.788 0.245 . . . . 0.0 112.301 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -59.04 94.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.895 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.605 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.2 mm -100.72 125.96 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.092 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.7 t -52.84 131.78 35.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.4 mm-40 -91.11 20.4 5.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.556 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.12 -48.8 2.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.0 p -115.45 -41.97 3.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . 0.426 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 127.98 -1.43 6.76 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.605 ' O ' HG23 ' A' ' 414' ' ' ILE . 17.4 mttp -50.99 179.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.879 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.4 143.83 11.76 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 15.2 m-85 -139.64 170.13 16.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.922 0.391 . . . . 0.0 110.836 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 5.3 m -99.96 -32.22 11.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.864 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.4 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 27.9 mtp180 -110.81 155.55 42.14 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.596 0.712 . . . . 0.0 110.86 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -45.33 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.65 2.233 . . . . 0.0 112.335 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.48 -40.15 92.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.844 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.4 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 54.7 m170 -54.68 -53.56 53.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.851 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.401 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.64 -44.18 96.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -49.92 -55.17 15.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.63 -40.77 17.9 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.451 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.7 t60 -64.95 -41.41 95.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.745 0.307 . . . . 0.0 110.868 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.401 HD11 HD11 ' A' ' 428' ' ' LEU . 13.7 mt -73.43 -18.34 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.123 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 61.0 tttt -108.84 1.42 20.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -120.16 -27.42 5.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.1 t -112.92 -41.69 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.556 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.8 m-70 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.876 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.749 0.229 . . . . 0.0 112.327 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.5 m-30 -61.44 93.4 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.661 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.1 mm -98.51 129.67 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.154 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 19.4 t -55.28 132.79 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.4 mm-40 -92.57 21.02 5.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.581 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.13 -48.5 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.83 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.7 p -115.64 -39.69 3.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 123.23 7.96 6.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.8 mttt -58.19 179.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.427 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.11 144.32 12.43 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.448 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.427 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 8.8 m-85 -138.93 -177.68 4.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.847 0.356 . . . . 0.0 110.927 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 23.9 m -112.32 -35.78 5.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.853 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.402 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 45.6 mtt180 -111.11 155.3 42.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.641 0.734 . . . . 0.0 110.831 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -29.58 23.39 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.65 2.234 . . . . 0.0 112.349 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -80.17 -32.05 38.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.859 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.402 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.9 m170 -65.2 -51.22 62.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.406 HD11 HD11 ' A' ' 432' ' ' ILE . 12.0 tp -63.53 -44.3 94.64 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -49.97 -53.04 28.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . 0.488 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.59 -39.46 23.11 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.456 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . 0.419 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.3 t60 -67.54 -42.74 82.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.406 HD11 HD11 ' A' ' 428' ' ' LEU . 11.7 mt -72.99 -19.39 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.109 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.484 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 32.8 tttt -108.35 1.71 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . 0.488 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 8.3 tp-100 -119.92 -28.9 5.08 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.938 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.4 t -112.8 -41.57 3.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.581 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.5 m-70 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 N--CA 1.465 -0.16 0 CA-C-O 120.825 0.26 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.3 m-30 -62.46 95.3 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.458 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.5 mm -105.87 124.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.084 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.9 t -51.02 128.6 21.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -89.57 19.28 4.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.878 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.558 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.69 -45.72 2.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 12.9 p -117.46 -49.49 2.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.897 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.53 -1.44 3.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.458 ' O ' HG23 ' A' ' 414' ' ' ILE . 26.4 mttm -54.24 174.72 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.811 0.339 . . . . 0.0 110.9 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.31 146.11 16.55 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.505 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -141.14 163.09 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.905 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.58 -27.94 14.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.807 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.41 ' HG3' ' ND1' ' A' ' 427' ' ' HIS . 14.7 mtp180 -110.07 148.94 39.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.849 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -33.17 17.1 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.335 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.52 -38.43 55.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.41 ' ND1' ' HG3' ' A' ' 424' ' ' ARG . 51.2 m170 -58.26 -52.54 65.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.804 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.607 HD11 HD11 ' A' ' 432' ' ' ILE . 8.9 tp -57.84 -46.62 84.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -49.5 -52.89 26.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . 0.479 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -49.2 -40.06 28.59 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.49 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.13 -42.96 88.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.607 HD11 HD11 ' A' ' 428' ' ' LEU . 12.1 mt -72.73 -19.93 19.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.139 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 23.8 ttmt -107.91 1.09 22.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.92 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . 0.479 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 71.0 tp60 -119.98 -26.27 5.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.92 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.6 t -114.39 -41.41 3.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.558 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.139 0 CA-C-O 120.759 0.233 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.7 m-30 -60.38 94.13 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.516 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.4 mm -98.16 128.09 49.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.103 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.8 t -59.23 132.95 55.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.874 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.7 mm-40 -91.9 2.23 56.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.584 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 7.6 m -93.69 -42.5 9.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.9 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.5 p -123.7 -46.44 2.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 132.78 4.46 3.41 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.455 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -58.25 178.08 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.824 0.345 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.98 143.06 11.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -138.37 169.59 17.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 9.8 m -101.48 -28.46 12.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -113.73 154.42 45.77 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.612 0.72 . . . . 0.0 110.925 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -47.5 0.93 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.717 2.278 . . . . 0.0 112.327 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -63.88 -37.5 87.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.4 m170 -58.27 -54.27 48.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.412 HD11 HD11 ' A' ' 432' ' ' ILE . 9.4 tp -59.66 -44.11 93.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -50.52 -54.31 23.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.934 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.12 -40.38 21.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -65.52 -40.74 93.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.412 HD11 HD11 ' A' ' 428' ' ' LEU . 11.4 mt -74.24 -19.01 17.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . . . . . . . . . 45.4 tttm -104.75 -4.25 22.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 45.2 tp60 -115.85 -26.27 7.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.6 t -114.78 -33.85 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.155 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.584 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.1 m-70 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.806 0.252 . . . . 0.0 112.334 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.76 94.8 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.912 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 420' ' ' LYS . 27.1 mm -102.94 133.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.125 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 38.4 t -57.47 128.42 36.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.896 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -85.75 22.39 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.481 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.1 t -122.98 -66.41 1.02 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.5 p -92.33 -42.55 9.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 121.86 12.53 5.4 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.707 ' O ' HG23 ' A' ' 414' ' ' ILE . 28.2 mttm -65.37 -179.48 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.419 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.18 143.53 11.71 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 11.7 m-85 -139.36 163.2 33.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.855 0.36 . . . . 0.0 110.873 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.3 m -95.47 -24.51 16.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.818 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.572 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.8 mmt85 -117.99 153.16 51.04 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.629 0.728 . . . . 0.0 110.847 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -40.09 5.77 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.643 2.229 . . . . 0.0 112.356 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -69.88 -42.51 73.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.572 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 59.1 m170 -56.48 -42.82 78.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.895 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -68.82 -44.55 73.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.945 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -51.97 -54.18 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.869 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.23 -40.05 21.34 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.516 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.21 -40.1 93.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.857 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 13.0 mt -75.33 -18.24 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.193 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 12.7 ttmt -107.15 -2.14 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.938 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -117.15 -25.46 7.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.92 -38.63 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.153 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.481 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.0 m-70 . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.815 0.256 . . . . 0.0 112.342 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.1 m-30 -63.31 97.18 0.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.914 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.5 mm -108.15 125.44 64.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.144 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.0 t -52.4 126.53 19.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 -87.32 21.48 2.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.57 -51.92 2.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.9 p -110.79 -47.09 3.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.37 11.63 2.44 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.599 ' O ' HG23 ' A' ' 414' ' ' ILE . 44.1 mttt -64.63 -179.4 0.49 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.76 143.21 11.16 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.46 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -139.04 159.66 41.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.891 0.377 . . . . 0.0 110.856 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.0 m -92.21 -30.16 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.415 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.2 mtp180 -112.16 154.95 44.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.639 0.733 . . . . 0.0 110.896 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -44.45 2.08 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.715 2.277 . . . . 0.0 112.316 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -66.98 -38.21 85.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.852 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.415 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.8 m170 -56.87 -49.28 75.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 432' ' ' ILE . 6.6 tp -63.55 -45.94 88.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.896 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -49.05 -53.98 17.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.3 -41.11 31.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.527 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 12.5 t60 -64.84 -40.97 96.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.787 0.327 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.653 HD11 HD11 ' A' ' 428' ' ' LEU . 20.6 mt -73.27 -20.83 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.142 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.421 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.5 OUTLIER -103.68 -2.71 26.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -114.56 -28.56 7.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.4 t -114.22 -37.51 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.532 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.9 m-70 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.232 0.203 0 CA-C-O 120.791 0.246 . . . . 0.0 112.364 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -61.25 93.98 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.497 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.7 mm -102.07 128.74 54.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 7.7 t -60.19 121.12 11.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 10.1 mm-40 -80.63 -4.19 53.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.589 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 3.2 m -86.95 -45.14 11.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.4 p -121.02 -49.09 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.61 0.77 2.86 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.501 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 414' ' ' ILE . 35.8 mttm -55.48 -179.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.842 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.31 147.56 18.44 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 5.3 m-85 -143.96 157.41 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.7 m -90.91 -21.92 21.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.416 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 13.3 mtp85 -120.95 155.52 57.56 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 0.0 110.858 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -48.74 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.701 2.268 . . . . 0.0 112.344 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -63.0 -36.28 83.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.416 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 56.1 m170 -58.85 -52.82 64.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 14.0 tp -61.47 -42.86 99.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -51.22 -55.05 20.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.888 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -46.86 -42.77 15.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -63.36 -43.28 98.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.785 0.326 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -72.33 -15.96 18.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.104 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.405 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 14.2 ttpp -105.26 -7.59 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -114.29 -22.97 9.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.86 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.6 t -116.53 -36.94 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.589 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.7 m-70 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.831 0.263 . . . . 0.0 112.371 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.74 89.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.3 mm -100.52 126.82 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 15.5 t -53.99 131.52 40.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 5.3 mm-40 -91.63 21.31 4.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.08 -46.24 2.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.843 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 17.9 p -117.97 -47.86 2.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 134.49 2.38 3.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.469 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 414' ' ' ILE . 22.1 mttm -55.97 176.24 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.28 144.24 12.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 17.2 m-85 -140.04 169.14 18.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.866 0.365 . . . . 0.0 110.87 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -103.03 -26.49 13.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.871 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 14.4 mtt-85 -112.1 149.51 41.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.591 0.71 . . . . 0.0 110.888 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -31.69 19.8 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.712 2.275 . . . . 0.0 112.347 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -78.73 -36.5 43.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 48.4 m170 -59.46 -53.32 59.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.864 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.38 -47.23 84.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.921 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.57 -52.8 27.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.39 -41.99 33.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -63.37 -40.78 98.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.778 0.323 . . . . 0.0 110.897 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -71.79 -22.92 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.485 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.8 tttm -102.83 1.8 34.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 72.0 tp60 -119.83 -27.66 5.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.5 t -114.92 -42.41 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.104 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.2 m-70 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.814 0.256 . . . . 0.0 112.354 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.21 95.49 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.535 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.2 mm -104.0 127.04 58.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.098 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.8 t -52.94 127.81 25.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 6.7 mm-40 -88.06 21.86 2.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.546 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.11 -51.25 2.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.2 p -112.36 -46.39 3.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.49 9.61 2.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.482 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.535 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.9 mttm -62.81 -179.52 0.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 110.887 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -145.19 142.09 10.48 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -137.51 164.39 28.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.871 0.367 . . . . 0.0 110.856 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.4 m -96.11 -28.37 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.876 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.577 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.5 mmt180 -114.56 152.83 46.57 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.576 0.703 . . . . 0.0 110.886 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -38.05 8.33 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.687 2.258 . . . . 0.0 112.349 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.22 -40.16 71.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.577 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 45.4 m170 -58.37 -44.59 88.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.551 HD11 HD11 ' A' ' 432' ' ' ILE . 5.3 tp -66.16 -45.3 81.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.942 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -51.37 -55.26 19.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.52 -40.66 16.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -64.3 -40.59 96.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.809 0.338 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.551 HD11 HD11 ' A' ' 428' ' ' LEU . 14.0 mt -72.85 -23.82 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.43 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 58.2 tttt -101.76 -1.99 31.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -115.77 -27.86 6.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.86 -36.88 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.546 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.153 0 CA-C-O 120.846 0.269 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.32 90.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.9 mm -101.75 127.24 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.128 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 9.5 t -53.16 127.67 25.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.882 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.6 mm-40 -88.35 17.96 4.83 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.593 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.6 m -113.44 -42.88 3.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.6 p -121.92 -49.75 2.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.861 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 138.47 -1.06 2.61 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.623 ' O ' HG23 ' A' ' 414' ' ' ILE . 39.2 mttt -52.69 179.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.816 0.341 . . . . 0.0 110.881 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.407 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -148.87 144.76 12.57 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.49 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 16.2 m-85 -140.01 165.04 28.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.856 0.36 . . . . 0.0 110.832 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.1 m -94.81 -33.59 12.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 19.7 mtp180 -109.3 155.25 41.42 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.613 0.721 . . . . 0.0 110.84 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -44.5 2.01 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.695 2.264 . . . . 0.0 112.32 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -65.5 -40.51 93.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.855 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.413 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 57.0 m170 -55.39 -51.12 67.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.907 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.14 -46.27 89.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -49.2 -54.12 18.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.02 -39.91 26.98 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -65.3 -39.04 91.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.846 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -75.27 -18.07 16.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.2 OUTLIER -107.28 -2.01 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.912 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 39.9 tp60 -116.36 -27.01 6.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.919 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 30.5 t -114.95 -40.41 3.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.593 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.4 m-70 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.813 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.786 0.244 . . . . 0.0 112.344 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -58.54 90.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.553 HG23 ' O ' ' A' ' 419' ' ' GLY . 10.9 mm -98.54 128.58 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.8 t -56.77 129.38 41.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 40.3 mm-40 -88.53 20.29 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.65 -44.84 2.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.3 p -121.59 -46.5 2.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.51 -8.16 3.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.5 mttt -46.34 170.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -140.91 144.03 14.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -138.1 170.37 16.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 110.881 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 36.9 m -100.23 -34.16 10.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.563 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 83.9 mtt-85 -107.92 155.0 40.74 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.602 0.715 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -46.18 1.3 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.705 2.27 . . . . 0.0 112.298 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.5 -36.25 83.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.563 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 54.6 m170 -58.65 -51.7 68.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.0 tp -62.27 -44.39 96.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -50.77 -53.38 32.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.57 -40.95 25.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -64.37 -40.75 96.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.816 0.341 . . . . 0.0 110.833 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.0 mt -73.57 -16.97 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.129 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 55.9 tttt -107.9 -1.25 20.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -117.9 -25.78 6.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.09 -39.28 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.7 m-70 . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.854 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.153 0 CA-C-O 120.798 0.249 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.41 97.88 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.6 mm -108.13 130.56 60.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -55.91 123.51 14.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.855 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -86.08 20.24 2.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.403 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.17 -46.74 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.864 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.6 p -115.99 -46.53 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.15 10.6 2.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.671 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.31 -179.75 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.857 0.361 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.16 142.88 10.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -138.87 162.02 35.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.908 0.385 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.7 m -93.24 -32.33 14.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.506 ' HE ' ' CE1' ' A' ' 427' ' ' HIS . 21.1 mtm180 -112.37 155.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -42.01 3.86 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.282 . . . . 0.0 112.38 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.27 -38.85 85.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.506 ' CE1' ' HE ' ' A' ' 424' ' ' ARG . 51.7 m170 -58.41 -49.24 77.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.688 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -62.68 -45.92 90.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -50.04 -55.29 15.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.852 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.43 -39.44 14.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . 0.422 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.9 t60 -66.54 -41.38 88.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.767 0.317 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.688 HD11 HD11 ' A' ' 428' ' ' LEU . 16.2 mt -74.17 -15.65 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.451 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 1.1 ttmp? -110.9 0.89 17.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 61.1 tp60 -119.05 -25.73 6.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.937 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 33.7 t -116.7 -42.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.1 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.403 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.156 0 CA-C-O 120.807 0.253 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -62.67 95.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.938 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.682 HG23 ' O ' ' A' ' 420' ' ' LYS . 28.9 mm -105.73 132.26 53.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.6 t -57.17 126.69 28.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -86.28 21.13 2.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.537 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.22 -55.83 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.836 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.3 p -106.78 -44.53 4.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.03 9.79 3.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.682 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -62.87 -179.79 0.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.828 0.347 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.4 144.64 13.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.424 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 10.7 m-85 -139.26 160.93 38.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 54.2 m -91.67 -32.72 15.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.487 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 26.4 mtt-85 -111.28 154.51 43.61 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.581 0.705 . . . . 0.0 110.877 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -42.62 3.24 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 36.9 t0 -66.77 -38.65 86.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.487 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -57.99 -49.5 76.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -63.51 -44.42 94.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -49.81 -52.84 29.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 434' ' ' GLN . . . -49.76 -43.5 38.42 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.513 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -63.34 -40.5 97.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 110.865 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 20.4 mt -74.78 -18.72 16.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.478 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.6 tttp -109.82 0.96 19.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.895 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . 0.42 ' N ' ' O ' ' A' ' 430' ' ' GLY . 54.1 tp60 -119.44 -25.8 5.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.9 t -116.39 -40.34 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.179 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.537 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 77.5 m-70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--O 1.232 0.193 0 CA-C-O 120.781 0.242 . . . . 0.0 112.294 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -61.02 90.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.947 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.5 mm -103.25 130.5 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.5 t -57.6 126.72 28.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -86.91 20.9 2.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.48 -52.41 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.816 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.4 p -110.75 -45.52 3.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.889 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.6 11.69 2.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.474 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.575 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.59 179.88 0.57 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.824 0.345 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.13 142.73 10.81 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.401 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 9.9 m-85 -137.96 162.4 34.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.893 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 15.8 m -94.67 -30.6 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.834 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.408 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 35.7 mtp85 -111.16 154.54 43.51 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.616 0.722 . . . . 0.0 110.865 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 -45.65 1.47 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.685 2.256 . . . . 0.0 112.321 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.46 -40.28 93.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.408 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 53.1 m170 -54.84 -51.16 66.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.845 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 432' ' ' ILE . 9.2 tp -62.34 -45.05 94.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -50.27 -55.68 14.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.21 -38.21 18.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -67.26 -40.79 86.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.747 0.308 . . . . 0.0 110.841 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.508 HD11 HD11 ' A' ' 428' ' ' LEU . 18.5 mt -74.3 -20.53 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.442 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 49.5 tttt -106.87 -0.82 23.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . 0.474 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.7 tp-100 -116.7 -27.6 6.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 32.1 t -114.96 -39.88 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.407 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.905 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.145 0 CA-C-O 120.824 0.26 . . . . 0.0 112.365 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -60.92 93.69 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.2 mm -100.79 131.51 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.138 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.9 t -56.57 125.29 21.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -86.1 20.29 2.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.594 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.61 -43.08 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.3 p -122.06 -46.99 2.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 135.4 -1.69 3.72 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.657 ' O ' HG23 ' A' ' 414' ' ' ILE . 40.0 mttt -51.67 179.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.868 0.366 . . . . 0.0 110.872 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -147.41 142.97 10.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -138.28 163.88 30.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.83 0.348 . . . . 0.0 110.93 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . 0.451 ' O ' ' NH1' ' A' ' 424' ' ' ARG . 3.1 m -96.39 -22.75 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.82 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.581 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 7.8 mmt-85 -119.22 152.95 53.05 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 110.873 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . 0.4 ' O ' ' OD1' ' A' ' 429' ' ' ASN . 53.6 Cg_endo -69.73 -41.99 3.82 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.692 2.262 . . . . 0.0 112.34 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -69.14 -42.02 76.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.581 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 58.8 m170 -55.22 -46.48 75.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.852 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.568 HD11 HD11 ' A' ' 432' ' ' ILE . 8.8 tp -65.92 -44.99 83.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 425' ' ' PRO . 16.6 m120 -50.16 -54.81 18.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.71 -43.16 21.95 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.513 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -62.98 -41.65 99.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.876 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 428' ' ' LEU . 20.0 mt -73.42 -15.92 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . . . . . . . . . 16.2 ttpp -105.11 -8.43 18.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -112.93 -24.28 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.34 -36.18 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.594 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 79.7 m-70 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.147 0 CA-C-O 120.854 0.272 . . . . 0.0 112.323 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -59.2 94.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.5 mm -105.33 123.86 59.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.096 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.1 t -50.95 127.72 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.863 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -88.56 19.23 4.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.904 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.58 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -114.59 -45.92 2.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.2 p -118.62 -49.34 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.72 1.19 2.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.422 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.4 mttt -55.12 173.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.907 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.403 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -142.41 145.64 15.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.403 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 21.3 m-85 -141.12 167.99 20.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 69.2 m -98.57 -33.63 10.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.859 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.407 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 38.0 mtp180 -110.37 155.15 42.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.654 0.74 . . . . 0.0 110.852 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -37.24 9.32 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.04 -35.3 69.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.819 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.407 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 63.5 m170 -60.66 -52.66 64.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.432 HD11 HD11 ' A' ' 432' ' ' ILE . 10.8 tp -62.34 -46.04 90.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.911 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.2 -53.66 20.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.13 -40.19 20.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.48 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -66.4 -42.52 87.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.771 0.319 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.432 HD11 HD11 ' A' ' 428' ' ' LEU . 15.3 mt -72.38 -19.42 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.122 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 46.6 tttm -107.91 2.11 23.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . 0.409 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 13.1 tp60 -120.96 -25.33 5.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.0 t -116.43 -41.74 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.58 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.3 m-70 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.192 0 CA-C-O 120.802 0.251 . . . . 0.0 112.381 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.09 91.56 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.518 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.8 mm -98.22 124.82 51.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.15 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -49.89 127.6 16.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 67.1 mm-40 -89.12 20.93 3.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.564 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.72 -45.35 2.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 19.6 p -120.36 -46.56 2.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.864 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.19 -0.48 3.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.438 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.518 ' O ' HG23 ' A' ' 414' ' ' ILE . 27.7 mttm -51.29 176.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.338 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.59 146.22 16.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.494 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . 0.466 ' CD1' HD13 ' A' ' 428' ' ' LEU . 14.3 m-85 -142.46 -179.73 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.896 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 27.9 m -110.77 -34.29 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.437 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 80.1 mtt-85 -111.37 154.54 43.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.569 0.7 . . . . 0.0 110.889 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -33.62 16.3 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.654 2.236 . . . . 0.0 112.355 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -76.42 -31.77 58.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.437 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -65.8 -51.34 59.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.882 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.466 HD13 ' CD1' ' A' ' 422' ' ' PHE . 12.7 tp -64.16 -43.42 95.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -51.92 -50.36 61.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.91 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -51.71 -39.74 47.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.496 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -65.71 -40.6 92.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.895 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 10.7 mt -71.44 -22.42 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -99.95 -1.04 38.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.938 179.854 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -115.76 -31.25 5.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.908 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.11 -38.27 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.137 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.564 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.752 0.23 . . . . 0.0 112.301 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -58.57 92.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.472 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.2 mm -95.78 133.64 36.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.143 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.1 t -60.62 124.36 20.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -84.76 16.6 3.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.559 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.2 m -112.63 -45.08 3.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 13.3 p -120.22 -47.75 2.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . 0.428 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.58 -4.19 3.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.517 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.472 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.9 mttt -50.43 175.25 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.366 . . . . 0.0 110.867 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.26 141.47 10.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -135.9 168.04 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.838 0.351 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 42.2 m -98.54 -31.02 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.886 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.8 mtt180 -113.12 155.32 44.51 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.725 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -45.39 1.58 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.332 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -65.1 -36.64 84.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 51.9 m170 -59.52 -51.41 69.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 13.9 tp -62.9 -45.78 90.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -48.48 -53.86 16.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.92 -42.09 29.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.48 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 14.3 t60 -64.14 -39.78 94.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.82 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 17.2 mt -75.39 -18.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.45 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 33.2 tttt -108.28 -0.82 20.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.91 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -117.75 -27.04 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.1 t -114.93 -36.82 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.559 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.851 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 120.79 0.246 . . . . 0.0 112.299 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -62.14 96.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.909 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.573 HG23 ' O ' ' A' ' 420' ' ' LYS . 12.6 mm -101.67 129.1 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.134 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 16.9 t -54.99 130.31 41.21 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 36.3 mm-40 -88.74 22.03 2.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.583 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -119.84 -57.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.3 p -105.56 -41.87 5.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.863 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 124.6 7.51 6.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.499 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . 0.573 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.0 mttt -58.97 179.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 110.943 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.64 139.51 8.57 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -134.49 170.59 15.54 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 68.3 m -101.75 -28.55 12.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.852 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 18.9 mtp180 -116.32 155.68 48.12 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.625 0.726 . . . . 0.0 110.88 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.656 2.237 . . . . 0.0 112.366 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.6 -34.56 78.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 50.7 m170 -61.65 -50.58 71.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.848 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.7 tp -62.9 -44.68 95.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -50.1 -54.61 19.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.859 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . 0.433 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -47.25 -37.11 10.88 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.484 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -69.6 -40.29 76.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.809 0.338 . . . . 0.0 110.895 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.5 mt -75.29 -16.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.46 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 51.7 tttt -110.86 0.99 17.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . 0.433 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.2 tp-100 -120.48 -29.16 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 34.2 t -110.76 -42.89 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.583 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.8 m-70 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.856 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.231 0.167 0 CA-C-O 120.795 0.248 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -60.92 94.09 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.1 mm -103.99 123.53 57.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.167 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.9 t -52.6 130.71 32.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -91.26 20.97 4.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.942 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 417' ' ' SER . . . . . 0.566 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.03 -45.97 2.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.851 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 16.8 p -119.03 -44.36 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.907 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 131.11 0.4 5.12 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 30.4 mttm -55.09 172.54 0.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 0.0 110.875 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -141.23 143.93 13.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.479 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -137.09 166.88 22.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.893 0.378 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 59.8 m -98.37 -32.27 11.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.837 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 424' ' ' ARG . . . . . 0.418 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 56.3 mtt-85 -110.97 156.22 41.18 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.885 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -46.43 1.24 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.737 2.291 . . . . 0.0 112.364 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -64.42 -38.34 90.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 427' ' ' HIS . . . . . 0.418 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 60.0 m170 -56.87 -53.3 59.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 428' ' ' LEU . . . . . 0.495 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.92 -45.18 95.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -49.32 -52.75 25.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.56 -42.99 36.16 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -63.3 -40.11 96.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.771 0.319 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 432' ' ' ILE . . . . . 0.495 HD11 HD11 ' A' ' 428' ' ' LEU . 13.6 mt -74.9 -16.36 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 433' ' ' LYS . . . . . 0.446 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 21.7 ttmt -108.94 -2.23 18.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.875 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 5.3 tp-100 -118.19 -25.68 6.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 14.5 t -115.46 -36.36 2.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 436' ' ' HIS . . . . . 0.566 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.0 m-70 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.891 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 33.8 t -87.58 -63.2 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 4.1 m 42.44 44.03 3.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.843 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -174.53 -141.79 3.76 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.516 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 9.7 t 61.33 45.75 8.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.88 0.372 . . . . 0.0 110.865 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 26.7 p -144.7 163.13 34.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.83 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -120.35 -143.9 6.97 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.463 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 61.1 p -128.43 132.48 48.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.914 0.388 . . . . 0.0 110.825 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 90.9 t -88.8 92.27 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.125 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 155.9 -69.94 0.28 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.471 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.456 ' HD2' ' N ' ' A' ' 411' ' ' LYS . 0.1 OUTLIER -102.64 97.21 8.65 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.633 0.73 . . . . 0.0 110.877 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.8 Cg_endo -69.79 -47.62 0.88 Allowed 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.665 2.243 . . . . 0.0 112.301 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -59.04 94.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.895 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.605 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.2 mm -100.72 125.96 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.092 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.7 t -52.84 131.78 35.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.4 mm-40 -91.11 20.4 5.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.556 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.12 -48.8 2.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.865 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.0 p -115.45 -41.97 3.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . 0.426 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 127.98 -1.43 6.76 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.605 ' O ' HG23 ' A' ' 414' ' ' ILE . 17.4 mttp -50.99 179.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.83 0.347 . . . . 0.0 110.879 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.4 143.83 11.76 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 15.2 m-85 -139.64 170.13 16.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.922 0.391 . . . . 0.0 110.836 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 5.3 m -99.96 -32.22 11.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.864 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.4 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 27.9 mtp180 -110.81 155.55 42.14 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.596 0.712 . . . . 0.0 110.86 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -45.33 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.65 2.233 . . . . 0.0 112.335 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.48 -40.15 92.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.844 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.4 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 54.7 m170 -54.68 -53.56 53.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.851 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.401 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.64 -44.18 96.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -49.92 -55.17 15.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.63 -40.77 17.9 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.451 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.7 t60 -64.95 -41.41 95.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.745 0.307 . . . . 0.0 110.868 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.401 HD11 HD11 ' A' ' 428' ' ' LEU . 13.7 mt -73.43 -18.34 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.123 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 61.0 tttt -108.84 1.42 20.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.892 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -120.16 -27.42 5.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.1 t -112.92 -41.69 3.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.556 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.8 m-70 -89.51 -22.63 22.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.876 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.9 t -40.77 129.49 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.135 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 25.1 m -164.95 174.28 10.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.821 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -111.24 141.18 45.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.883 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -136.75 144.05 45.27 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.571 0.701 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 149.79 67.34 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.654 2.236 . . . . 0.0 112.376 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 23.0 p80 -126.34 168.58 13.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 11.0 mmtp -57.06 174.57 0.17 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 32.1 m -80.94 42.37 0.63 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 60.45 36.27 20.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 6.2 p -173.49 150.05 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.144 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 15.7 t-105 -57.35 -61.5 2.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . . . . . . . . . 7.2 p -122.45 133.01 69.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 36.5 t -111.87 -38.35 4.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.886 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -60.92 -158.31 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.517 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 -37.76 8.88 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.675 2.25 . . . . 0.0 112.375 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 4.8 m -171.85 167.63 6.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.846 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 40.5 t -174.13 161.9 3.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.866 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.531 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 1.8 m -134.8 176.95 8.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.844 0.355 . . . . 0.0 110.843 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 67.1 p -112.55 -54.3 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.897 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 108.03 68.74 0.65 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 19.4 m -133.38 -46.53 0.83 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.899 0.38 . . . . 0.0 110.873 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 15.5 t -62.46 132.22 51.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.91 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -138.69 -159.35 8.02 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.477 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 20.4 m -78.13 140.11 39.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 60.4 t -121.82 132.94 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.117 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -149.5 31.94 1.13 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.427 ' CB ' ' O ' ' A' ' 422' ' ' PHE . 6.5 mptt -132.2 98.58 16.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 0.0 110.85 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . 0.421 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.78 -47.0 1.01 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.673 2.249 . . . . 0.0 112.327 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.5 m-30 -61.44 93.4 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.661 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.1 mm -98.51 129.67 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.154 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 19.4 t -55.28 132.79 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.4 mm-40 -92.57 21.02 5.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.581 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.13 -48.5 2.53 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.83 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.7 p -115.64 -39.69 3.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 123.23 7.96 6.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.8 mttt -58.19 179.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.427 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.11 144.32 12.43 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.448 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.427 ' O ' ' CB ' ' A' ' 411' ' ' LYS . 8.8 m-85 -138.93 -177.68 4.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.847 0.356 . . . . 0.0 110.927 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 23.9 m -112.32 -35.78 5.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.853 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.402 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 45.6 mtt180 -111.11 155.3 42.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.641 0.734 . . . . 0.0 110.831 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -29.58 23.39 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.65 2.234 . . . . 0.0 112.349 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -80.17 -32.05 38.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.859 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.402 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.9 m170 -65.2 -51.22 62.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.406 HD11 HD11 ' A' ' 432' ' ' ILE . 12.0 tp -63.53 -44.3 94.64 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -49.97 -53.04 28.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . 0.488 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.59 -39.46 23.11 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.456 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . 0.419 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.3 t60 -67.54 -42.74 82.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.406 HD11 HD11 ' A' ' 428' ' ' LEU . 11.7 mt -72.99 -19.39 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.109 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.484 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 32.8 tttt -108.35 1.71 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . 0.488 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 8.3 tp-100 -119.92 -28.9 5.08 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.938 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.4 t -112.8 -41.57 3.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.581 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.5 m-70 -89.16 -17.74 28.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.415 ' HB ' ' C ' ' A' ' 433' ' ' LYS . 3.5 t -47.66 132.98 13.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 53.8 m -50.77 146.51 5.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -123.99 164.89 18.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 46.9 mtm180 -70.52 144.72 91.89 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.608 0.718 . . . . 0.0 110.917 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 98.27 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.716 2.277 . . . . 0.0 112.323 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 25.7 m170 -89.42 154.52 19.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.896 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? -44.04 124.62 3.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 30.1 p -128.97 163.75 24.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.884 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -82.87 146.37 28.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 96.4 t -48.86 137.29 4.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.111 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 29.5 t-105 -85.68 -47.67 9.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . . . . . . . . . 10.5 p -149.54 148.98 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.131 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 85.1 p -60.56 170.26 1.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.837 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -76.23 -158.19 7.88 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.485 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 148.04 64.61 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 54.8 p -158.04 162.14 38.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.876 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 49.0 m -77.67 112.29 14.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.531 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 87.4 p -169.07 124.0 0.86 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.838 0.352 . . . . 0.0 110.877 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 80.7 p -157.23 156.83 33.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -125.03 131.5 7.76 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 65.6 m -132.22 112.44 12.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.86 0.362 . . . . 0.0 110.882 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 78.9 p -135.73 174.75 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 139.02 69.2 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.463 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 20.7 m -70.84 90.26 0.79 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.897 0.38 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 84.2 t -97.65 88.61 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 167.4 -68.79 0.18 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.53 119.35 76.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -46.66 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.667 2.245 . . . . 0.0 112.38 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.3 m-30 -62.46 95.3 0.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.458 HG23 ' O ' ' A' ' 420' ' ' LYS . 17.5 mm -105.87 124.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.084 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.9 t -51.02 128.6 21.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.888 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -89.57 19.28 4.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.878 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.558 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.69 -45.72 2.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 12.9 p -117.46 -49.49 2.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.897 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.53 -1.44 3.28 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.458 ' O ' HG23 ' A' ' 414' ' ' ILE . 26.4 mttm -54.24 174.72 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.811 0.339 . . . . 0.0 110.9 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.31 146.11 16.55 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.505 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -141.14 163.09 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.905 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.58 -27.94 14.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.807 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.41 ' HG3' ' ND1' ' A' ' 427' ' ' HIS . 14.7 mtp180 -110.07 148.94 39.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.849 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -33.17 17.1 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.335 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.52 -38.43 55.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.41 ' ND1' ' HG3' ' A' ' 424' ' ' ARG . 51.2 m170 -58.26 -52.54 65.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.804 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.607 HD11 HD11 ' A' ' 432' ' ' ILE . 8.9 tp -57.84 -46.62 84.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -49.5 -52.89 26.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . 0.479 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -49.2 -40.06 28.59 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.49 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -66.13 -42.96 88.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.607 HD11 HD11 ' A' ' 428' ' ' LEU . 12.1 mt -72.73 -19.93 19.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.139 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 23.8 ttmt -107.91 1.09 22.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.92 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . 0.479 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 71.0 tp60 -119.98 -26.27 5.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.92 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.6 t -114.39 -41.41 3.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.142 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.558 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 -89.97 -19.77 24.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 3.4 t -45.35 -44.94 12.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.131 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 88.2 p -47.88 99.59 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -115.35 133.45 56.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -47.9 143.85 6.0 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.633 0.73 . . . . 0.0 110.905 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 168.8 20.46 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.693 2.262 . . . . 0.0 112.343 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 5.7 m170 -99.35 131.88 45.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -75.72 -60.43 2.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 5.0 t -171.7 164.49 6.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.866 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -97.73 89.67 4.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 93.9 t -137.01 138.44 45.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.442 ' O ' ' C ' ' A' ' 448' ' ' VAL . 37.8 t-105 -130.79 133.7 46.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.919 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' A' ' 447' ' ' TRP . 94.5 t -34.37 109.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.095 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 23.1 m -79.06 103.35 8.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.855 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -116.4 -94.71 1.87 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.463 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 103.7 1.19 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.694 2.263 . . . . 0.0 112.377 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 45.3 m -82.73 41.67 0.74 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 16.3 m -128.4 143.55 51.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.833 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.458 -179.962 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 74.4 p -45.1 161.0 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.876 0.369 . . . . 0.0 110.84 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 51.2 p -67.28 128.19 35.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 171.66 118.52 0.48 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 63.6 m -148.94 133.14 17.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.828 0.346 . . . . 0.0 110.853 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 1.9 t -112.32 38.9 2.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.806 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 50.64 101.72 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 17.1 m -74.36 120.66 20.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.915 0.388 . . . . 0.0 110.825 -179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 409' ' ' VAL . 4.7 p -78.21 -13.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -88.73 -67.72 1.27 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.408 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 8.7 mptt -114.1 95.14 37.42 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.565 0.698 . . . . 0.0 110.936 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.3 Cg_endo -69.79 -46.88 1.05 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.68 2.253 . . . . 0.0 112.32 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.7 m-30 -60.38 94.13 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.516 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.4 mm -98.16 128.09 49.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.103 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.8 t -59.23 132.95 55.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.874 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 55.7 mm-40 -91.9 2.23 56.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.584 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 7.6 m -93.69 -42.5 9.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.9 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 20.5 p -123.7 -46.44 2.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 132.78 4.46 3.41 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.455 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -58.25 178.08 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.824 0.345 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.98 143.06 11.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -138.37 169.59 17.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 9.8 m -101.48 -28.46 12.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . . . . . . . . . 14.3 mtp180 -113.73 154.42 45.77 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.612 0.72 . . . . 0.0 110.925 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -47.5 0.93 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.717 2.278 . . . . 0.0 112.327 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -63.88 -37.5 87.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . . . . . . . . . 54.4 m170 -58.27 -54.27 48.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.412 HD11 HD11 ' A' ' 432' ' ' ILE . 9.4 tp -59.66 -44.11 93.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -50.52 -54.31 23.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.934 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.12 -40.38 21.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -65.52 -40.74 93.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.412 HD11 HD11 ' A' ' 428' ' ' LEU . 11.4 mt -74.24 -19.01 17.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.13 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.498 ' O ' HG21 ' A' ' 437' ' ' THR . 45.4 tttm -104.75 -4.25 22.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.896 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 45.2 tp60 -115.85 -26.27 7.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.6 t -114.78 -33.85 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.155 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.584 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.1 m-70 -102.74 15.99 27.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.498 HG21 ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -89.14 -32.74 17.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.178 -179.95 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 40.6 p -95.11 -47.43 6.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -106.6 132.56 52.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -157.59 151.89 20.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.595 0.712 . . . . 0.0 110.88 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -169.35 0.32 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.67 2.247 . . . . 0.0 112.335 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 50.2 m170 -78.09 133.44 37.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -88.81 140.85 29.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 18.3 m -138.94 130.19 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -83.64 79.4 9.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 447' ' ' TRP . 9.3 p -109.19 -41.55 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.624 ' O ' HG23 ' A' ' 448' ' ' VAL . 1.4 p-90 -47.95 -34.2 8.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 447' ' ' TRP . 20.2 t -161.29 131.12 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 8.4 t -131.43 93.27 3.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.858 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 156.89 158.17 8.75 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.83 -5.35 16.04 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.659 2.24 . . . . 0.0 112.287 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 27.1 p -46.86 131.03 12.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 15.1 t -130.08 152.19 49.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 -179.926 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.491 -0.243 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 34.9 m -91.43 165.68 13.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.8 0.333 . . . . 0.0 110.89 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 48.4 t -84.89 82.01 8.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.792 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -126.44 49.03 0.94 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.49 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 27.9 m -157.95 117.02 3.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.885 0.374 . . . . 0.0 110.866 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 35.0 m -76.63 123.25 25.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -43.53 -93.42 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.6 t -126.37 173.46 9.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.945 0.402 . . . . 0.0 110.829 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 84.8 t -69.58 -61.94 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.142 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 163.08 74.3 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.11 98.49 51.51 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.552 0.691 . . . . 0.0 110.885 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -47.18 0.97 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.692 2.261 . . . . 0.0 112.334 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.76 94.8 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.912 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 420' ' ' LYS . 27.1 mm -102.94 133.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.125 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 38.4 t -57.47 128.42 36.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.896 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -85.75 22.39 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.481 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.1 t -122.98 -66.41 1.02 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.5 p -92.33 -42.55 9.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 121.86 12.53 5.4 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.707 ' O ' HG23 ' A' ' 414' ' ' ILE . 28.2 mttm -65.37 -179.48 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.419 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.18 143.53 11.71 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 11.7 m-85 -139.36 163.2 33.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.855 0.36 . . . . 0.0 110.873 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.3 m -95.47 -24.51 16.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.818 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.572 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.8 mmt85 -117.99 153.16 51.04 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.629 0.728 . . . . 0.0 110.847 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -40.09 5.77 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.643 2.229 . . . . 0.0 112.356 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -69.88 -42.51 73.38 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.572 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 59.1 m170 -56.48 -42.82 78.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.895 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -68.82 -44.55 73.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.945 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -51.97 -54.18 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.869 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.23 -40.05 21.34 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.516 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.21 -40.1 93.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.857 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 13.0 mt -75.33 -18.24 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.193 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.476 ' O ' HG21 ' A' ' 437' ' ' THR . 12.7 ttmt -107.15 -2.14 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.938 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -117.15 -25.46 7.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.92 -38.63 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.153 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.481 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.0 m-70 -93.33 3.77 55.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.476 HG21 ' O ' ' A' ' 433' ' ' LYS . 2.8 t -81.12 -41.76 21.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 29.1 t -64.82 160.03 21.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -80.1 175.0 11.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.55 144.56 19.54 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.624 0.726 . . . . 0.0 110.819 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 -171.89 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.701 2.267 . . . . 0.0 112.301 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -168.18 176.06 6.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.98 174.56 3.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 28.6 p -43.34 162.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -120.35 176.65 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 19.6 m -91.38 177.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.457 ' O ' ' C ' ' A' ' 448' ' ' VAL . 76.3 t-105 -166.5 116.96 0.95 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 448' ' ' VAL . 9.1 p 33.56 40.73 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.147 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 29.7 p -89.71 84.95 6.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.821 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -119.3 -76.65 0.51 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -29.38 24.06 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.708 2.272 . . . . 0.0 112.376 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 1.4 t -56.92 146.37 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.85 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 60.3 p -81.36 48.26 1.13 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.8 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.481 179.972 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 11.7 t -173.23 157.43 3.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.871 0.367 . . . . 0.0 110.851 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 16.3 m -70.97 94.51 1.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -125.53 126.94 6.05 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 15.5 t -166.82 108.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.867 0.365 . . . . 0.0 110.84 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 45.8 t -136.09 130.07 32.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -135.49 140.2 11.44 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.47 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 84.2 p -87.39 86.59 7.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.878 0.37 . . . . 0.0 110.851 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 99.6 t -101.13 90.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.124 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 140.21 -83.92 0.23 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.525 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -80.57 121.97 81.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.571 0.701 . . . . 0.0 110.889 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 -47.12 1.01 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.681 2.254 . . . . 0.0 112.342 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 413' ' ' TYR . 7.1 m-30 -63.31 97.18 0.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.914 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.5 mm -108.15 125.44 64.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.144 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.0 t -52.4 126.53 19.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 62.2 mm-40 -87.32 21.48 2.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.57 -51.92 2.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.9 p -110.79 -47.09 3.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.37 11.63 2.44 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.599 ' O ' HG23 ' A' ' 414' ' ' ILE . 44.1 mttt -64.63 -179.4 0.49 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.76 143.21 11.16 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.46 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -139.04 159.66 41.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.891 0.377 . . . . 0.0 110.856 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.0 m -92.21 -30.16 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.415 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.2 mtp180 -112.16 154.95 44.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.639 0.733 . . . . 0.0 110.896 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -44.45 2.08 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.715 2.277 . . . . 0.0 112.316 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -66.98 -38.21 85.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.852 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.415 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 62.8 m170 -56.87 -49.28 75.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 432' ' ' ILE . 6.6 tp -63.55 -45.94 88.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.896 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -49.05 -53.98 17.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.3 -41.11 31.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.527 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 12.5 t60 -64.84 -40.97 96.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.787 0.327 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.653 HD11 HD11 ' A' ' 428' ' ' LEU . 20.6 mt -73.27 -20.83 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.142 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.508 ' O ' HG21 ' A' ' 437' ' ' THR . 0.5 OUTLIER -103.68 -2.71 26.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.867 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -114.56 -28.56 7.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.4 t -114.22 -37.51 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.532 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.9 m-70 -97.18 12.89 31.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.85 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.508 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.1 t -86.74 132.43 33.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 67.2 p -137.05 130.56 31.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 48.6 mm-40 -93.24 137.72 32.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -167.52 144.1 3.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.613 0.721 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -176.69 1.56 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.344 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 45.0 m80 -57.97 102.36 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.872 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.71 98.33 7.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.917 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 84.2 m -78.67 119.08 21.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -104.39 95.96 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.969 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 12.7 p -168.79 137.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.722 ' CD2' HG23 ' A' ' 448' ' ' VAL . 3.4 p-90 -110.25 -35.77 6.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.722 HG23 ' CD2' ' A' ' 447' ' ' TRP . 63.8 t -146.87 132.92 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 20.4 p -127.01 144.82 50.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.929 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 138.7 -78.05 0.32 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.458 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 164.98 32.5 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.63 2.22 . . . . 0.0 112.372 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 46.5 t 62.64 42.95 7.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 2.7 t -86.5 158.92 19.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.861 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.514 179.973 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.519 -0.232 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 51.6 p -97.83 147.11 24.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.869 0.366 . . . . 0.0 110.884 -179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 5.7 m -139.01 154.15 48.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.843 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 126.29 95.35 0.96 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 71.1 m -114.44 150.78 34.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 43.9 m -83.53 164.18 19.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -132.36 -147.02 5.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.499 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . 0.487 ' O ' ' N ' ' A' ' 410' ' ' GLY . 86.8 p -120.43 -49.41 2.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 409' ' ' VAL . 8.3 p 37.98 27.5 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.092 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 408' ' ' SER . . . -162.53 -105.19 0.19 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.49 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -85.87 119.78 72.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.612 0.72 . . . . 0.0 110.876 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -47.87 0.83 Allowed 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.679 2.252 . . . . 0.0 112.364 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -61.25 93.98 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.497 HG23 ' O ' ' A' ' 420' ' ' LYS . 11.7 mm -102.07 128.74 54.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 7.7 t -60.19 121.12 11.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 10.1 mm-40 -80.63 -4.19 53.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.902 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.589 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 3.2 m -86.95 -45.14 11.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.4 p -121.02 -49.09 2.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.61 0.77 2.86 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.501 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 414' ' ' ILE . 35.8 mttm -55.48 -179.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.842 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -147.31 147.56 18.44 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 5.3 m-85 -143.96 157.41 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.7 m -90.91 -21.92 21.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.416 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 13.3 mtp85 -120.95 155.52 57.56 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 0.0 110.858 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -48.74 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.701 2.268 . . . . 0.0 112.344 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -63.0 -36.28 83.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.416 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 56.1 m170 -58.85 -52.82 64.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 14.0 tp -61.47 -42.86 99.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -51.22 -55.05 20.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.888 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -46.86 -42.77 15.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -63.36 -43.28 98.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.785 0.326 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -72.33 -15.96 18.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.104 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.507 ' O ' HG21 ' A' ' 437' ' ' THR . 14.2 ttpp -105.26 -7.59 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -114.29 -22.97 9.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.86 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.6 t -116.53 -36.94 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.589 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.7 m-70 -98.99 13.69 31.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.507 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.3 t -87.58 149.47 24.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 23.1 t 66.05 35.09 6.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -83.5 -176.27 6.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . 0.405 ' HD2' ' N ' ' A' ' 440' ' ' ARG . 3.2 mpt_? -105.27 148.37 36.14 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.591 0.71 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 442' ' ' HIS . 54.0 Cg_endo -69.79 -5.31 15.92 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.644 2.229 . . . . 0.0 112.372 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . 0.429 ' C ' ' O ' ' A' ' 441' ' ' PRO . 5.5 t-80 -35.17 147.65 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.876 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -135.88 149.11 48.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . 0.527 ' O ' HG23 ' A' ' 446' ' ' VAL . 19.8 t -58.78 96.71 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 26.8 tp60 -54.6 108.66 0.41 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 444' ' ' CYS . 98.7 t -104.49 133.21 49.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.453 ' CD1' ' N ' ' A' ' 448' ' ' VAL . 46.8 p90 -83.55 -49.78 8.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.908 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.453 ' N ' ' CD1' ' A' ' 447' ' ' TRP . 14.6 p -105.43 137.78 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.132 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 50.3 m 52.15 41.44 30.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.875 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -97.72 -95.16 1.94 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 138.08 37.07 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 80.3 p -44.04 -50.28 8.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 454' ' ' GLY . 12.7 t -54.94 -66.17 0.45 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.853 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 453' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.466 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 21.3 m -158.78 177.2 11.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.865 0.364 . . . . 0.0 110.834 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 7.4 t -89.75 42.5 1.1 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.83 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 53.69 -158.04 5.06 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 31.1 t -71.78 90.93 1.11 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.895 0.378 . . . . 0.0 110.882 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 24.6 t -117.33 98.17 6.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.881 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -102.45 47.24 1.15 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.509 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 82.6 p -97.25 42.66 1.08 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.895 0.379 . . . . 0.0 110.859 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 34.5 m -116.79 144.85 23.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -82.2 -67.67 1.49 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.49 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 2.7 mptp? -54.7 117.81 14.91 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.606 0.717 . . . . 0.0 110.931 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -48.35 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.66 2.24 . . . . 0.0 112.371 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.74 89.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.3 mm -100.52 126.82 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 15.5 t -53.99 131.52 40.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 5.3 mm-40 -91.63 21.31 4.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.08 -46.24 2.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.843 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 17.9 p -117.97 -47.86 2.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 134.49 2.38 3.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.469 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 414' ' ' ILE . 22.1 mttm -55.97 176.24 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.28 144.24 12.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 17.2 m-85 -140.04 169.14 18.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.866 0.365 . . . . 0.0 110.87 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -103.03 -26.49 13.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.871 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 14.4 mtt-85 -112.1 149.51 41.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.591 0.71 . . . . 0.0 110.888 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -31.69 19.8 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.712 2.275 . . . . 0.0 112.347 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -78.73 -36.5 43.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.413 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 48.4 m170 -59.46 -53.32 59.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.864 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.38 -47.23 84.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.921 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.57 -52.8 27.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.39 -41.99 33.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -63.37 -40.78 98.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.778 0.323 . . . . 0.0 110.897 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 13.3 mt -71.79 -22.92 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.485 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.8 tttm -102.83 1.8 34.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 72.0 tp60 -119.83 -27.66 5.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 22.5 t -114.92 -42.41 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.104 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.2 m-70 -89.66 -3.19 58.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.584 HG23 ' O ' ' A' ' 437' ' ' THR . 5.3 t -67.53 88.63 0.22 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 34.6 t -121.34 -46.96 2.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.892 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -103.92 171.61 7.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -150.48 145.92 19.13 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.609 0.719 . . . . 0.0 110.896 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 84.21 0.67 Allowed 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.642 2.228 . . . . 0.0 112.336 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . 0.411 ' NE2' ' O ' ' A' ' 443' ' ' LYS . 11.4 t-80 -83.24 155.03 23.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . 0.411 ' O ' ' NE2' ' A' ' 442' ' ' HIS . 1.4 pmtp? -124.44 152.65 43.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 84.8 m -68.76 122.02 17.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -64.33 135.44 56.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 446' ' ' VAL . 11.6 p -127.61 127.66 68.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.135 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.496 ' CD2' HG23 ' A' ' 448' ' ' VAL . 16.0 t-105 -66.9 -53.07 35.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.958 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.496 HG23 ' CD2' ' A' ' 447' ' ' TRP . 94.2 t -159.4 136.38 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . 0.47 ' CB ' ' HB3' ' A' ' 452' ' ' SER . 69.6 m -52.5 174.21 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -110.07 -87.23 1.8 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.463 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.91 3.12 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.675 2.25 . . . . 0.0 112.367 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . 0.47 ' HB3' ' CB ' ' A' ' 449' ' ' SER . 11.0 p -39.48 159.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.811 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 22.7 m -64.08 177.99 0.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.506 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.439 -0.264 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.8 t -91.82 42.19 1.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 66.9 m -101.13 86.11 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -77.16 91.33 1.02 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 72.9 m -79.45 128.51 33.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.863 0.363 . . . . 0.0 110.844 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 95.7 p -164.26 145.6 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.849 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 136.78 170.51 11.96 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 53.6 p -164.73 135.3 4.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.808 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 72.1 t -106.93 130.44 58.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.148 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 145.76 -52.25 0.58 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.449 ' HE3' ' N ' ' A' ' 411' ' ' LYS . 0.0 OUTLIER -88.65 110.2 35.31 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -49.06 0.6 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.674 2.249 . . . . 0.0 112.354 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.21 95.49 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.535 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.2 mm -104.0 127.04 58.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.098 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.8 t -52.94 127.81 25.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.856 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 6.7 mm-40 -88.06 21.86 2.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.546 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.11 -51.25 2.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.2 p -112.36 -46.39 3.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.49 9.61 2.88 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.482 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.535 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.9 mttm -62.81 -179.52 0.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 110.887 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -145.19 142.09 10.48 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -137.51 164.39 28.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.871 0.367 . . . . 0.0 110.856 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.4 m -96.11 -28.37 14.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.876 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.577 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 9.5 mmt180 -114.56 152.83 46.57 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.576 0.703 . . . . 0.0 110.886 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -38.05 8.33 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.687 2.258 . . . . 0.0 112.349 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.22 -40.16 71.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.577 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 45.4 m170 -58.37 -44.59 88.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.551 HD11 HD11 ' A' ' 432' ' ' ILE . 5.3 tp -66.16 -45.3 81.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.942 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -51.37 -55.26 19.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.52 -40.66 16.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.6 t60 -64.3 -40.59 96.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.809 0.338 . . . . 0.0 110.865 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.551 HD11 HD11 ' A' ' 428' ' ' LEU . 14.0 mt -72.85 -23.82 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.117 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.501 ' O ' HG21 ' A' ' 437' ' ' THR . 58.2 tttt -101.76 -1.99 31.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.86 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -115.77 -27.86 6.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.86 -36.88 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.546 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 -98.74 15.34 25.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.501 HG21 ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -88.96 145.54 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.888 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 437' ' ' THR . 25.5 t -34.55 148.89 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.898 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -55.79 163.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.901 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 73.7 mtm180 -135.68 145.91 55.1 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.586 0.707 . . . . 0.0 110.856 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 151.34 68.83 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.636 2.224 . . . . 0.0 112.373 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -108.48 -50.13 3.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.872 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 5.7 mtpm? -119.66 37.15 4.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.916 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 2.5 m -131.92 93.11 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -122.26 42.07 3.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.913 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 58.3 t -132.36 133.78 59.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.448 ' CG ' ' N ' ' A' ' 448' ' ' VAL . 4.6 p-90 -88.07 -42.61 12.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.962 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.449 ' O ' HG13 ' A' ' 448' ' ' VAL . 13.5 p -80.65 126.49 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.115 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 5.9 m -128.12 135.58 49.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.79 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -124.2 -94.94 1.1 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.511 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -50.73 0.43 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.726 2.284 . . . . 0.0 112.325 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 81.0 p -175.02 176.92 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 41.7 t -67.57 -56.25 10.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.842 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.456 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 79.0 p -124.28 163.22 22.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.822 0.344 . . . . 0.0 110.883 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 56.9 p -69.88 -51.28 34.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.846 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 69.02 -169.86 42.04 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.523 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 89.5 p -137.09 109.01 7.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.898 0.38 . . . . 0.0 110.855 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 24.6 t -132.39 139.91 48.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.868 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 87.6 82.02 1.22 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.496 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.6 m -84.45 104.4 14.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.952 0.406 . . . . 0.0 110.868 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 3.8 p -173.48 141.01 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.174 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 117.92 -146.64 18.65 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.496 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 6.0 mptt -86.87 121.27 71.84 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.551 0.691 . . . . 0.0 110.895 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -48.76 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.676 2.251 . . . . 0.0 112.349 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -60.32 90.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.9 mm -101.75 127.24 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.128 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 9.5 t -53.16 127.67 25.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.882 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.6 mm-40 -88.35 17.96 4.83 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.593 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.6 m -113.44 -42.88 3.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.6 p -121.92 -49.75 2.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.861 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 138.47 -1.06 2.61 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.623 ' O ' HG23 ' A' ' 414' ' ' ILE . 39.2 mttt -52.69 179.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.816 0.341 . . . . 0.0 110.881 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.407 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -148.87 144.76 12.57 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.49 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 16.2 m-85 -140.01 165.04 28.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.856 0.36 . . . . 0.0 110.832 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 11.1 m -94.81 -33.59 12.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.413 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 19.7 mtp180 -109.3 155.25 41.42 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.613 0.721 . . . . 0.0 110.84 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -44.5 2.01 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.695 2.264 . . . . 0.0 112.32 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -65.5 -40.51 93.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.855 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.413 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 57.0 m170 -55.39 -51.12 67.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.907 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.14 -46.27 89.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -49.2 -54.12 18.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.862 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.02 -39.91 26.98 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -65.3 -39.04 91.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.785 0.326 . . . . 0.0 110.846 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 15.3 mt -75.27 -18.07 16.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 0.2 OUTLIER -107.28 -2.01 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.912 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 39.9 tp60 -116.36 -27.01 6.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.919 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 30.5 t -114.95 -40.41 3.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.593 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.4 m-70 -93.18 14.55 17.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.813 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.3 t -90.03 100.82 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 87.1 p -55.3 -46.35 76.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.818 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -127.75 138.23 52.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.39 144.99 83.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.668 0.747 . . . . 0.0 110.851 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 109.4 2.31 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.674 2.25 . . . . 0.0 112.33 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . 0.532 ' O ' ' CD2' ' A' ' 442' ' ' HIS . 0.1 OUTLIER -119.54 130.91 55.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.882 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -103.97 73.53 1.16 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.946 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 6.7 t -168.77 105.29 0.42 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.903 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -151.87 139.48 19.7 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.903 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 14.9 p -170.21 152.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.135 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.476 ' CE2' HG12 ' A' ' 448' ' ' VAL . 75.8 t-105 -138.62 146.06 41.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.93 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.476 HG12 ' CE2' ' A' ' 447' ' ' TRP . 7.5 p -34.09 137.68 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 21.9 t -128.1 91.0 3.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 56.12 -155.4 12.96 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.476 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . 0.455 ' O ' ' C ' ' A' ' 452' ' ' SER . 53.4 Cg_endo -69.8 2.94 3.1 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.691 2.261 . . . . 0.0 112.314 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 451' ' ' PRO . 13.4 t -34.32 130.85 0.34 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.822 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 7.6 t -61.91 133.15 55.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.889 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.5 m -140.08 113.61 8.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.939 0.4 . . . . 0.0 110.867 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 55.1 p -67.89 163.73 21.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -178.62 61.47 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.51 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 7.5 t -118.25 110.72 17.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.842 0.353 . . . . 0.0 110.844 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 33.1 t -152.17 132.24 13.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -132.55 -59.99 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 29.5 t -55.89 143.99 29.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.896 0.379 . . . . 0.0 110.862 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 26.8 m -74.25 141.35 16.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -151.3 -164.06 11.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.475 ' HE3' ' N ' ' A' ' 411' ' ' LYS . 0.0 OUTLIER -50.82 107.56 0.84 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.525 0.679 . . . . 0.0 110.874 -179.963 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -49.67 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.624 2.216 . . . . 0.0 112.344 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -58.54 90.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.553 HG23 ' O ' ' A' ' 419' ' ' GLY . 10.9 mm -98.54 128.58 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.8 t -56.77 129.38 41.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 40.3 mm-40 -88.53 20.29 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.59 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -115.65 -44.84 2.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.9 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 14.3 p -121.59 -46.5 2.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . 0.553 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.51 -8.16 3.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 28.5 mttt -46.34 170.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -140.91 144.03 14.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -138.1 170.37 16.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 110.881 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 36.9 m -100.23 -34.16 10.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.563 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 83.9 mtt-85 -107.92 155.0 40.74 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.602 0.715 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -46.18 1.3 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.705 2.27 . . . . 0.0 112.298 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -65.5 -36.25 83.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.563 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 54.6 m170 -58.65 -51.7 68.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 10.0 tp -62.27 -44.39 96.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -50.77 -53.38 32.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.9 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.57 -40.95 25.23 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -64.37 -40.75 96.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.816 0.341 . . . . 0.0 110.833 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 12.0 mt -73.57 -16.97 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.129 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 55.9 tttt -107.9 -1.25 20.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -117.9 -25.78 6.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.2 t -116.09 -39.28 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.59 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.7 m-70 -95.32 14.45 22.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.854 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.436 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.3 t -89.96 99.89 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.109 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 68.2 m -133.13 -176.15 4.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.878 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -82.49 148.23 28.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.874 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 29.3 mtt-85 -121.68 150.54 55.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.595 0.712 . . . . 0.0 110.858 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 177.17 5.85 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.679 2.253 . . . . 0.0 112.354 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 13.0 p-80 -51.54 103.49 0.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 444' ' ' CYS . 0.3 OUTLIER -166.8 111.88 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.89 179.98 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 443' ' ' LYS . 27.7 p -34.8 127.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.856 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -110.21 40.87 1.85 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.888 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . 0.555 HG11 ' HA2' ' A' ' 450' ' ' GLY . 3.0 m -109.03 -174.98 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.114 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.504 ' CD1' HG12 ' A' ' 448' ' ' VAL . 2.0 p-90 -131.98 -40.64 1.04 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.504 HG12 ' CD1' ' A' ' 447' ' ' TRP . 5.9 p -103.74 -41.85 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.116 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 89.1 p -172.0 172.33 4.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . 0.555 ' HA2' HG11 ' A' ' 446' ' ' VAL . . . -55.36 -93.37 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.452 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.57 3.62 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.647 2.231 . . . . 0.0 112.359 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 7.3 t -81.36 179.82 7.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.837 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 15.9 m -114.98 -49.47 2.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.863 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.952 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.377 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 3.4 m -84.21 45.73 1.14 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.859 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 2.4 m -135.29 150.82 50.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -128.51 -89.89 0.63 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.524 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 77.8 p -66.6 91.97 0.2 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.898 0.38 . . . . 0.0 110.868 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 5.1 t -124.07 41.66 3.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 168.2 -104.17 0.21 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.458 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . 0.447 ' O ' ' C ' ' A' ' 409' ' ' VAL . 30.4 t -48.86 147.97 2.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.902 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . 0.52 HG22 ' O ' ' A' ' 409' ' ' VAL . 10.2 p 34.33 39.38 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -76.16 -178.92 45.6 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.33 118.67 72.25 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.549 0.69 . . . . 0.0 110.932 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -47.59 0.9 Allowed 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.712 2.275 . . . . 0.0 112.38 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -62.41 97.88 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 420' ' ' LYS . 21.6 mm -108.13 130.56 60.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -55.91 123.51 14.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.855 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -86.08 20.24 2.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.403 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -117.17 -46.74 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.864 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 25.6 p -115.99 -46.53 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 130.15 10.6 2.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.671 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.31 -179.75 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.857 0.361 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -146.16 142.88 10.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -138.87 162.02 35.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.908 0.385 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 3.7 m -93.24 -32.33 14.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.506 ' HE ' ' CE1' ' A' ' 427' ' ' HIS . 21.1 mtm180 -112.37 155.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.904 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -42.01 3.86 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.282 . . . . 0.0 112.38 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -67.27 -38.85 85.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.506 ' CE1' ' HE ' ' A' ' 424' ' ' ARG . 51.7 m170 -58.41 -49.24 77.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.688 HD11 HD11 ' A' ' 432' ' ' ILE . 6.5 tp -62.68 -45.92 90.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -50.04 -55.29 15.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.852 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.43 -39.44 14.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.46 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . 0.422 ' CE1' ' HD2' ' A' ' 420' ' ' LYS . 11.9 t60 -66.54 -41.38 88.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.767 0.317 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.688 HD11 HD11 ' A' ' 428' ' ' LEU . 16.2 mt -74.17 -15.65 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.451 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 1.1 ttmp? -110.9 0.89 17.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.85 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 61.1 tp60 -119.05 -25.73 6.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.937 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 33.7 t -116.7 -42.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.1 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.403 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 81.4 m-70 -89.06 -18.14 27.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.401 ' HB ' ' C ' ' A' ' 433' ' ' LYS . 2.6 t -44.02 148.8 0.38 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.164 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 1.4 m 73.12 51.92 0.13 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . 0.414 ' C ' ' HD2' ' A' ' 440' ' ' ARG . 8.0 pt-20 -149.54 147.29 28.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.91 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . 0.414 ' HD2' ' C ' ' A' ' 439' ' ' GLU . 2.3 mpt_? -144.62 144.59 25.33 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.673 0.749 . . . . 0.0 110.893 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 442' ' ' HIS . 53.6 Cg_endo -69.78 0.44 5.65 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.717 2.278 . . . . 0.0 112.313 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 441' ' ' PRO . 5.7 t60 -36.56 -41.54 0.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.853 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 11.4 mptt -80.61 48.0 1.01 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 1.8 t -141.8 158.94 43.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 1.5 pm0 -110.02 79.94 1.26 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 7.9 p -103.17 142.9 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.446 ' CD1' ' N ' ' A' ' 448' ' ' VAL . 43.9 p90 -73.36 -47.83 39.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.917 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.446 ' N ' ' CD1' ' A' ' 447' ' ' TRP . 5.2 p -94.41 136.43 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 1.8 t -54.21 -69.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 152.98 145.86 4.24 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.473 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 452' ' ' SER . 53.5 Cg_endo -69.76 2.15 3.79 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.713 2.276 . . . . 0.0 112.324 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 451' ' ' PRO . 1.4 t -34.65 102.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.82 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 70.0 m -107.1 49.35 0.8 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.84 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.516 179.964 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 97.4 p -130.31 106.42 8.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.844 0.355 . . . . 0.0 110.869 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 86.9 p -164.83 173.38 11.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 174.92 52.08 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.546 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 41.1 t -171.98 133.9 0.74 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.832 0.349 . . . . 0.0 110.862 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 5.9 t -142.6 129.44 20.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -156.76 114.92 0.63 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . 0.509 ' O ' ' C ' ' A' ' 409' ' ' VAL . 48.0 m -74.47 -41.16 61.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 110.833 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . 0.674 ' O ' HG23 ' A' ' 409' ' ' VAL . 6.8 m 29.03 46.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.105 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 152.68 178.6 27.49 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.491 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -45.99 118.1 4.24 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.551 0.691 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -47.02 1.03 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -62.67 95.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.938 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.682 HG23 ' O ' ' A' ' 420' ' ' LYS . 28.9 mm -105.73 132.26 53.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.6 t -57.17 126.69 28.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -86.28 21.13 2.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.537 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -118.22 -55.83 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.836 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.3 p -106.78 -44.53 4.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.03 9.79 3.69 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.682 ' O ' HG23 ' A' ' 414' ' ' ILE . 31.1 mttm -62.87 -179.79 0.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.828 0.347 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.4 144.64 13.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.487 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.424 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 10.7 m-85 -139.26 160.93 38.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 54.2 m -91.67 -32.72 15.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.487 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 26.4 mtt-85 -111.28 154.51 43.61 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.581 0.705 . . . . 0.0 110.877 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -42.62 3.24 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 36.9 t0 -66.77 -38.65 86.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.487 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -57.99 -49.5 76.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.581 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -63.51 -44.42 94.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -49.81 -52.84 29.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 434' ' ' GLN . . . -49.76 -43.5 38.42 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.513 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -63.34 -40.5 97.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 110.865 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.581 HD11 HD11 ' A' ' 428' ' ' LEU . 20.4 mt -74.78 -18.72 16.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.478 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 39.6 tttp -109.82 0.96 19.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.895 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . 0.42 ' N ' ' O ' ' A' ' 430' ' ' GLY . 54.1 tp60 -119.44 -25.8 5.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 20.9 t -116.39 -40.34 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.179 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.537 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 77.5 m-70 -92.47 9.17 35.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.861 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.476 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.9 t -87.76 -38.97 15.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.106 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 70.1 m -51.78 116.65 2.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.872 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -52.18 141.14 19.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.882 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 18.7 mtt-85 -132.15 154.52 81.69 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.587 0.708 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 179.71 3.53 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.657 2.238 . . . . 0.0 112.364 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 63.9 t-80 -127.62 144.65 51.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.861 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.51 148.09 16.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.938 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 42.4 t -55.9 109.01 0.51 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.823 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 -65.9 176.0 1.78 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 12.5 p -71.59 152.91 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.081 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.432 ' O ' ' C ' ' A' ' 448' ' ' VAL . 45.0 t-105 -90.38 139.57 30.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.914 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 447' ' ' TRP . 70.8 t -34.4 128.91 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.146 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 5.9 t -38.95 -54.54 1.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 135.73 -81.78 0.29 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 92.75 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.273 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 453' ' ' SER . 21.8 t -76.34 -51.33 12.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.87 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 452' ' ' SER . 2.1 t -35.36 113.21 0.19 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 179.979 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 4.1 t -96.69 137.45 35.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.908 0.385 . . . . 0.0 110.88 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 3.2 t -124.22 169.61 11.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -114.87 -154.0 10.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.509 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 57.9 m -117.53 134.13 55.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.883 0.373 . . . . 0.0 110.839 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 46.3 m -140.24 155.59 46.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 173.0 140.07 3.05 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.472 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 38.6 m -118.92 130.42 55.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.938 0.399 . . . . 0.0 110.867 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 14.7 p -82.17 147.91 5.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.134 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 156.68 -73.48 0.23 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.473 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -66.92 124.3 88.34 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.562 0.696 . . . . 0.0 110.891 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -48.8 0.64 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.665 2.243 . . . . 0.0 112.294 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -61.02 90.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.947 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.5 mm -103.25 130.5 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 13.5 t -57.6 126.72 28.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -86.91 20.9 2.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -117.48 -52.41 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.816 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 26.4 p -110.75 -45.52 3.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.889 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 128.6 11.69 2.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.474 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.575 ' O ' HG23 ' A' ' 414' ' ' ILE . 32.2 mttt -64.59 179.88 0.57 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.824 0.345 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -146.13 142.73 10.81 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.401 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 9.9 m-85 -137.96 162.4 34.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.893 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 15.8 m -94.67 -30.6 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.834 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.408 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 35.7 mtp85 -111.16 154.54 43.51 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.616 0.722 . . . . 0.0 110.865 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 -45.65 1.47 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.685 2.256 . . . . 0.0 112.321 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.46 -40.28 93.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.867 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.408 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 53.1 m170 -54.84 -51.16 66.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.845 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 432' ' ' ILE . 9.2 tp -62.34 -45.05 94.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -50.27 -55.68 14.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.21 -38.21 18.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 12.0 t60 -67.26 -40.79 86.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.747 0.308 . . . . 0.0 110.841 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.508 HD11 HD11 ' A' ' 428' ' ' LEU . 18.5 mt -74.3 -20.53 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.442 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 49.5 tttt -106.87 -0.82 23.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . 0.474 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.7 tp-100 -116.7 -27.6 6.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 32.1 t -114.96 -39.88 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.138 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.407 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.9 m-70 -93.47 11.36 28.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.905 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.403 ' H ' HG22 ' A' ' 437' ' ' THR . 1.4 t -86.4 128.07 34.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 30.7 m -53.87 111.25 0.71 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.844 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -166.71 123.97 1.3 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -142.14 147.38 43.88 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.548 0.69 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 161.58 45.38 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.627 2.218 . . . . 0.0 112.349 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 17.8 m-70 -108.08 42.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.845 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -117.34 86.4 2.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 18.9 p -164.3 156.34 16.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.57 112.52 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 13.6 p -95.46 146.84 6.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.147 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.599 ' CH2' ' O ' ' A' ' 448' ' ' VAL . 0.1 OUTLIER -128.91 141.27 51.33 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.599 ' O ' ' CH2' ' A' ' 447' ' ' TRP . 3.9 m -34.42 98.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.122 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . 0.44 ' HB2' ' CE3' ' A' ' 447' ' ' TRP . 42.7 t -126.71 86.71 2.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.848 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 141.2 -94.98 0.19 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 98.57 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.631 2.221 . . . . 0.0 112.387 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 68.6 p -81.85 40.9 0.63 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 71.2 p -134.5 165.97 23.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.497 -179.955 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 55.3 p -129.44 147.17 51.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 0.0 110.844 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 40.9 m -79.95 173.03 13.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 136.94 102.72 0.64 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 26.0 p -171.82 145.87 1.99 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 32.3 m -105.56 152.05 23.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -161.39 165.91 35.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 80.7 p -138.97 128.51 24.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.967 0.413 . . . . 0.0 110.884 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 35.2 m -141.59 154.5 19.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.116 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -126.74 52.61 0.81 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.496 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.409 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 11.5 mptt -133.19 107.22 12.34 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.538 0.685 . . . . 0.0 110.922 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.74 -48.04 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.718 2.279 . . . . 0.0 112.365 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.1 m-30 -60.92 93.69 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.9 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 420' ' ' LYS . 19.2 mm -100.79 131.51 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.138 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.9 t -56.57 125.29 21.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -86.1 20.29 2.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.594 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.61 -43.08 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.884 -179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.3 p -122.06 -46.99 2.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 135.4 -1.69 3.72 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.657 ' O ' HG23 ' A' ' 414' ' ' ILE . 40.0 mttt -51.67 179.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.868 0.366 . . . . 0.0 110.872 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -147.41 142.97 10.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -138.28 163.88 30.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.83 0.348 . . . . 0.0 110.93 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . 0.451 ' O ' ' NH1' ' A' ' 424' ' ' ARG . 3.1 m -96.39 -22.75 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.82 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.581 ' HG3' ' CE1' ' A' ' 427' ' ' HIS . 7.8 mmt-85 -119.22 152.95 53.05 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 110.873 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . 0.4 ' O ' ' OD1' ' A' ' 429' ' ' ASN . 53.6 Cg_endo -69.73 -41.99 3.82 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.692 2.262 . . . . 0.0 112.34 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -69.14 -42.02 76.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.581 ' CE1' ' HG3' ' A' ' 424' ' ' ARG . 58.8 m170 -55.22 -46.48 75.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.852 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.568 HD11 HD11 ' A' ' 432' ' ' ILE . 8.8 tp -65.92 -44.99 83.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 425' ' ' PRO . 16.6 m120 -50.16 -54.81 18.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -47.71 -43.16 21.95 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.513 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -62.98 -41.65 99.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.876 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 428' ' ' LEU . 20.0 mt -73.42 -15.92 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.498 ' O ' ' CG2' ' A' ' 437' ' ' THR . 16.2 ttpp -105.11 -8.43 18.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.934 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -112.93 -24.28 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.34 -36.18 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.594 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 79.7 m-70 -100.82 17.81 21.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.498 ' CG2' ' O ' ' A' ' 433' ' ' LYS . 0.7 OUTLIER -90.01 90.53 8.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.171 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 37.4 p -164.36 173.74 11.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -86.48 131.54 34.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 77.4 mtt180 -140.47 150.51 61.05 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.632 0.729 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 90.44 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.715 2.276 . . . . 0.0 112.292 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -97.49 129.15 44.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.878 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 44.3 mmtt -57.56 162.62 2.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.887 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 74.7 m -64.17 82.72 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.887 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . 0.403 ' O ' ' CD ' ' A' ' 445' ' ' GLN . 0.8 OUTLIER -90.06 38.63 0.93 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.9 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 447' ' ' TRP . 7.1 p -158.17 139.75 5.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.598 ' CE2' HG23 ' A' ' 448' ' ' VAL . 18.3 t-105 -35.33 -64.74 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.598 HG23 ' CE2' ' A' ' 447' ' ' TRP . 96.3 t -144.81 116.02 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . 0.405 ' HB2' ' CG1' ' A' ' 446' ' ' VAL . 35.5 t -100.28 -45.62 5.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.889 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 174.22 163.13 27.08 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 131.0 20.38 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.702 2.268 . . . . 0.0 112.35 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 90.3 p -135.5 113.2 10.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.853 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 44.0 t -61.83 -44.71 96.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.495 -180.0 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 40.8 m -59.66 110.97 1.26 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.866 0.365 . . . . 0.0 110.884 -179.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 82.4 p -98.4 161.45 13.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.873 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -141.52 -115.06 1.13 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.528 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 73.7 m -117.22 127.25 53.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.863 0.364 . . . . 0.0 110.875 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 42.5 p -74.67 -48.13 27.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.858 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -176.0 -126.55 0.96 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.476 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 2.0 t -142.37 143.99 32.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.961 0.41 . . . . 0.0 110.837 -179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 34.9 m -64.69 164.59 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 128.43 -93.37 0.35 Allowed Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.467 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -97.37 113.95 64.06 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.573 0.702 . . . . 0.0 110.902 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -48.89 0.63 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.323 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -59.2 94.1 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 420' ' ' LYS . 13.5 mm -105.33 123.86 59.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.096 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 12.1 t -50.95 127.72 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.863 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -88.56 19.23 4.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.904 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.58 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -114.59 -45.92 2.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 15.2 p -118.62 -49.34 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.72 1.19 2.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.422 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.4 mttt -55.12 173.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.907 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.403 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -142.41 145.64 15.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.403 ' CD1' ' C ' ' A' ' 421' ' ' GLY . 21.3 m-85 -141.12 167.99 20.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.889 0.376 . . . . 0.0 110.871 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 69.2 m -98.57 -33.63 10.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.859 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.407 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 38.0 mtp180 -110.37 155.15 42.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.654 0.74 . . . . 0.0 110.852 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -37.24 9.32 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.04 -35.3 69.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.819 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.407 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 63.5 m170 -60.66 -52.66 64.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.432 HD11 HD11 ' A' ' 432' ' ' ILE . 10.8 tp -62.34 -46.04 90.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.911 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -49.2 -53.66 20.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -48.13 -40.19 20.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.48 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -66.4 -42.52 87.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.771 0.319 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.432 HD11 HD11 ' A' ' 428' ' ' LEU . 15.3 mt -72.38 -19.42 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.122 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 46.6 tttm -107.91 2.11 23.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.901 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . 0.409 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 13.1 tp60 -120.96 -25.33 5.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 23.0 t -116.43 -41.74 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.58 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 82.3 m-70 -89.17 -26.21 21.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.906 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.447 ' C ' ' O ' ' A' ' 436' ' ' HIS . 6.3 t -33.9 146.68 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 23.5 m 66.09 54.55 0.97 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -78.18 177.36 8.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -114.87 148.51 40.63 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.577 0.703 . . . . 0.0 110.853 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . 0.453 ' O ' ' CD2' ' A' ' 442' ' ' HIS . 53.7 Cg_endo -69.76 92.69 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.695 2.263 . . . . 0.0 112.312 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . 0.453 ' CD2' ' O ' ' A' ' 441' ' ' PRO . 16.7 m170 -161.85 179.0 8.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.836 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 442' ' ' HIS . 8.2 ptpp? 34.84 44.0 0.11 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 56.7 m -105.39 121.78 44.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.855 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 57.2 tp60 -108.39 87.54 2.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . 0.441 ' CG1' HG22 ' A' ' 448' ' ' VAL . 86.2 t -141.98 133.2 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.812 ' CE2' HG13 ' A' ' 448' ' ' VAL . 9.2 p90 -89.12 -42.94 11.4 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.812 HG13 ' CE2' ' A' ' 447' ' ' TRP . 35.7 m -59.69 -178.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.107 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 84.3 p -131.55 100.82 5.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 179.45 138.54 3.33 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 163.12 39.43 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 0.0 112.34 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 31.0 m -66.6 -44.62 81.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.84 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 31.1 t -162.97 150.91 13.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.453 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 20.0 m -97.33 120.51 37.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.917 0.389 . . . . 0.0 110.785 -179.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 2.7 m -146.12 125.74 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.84 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -137.49 -153.15 6.27 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.483 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 1.8 m 43.44 47.88 6.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.864 0.364 . . . . 0.0 110.849 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 29.5 t -104.32 120.61 41.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 66.27 -178.15 14.37 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.475 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 66.4 m -121.8 163.7 18.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.888 0.375 . . . . 0.0 110.884 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 67.8 t -72.28 104.88 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.163 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -137.38 -84.9 0.15 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.451 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.462 ' CG ' ' C ' ' A' ' 422' ' ' PHE . 12.5 mptt -48.16 105.65 0.52 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.521 0.676 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.76 -48.5 0.71 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.68 2.253 . . . . 0.0 112.381 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.2 m-30 -60.09 91.56 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.518 HG23 ' O ' ' A' ' 420' ' ' LYS . 18.8 mm -98.22 124.82 51.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.15 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 14.0 t -49.89 127.6 16.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 67.1 mm-40 -89.12 20.93 3.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.564 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.9 m -116.72 -45.35 2.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 19.6 p -120.36 -46.56 2.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.864 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 136.19 -0.48 3.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.438 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.518 ' O ' HG23 ' A' ' 414' ' ' ILE . 27.7 mttm -51.29 176.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.338 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . 0.458 ' C ' ' CD1' ' A' ' 422' ' ' PHE . . . -145.59 146.22 16.2 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.494 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . 0.466 ' CD1' HD13 ' A' ' 428' ' ' LEU . 14.3 m-85 -142.46 -179.73 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.896 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 27.9 m -110.77 -34.29 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.437 ' HD2' ' CE1' ' A' ' 427' ' ' HIS . 80.1 mtt-85 -111.37 154.54 43.68 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.569 0.7 . . . . 0.0 110.889 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -33.62 16.3 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.654 2.236 . . . . 0.0 112.355 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -76.42 -31.77 58.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.437 ' CE1' ' HD2' ' A' ' 424' ' ' ARG . 56.6 m170 -65.8 -51.34 59.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.882 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.466 HD13 ' CD1' ' A' ' 422' ' ' PHE . 12.7 tp -64.16 -43.42 95.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -51.92 -50.36 61.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.91 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -51.71 -39.74 47.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.496 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -65.71 -40.6 92.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.895 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 10.7 mt -71.44 -22.42 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.471 ' O ' HG21 ' A' ' 437' ' ' THR . 0.8 OUTLIER -99.95 -1.04 38.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.938 179.854 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -115.76 -31.25 5.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.908 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.11 -38.27 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.137 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.564 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 -95.65 13.13 27.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.471 HG21 ' O ' ' A' ' 433' ' ' LYS . 1.8 t -88.81 146.51 24.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.14 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 439' ' ' GLU . 1.5 t -167.71 159.31 11.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 438' ' ' SER . 6.8 pt-20 -37.22 141.9 0.13 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 8.4 mmp_? -69.47 146.51 96.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 110.858 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -2.55 10.4 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.641 2.227 . . . . 0.0 112.34 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -104.12 102.39 12.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -151.91 107.63 3.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 32.9 m -135.19 172.55 12.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 27.7 mm-40 -84.33 44.16 1.01 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.912 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . 0.427 HG23 ' N ' ' A' ' 447' ' ' TRP . 32.2 m -90.9 -40.75 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.466 ' CG ' ' N ' ' A' ' 448' ' ' VAL . 2.4 p-90 -46.71 -42.69 17.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.901 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.466 ' N ' ' CG ' ' A' ' 447' ' ' TRP . 56.1 t -155.2 141.88 11.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 9.1 m -45.17 155.78 0.12 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . 177.46 139.34 3.3 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.476 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 108.55 2.1 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.716 2.277 . . . . 0.0 112.36 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 8.6 t -98.14 80.38 2.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.81 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 3.5 t -145.62 118.48 8.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.837 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.989 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.504 -0.239 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 71.2 m -95.16 114.73 26.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.833 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 57.6 p -114.22 129.81 56.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.827 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -93.76 -129.32 5.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.491 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 37.3 p -162.96 122.1 2.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.904 0.383 . . . . 0.0 110.817 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 2.9 t -87.62 106.35 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.898 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -113.91 68.36 0.25 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.515 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 47.8 t -71.44 124.05 23.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.88 0.371 . . . . 0.0 110.876 -179.726 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 97.2 t -71.37 113.35 7.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.158 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . -132.65 -64.92 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.409 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 11.8 mptt -115.17 99.05 51.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.601 0.715 . . . . 0.0 110.883 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.1 Cg_endo -69.82 -48.47 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.651 2.234 . . . . 0.0 112.301 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.6 m-30 -58.57 92.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.472 HG23 ' O ' ' A' ' 420' ' ' LYS . 16.2 mm -95.78 133.64 36.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.143 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 11.1 t -60.62 124.36 20.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -84.76 16.6 3.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.559 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 2.2 m -112.63 -45.08 3.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 13.3 p -120.22 -47.75 2.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . 0.428 ' O ' HG23 ' A' ' 414' ' ' ILE . . . 136.58 -4.19 3.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.517 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.472 ' O ' HG23 ' A' ' 414' ' ' ILE . 34.9 mttt -50.43 175.25 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.366 . . . . 0.0 110.867 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -143.26 141.47 10.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -135.9 168.04 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.838 0.351 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 42.2 m -98.54 -31.02 12.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.886 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 30.8 mtt180 -113.12 155.32 44.51 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.725 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -45.39 1.58 Allowed 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.332 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -65.1 -36.64 84.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 51.9 m170 -59.52 -51.41 69.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 13.9 tp -62.9 -45.78 90.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.926 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -48.48 -53.86 16.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -48.92 -42.09 29.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.48 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 14.3 t60 -64.14 -39.78 94.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.742 0.306 . . . . 0.0 110.82 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 17.2 mt -75.39 -18.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.48 ' O ' HG21 ' A' ' 437' ' ' THR . 33.2 tttt -108.28 -0.82 20.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.91 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -117.75 -27.04 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 26.1 t -114.93 -36.82 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.559 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 80.7 m-70 -95.12 7.41 46.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.851 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.48 HG21 ' O ' ' A' ' 433' ' ' LYS . 2.2 t -86.04 -41.57 14.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.117 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 6.2 t -64.37 170.29 3.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.853 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -96.15 139.16 32.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 42.0 mtm180 -80.58 153.51 73.46 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.573 0.702 . . . . 0.0 110.904 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -15.63 37.26 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.682 2.255 . . . . 0.0 112.343 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -74.57 -39.02 62.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 10.8 mmmt -104.16 83.7 2.12 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.935 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 24.2 p -114.76 171.88 7.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . 0.419 ' HA ' ' NE2' ' A' ' 445' ' ' GLN . 8.8 mm-40 -69.33 172.72 6.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 90.6 t -67.28 144.52 14.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.109 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.59 ' CH2' ' O ' ' A' ' 448' ' ' VAL . 0.1 OUTLIER -147.17 140.81 25.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.899 -179.995 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.59 ' O ' ' CH2' ' A' ' 447' ' ' TRP . 5.1 m -35.47 100.1 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.069 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . 0.411 ' HA ' ' CZ3' ' A' ' 447' ' ' TRP . 10.1 p -128.62 164.76 22.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -116.79 -76.91 0.61 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.483 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 92.81 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.682 2.254 . . . . 0.0 112.353 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 57.7 p -139.18 126.18 21.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 98.9 p -95.13 -47.95 6.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.835 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.947 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 15.1 t 56.43 45.89 21.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 0.0 110.899 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 54.6 p -97.41 133.25 42.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.838 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . 113.12 53.27 0.47 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.53 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 31.0 p -101.76 87.6 3.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.899 0.38 . . . . 0.0 110.84 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 16.7 t -129.81 88.64 2.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.881 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . -110.05 101.99 1.5 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 72.3 m -129.04 129.59 45.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.895 0.379 . . . . 0.0 110.827 -179.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 10.1 p -137.99 143.67 32.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 77.51 -81.17 1.24 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.504 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . 0.4 ' HA ' ' HD2' ' A' ' 412' ' ' PRO . 0.2 OUTLIER -108.5 107.47 60.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.614 0.721 . . . . 0.0 110.87 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 411' ' ' LYS . 53.6 Cg_endo -69.79 -48.16 0.77 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.744 2.296 . . . . 0.0 112.299 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -62.14 96.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.909 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.573 HG23 ' O ' ' A' ' 420' ' ' LYS . 12.6 mm -101.67 129.1 53.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.134 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 16.9 t -54.99 130.31 41.21 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 36.3 mm-40 -88.74 22.03 2.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.583 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.7 m -119.84 -57.06 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 24.3 p -105.56 -41.87 5.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.863 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 124.6 7.51 6.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.499 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . 0.573 ' O ' HG23 ' A' ' 414' ' ' ILE . 36.0 mttt -58.97 179.11 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.81 0.338 . . . . 0.0 110.943 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -144.64 139.51 8.57 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -134.49 170.59 15.54 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 68.3 m -101.75 -28.55 12.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.852 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.409 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 18.9 mtp180 -116.32 155.68 48.12 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.625 0.726 . . . . 0.0 110.88 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.656 2.237 . . . . 0.0 112.366 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.6 -34.56 78.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.409 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 50.7 m170 -61.65 -50.58 71.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.848 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 11.7 tp -62.9 -44.68 95.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -50.1 -54.61 19.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.859 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . 0.433 ' O ' ' CB ' ' A' ' 434' ' ' GLN . . . -47.25 -37.11 10.88 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.484 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -69.6 -40.29 76.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.809 0.338 . . . . 0.0 110.895 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . . . . . . . . . 11.5 mt -75.29 -16.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.46 ' O ' ' CG ' ' A' ' 433' ' ' LYS . 51.7 tttt -110.86 0.99 17.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.901 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . 0.433 ' CB ' ' O ' ' A' ' 430' ' ' GLY . 11.2 tp-100 -120.48 -29.16 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 34.2 t -110.76 -42.89 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.583 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.8 m-70 -88.3 -18.78 27.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.856 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . . . . . . . . . 1.7 t -44.27 143.01 1.33 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.102 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 74.1 m -142.71 171.1 14.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.86 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -116.75 162.89 16.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -144.35 141.32 17.86 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.608 0.718 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 172.29 12.89 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.694 2.263 . . . . 0.0 112.352 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . 0.435 ' CG ' ' O ' ' A' ' 442' ' ' HIS . 3.0 p-80 -40.39 104.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 2.0 ttmp? -130.02 160.56 33.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 73.5 m 56.94 45.19 21.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . 0.679 ' O ' HG12 ' A' ' 448' ' ' VAL . 2.8 tp-100 -69.5 161.52 29.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 29.5 m -51.15 -20.87 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -55.27 -27.37 46.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.855 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.679 HG12 ' O ' ' A' ' 445' ' ' GLN . 10.7 p -98.88 46.62 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.104 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . . . . . . . . . 35.9 t -147.45 129.41 15.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.877 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . . . . . . . . . . . -53.41 -175.24 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 103.47 1.16 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.665 2.243 . . . . 0.0 112.337 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 60.8 m -109.05 135.61 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 1.4 t -85.56 97.14 9.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.872 -179.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.491 -179.964 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 401' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 402' ' ' SER . . . . . . . . . . . . . 63.8 m -82.7 44.46 0.91 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 110.837 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 403' ' ' SER . . . . . . . . . . . . . 14.5 t -82.54 41.86 0.73 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 404' ' ' GLY . . . . . . . . . . . . . . . -84.53 160.56 36.14 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.495 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 405' ' ' SER . . . . . . . . . . . . . 23.3 p -141.92 167.54 21.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.867 0.365 . . . . 0.0 110.894 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 1.2 t -165.87 157.69 14.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 407' ' ' GLY . . . . . . . . . . . . . . . 122.93 89.73 0.94 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.484 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 408' ' ' SER . . . . . . . . . . . . . 37.3 p -119.81 119.52 33.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.932 0.396 . . . . 0.0 110.856 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 409' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.55 116.03 41.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 410' ' ' GLY . . . . . . . . . . . . . . . 172.05 -127.31 1.39 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 411' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.9 117.68 23.15 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.909 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 412' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -47.74 0.89 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.724 2.283 . . . . 0.0 112.349 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 7.4 m-30 -60.92 94.09 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 12.1 mm -103.99 123.53 57.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.167 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 415' ' ' CYS . . . . . . . . . . . . . 10.9 t -52.6 130.71 32.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 416' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -91.26 20.97 4.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.942 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 417' ' ' SER . . . . . 0.566 ' HB3' ' CE1' ' A' ' 436' ' ' HIS . 1.8 m -116.03 -45.97 2.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.851 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 418' ' ' CYS . . . . . . . . . . . . . 16.8 p -119.03 -44.36 2.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.907 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 419' ' ' GLY . . . . . . . . . . . . . . . 131.11 0.4 5.12 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 420' ' ' LYS . . . . . . . . . . . . . 30.4 mttm -55.09 172.54 0.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 0.0 110.875 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 421' ' ' GLY . . . . . . . . . . . . . . . -141.23 143.93 13.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.479 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 422' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -137.09 166.88 22.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.893 0.378 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 423' ' ' SER . . . . . . . . . . . . . 59.8 m -98.37 -32.27 11.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.837 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 424' ' ' ARG . . . . . 0.418 ' HB2' ' ND1' ' A' ' 427' ' ' HIS . 56.3 mtt-85 -110.97 156.22 41.18 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.885 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 425' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -46.43 1.24 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.737 2.291 . . . . 0.0 112.364 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 426' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -64.42 -38.34 90.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 427' ' ' HIS . . . . . 0.418 ' ND1' ' HB2' ' A' ' 424' ' ' ARG . 60.0 m170 -56.87 -53.3 59.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.495 HD11 HD11 ' A' ' 432' ' ' ILE . 10.3 tp -60.92 -45.18 95.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 429' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -49.32 -52.75 25.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 430' ' ' GLY . . . . . . . . . . . . . . . -49.56 -42.99 36.16 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -63.3 -40.11 96.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.771 0.319 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 432' ' ' ILE . . . . . 0.495 HD11 HD11 ' A' ' 428' ' ' LEU . 13.6 mt -74.9 -16.36 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 433' ' ' LYS . . . . . 0.511 ' O ' HG21 ' A' ' 437' ' ' THR . 21.7 ttmt -108.94 -2.23 18.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.875 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 434' ' ' GLN . . . . . . . . . . . . . 5.3 tp-100 -118.19 -25.68 6.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.938 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 435' ' ' VAL . . . . . . . . . . . . . 14.5 t -115.46 -36.36 2.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 436' ' ' HIS . . . . . 0.566 ' CE1' ' HB3' ' A' ' 417' ' ' SER . 83.0 m-70 -100.4 15.52 27.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.891 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 437' ' ' THR . . . . . 0.511 HG21 ' O ' ' A' ' 433' ' ' LYS . 0.8 OUTLIER -89.45 142.99 27.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.105 -179.894 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 438' ' ' SER . . . . . . . . . . . . . 24.2 m -49.81 125.78 12.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.802 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 439' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -172.13 125.78 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 440' ' ' ARG . . . . . . . . . . . . . 3.4 ptp180 -155.57 144.32 14.78 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 441' ' ' PRO . . . . . 0.412 ' O ' ' C ' ' A' ' 442' ' ' HIS . 53.6 Cg_endo -69.77 -177.52 1.92 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.702 2.268 . . . . 0.0 112.348 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 442' ' ' HIS . . . . . 0.489 ' CG ' ' O ' ' A' ' 442' ' ' HIS . 9.4 p80 -37.37 113.28 0.25 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 443' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -122.43 135.19 54.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.914 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 444' ' ' CYS . . . . . . . . . . . . . 29.5 p -122.35 60.81 0.99 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 445' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -74.45 95.71 2.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 446' ' ' VAL . . . . . . . . . . . . . 13.1 p -52.76 145.73 2.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.131 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 447' ' ' TRP . . . . . 0.779 ' CE2' HG22 ' A' ' 448' ' ' VAL . 24.6 t-105 -128.08 145.35 51.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.908 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 448' ' ' VAL . . . . . 0.779 HG22 ' CE2' ' A' ' 447' ' ' TRP . 26.9 m -35.25 142.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.165 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 449' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 450' ' ' GLY . 1.9 m -175.03 161.0 2.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 450' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 449' ' ' SER . . . 33.86 -96.31 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.492 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 451' ' ' PRO . . . . . 0.432 ' N ' ' O ' ' A' ' 449' ' ' SER . 54.0 Cg_endo -69.7 87.68 0.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.729 2.286 . . . . 0.0 112.359 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 452' ' ' SER . . . . . . . . . . . . . 24.6 p -84.5 141.8 30.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 453' ' ' SER . . . . . . . . . . . . . 70.9 m -117.69 99.37 6.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.878 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 454' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.478 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_